Dosage assessment for radioiodine therapy in benign thyroid disorders by Isselt, J.W. van
Dosage assessment for radioiodine therapy
in benign thyroid disorders
Dosisbepaling bij de behandeling van goedaardige
schildklieraandoeningen met radioactief jodium
(met een samenvatting in het Nederlands)
PROEFSCHRIFT
ter verkrijging van de graad van doctor
aan de Universiteit Utrecht,
op gezag van de rector magnificus, Prof.Dr. H.O. Voorma,
ingevolge het besluit van het College voor Promoties
in het openbaar te verdedigen op dinsdag 16 januari 2001
des middags te 12.45 uur
door
Johannes Willem van Isselt
geboren op 14 februari 1949 te Steenbergen en Kruisland
Promotor: Prof.Dr. C.J.M. Lips
Co-promotors: Dr. J.M.H. de Klerk
Dr. A.P.G. van Gils
The research presented in this thesis was done at the Department of Nuclear
Medicine of the University Medical Center Utrecht, The Netherlands
This publication was financially supported by:
Mallinckrodt Medical B.V., Petten, The Netherlands
Drukkerij Hoonte Bosch en Keuning, Utrecht, The Netherlands
Beoordelingscommissie: Prof.Dr. T.W.A. de Bruin
Prof.Dr. E.P. Krenning
Prof.Dr. W.P.Th.M. Mali
Prof.Dr. G.J.J. Teule
Prof.Dr.Ir. M.A. Viergever
Prof.Dr. W.M. Wiersinga
This thesis was type-set in Stone.
Contents
1 Radioiodine therapy: from medical tradition to clinical science
1.1 The history of radioiodine therapy 13
1.2 Physical and radiobiologic properties of iodine-131 17
The key to the applicability of radioiodine as a therapeutic agent
Physical characteristics of 131I
Radiation effects of 131I on the thyroid cell
Dose response relationships
1.3 Factors influencing the outcome of radioiodine therapy 19
The dosage model
Radiosensitivity
Thyroid blocking medication
Iodine excess
Lithium
Other drugs, dietary ingredients
Medicolegal background
1.4 Indications for radioiodine therapy 22
1.4.1 Toxic nodular thyroid disorders 22
Toxic multinodular goiter
Toxic adenoma
Treatment options in toxic nodular thyroid disease
1.4.2 Nontoxic goiter 24
1.4.3 Graves’ disease 25
Dosage strategies
1.5 Aims of this thesis 28
1.6 References 29
2 Standardized radioiodine therapy for toxic nodular thyroid disease
2.1 Introduction 37
Therapeutic options
2.2 Patients and methods 39
Patients
Methods
2.3 Results 41
Toxic adenoma
Toxic multinodular goiter
2.4 Discussion 42
2.5 Acknowledgements 43
2.6 References 44
3 Iodine-131 therapy in sporadic nontoxic goiter
3.1 Introduction 49
3.2 Methods 50
Patients
Imaging protocol
Dose effect relationship
Statistical analysis
3.3 Results 53
Pretreatment thyroid volume measurements by CT and scintigraphy
Iodine-131 dosage versus thyroid volume reduction
Dose effect relationship
Side effects
Clinical response
3.4 Discussion 57
3.5 Conclusion 58
3.6 Acknowledgements 58
3.7 References 59
4 Standardized radioiodine therapy in Graves’ disease:
the persistent effect of thyroid weight and radioiodine
uptake on outcome
4.1 Introduction 63
4.2 Patients and methods 64
Patients
Radioiodine therapy
Other methods
4.3 Results 67
Thyroid weight and outcome
24-h 131I uptake and outcome
Outcome and other variables
4.4 Discussion 69
4.5 Acknowledgement 71
4.6 References 71
5 Iodine-131 uptake and turnover rate vary over short
intervals in Graves’ disease
5.1 Introduction 77
5.2 Dutch radioiodine therapy survey 78
5.3 Patients and methods 79
Patients
Uptake measurements (‘test 1’)
Follow-up measurements (‘test 2’)
Reproducibility
Product specifications of 131I capsules
Measurements of functioning thyroid volume
Biochemical parameters
Statistical analysis
5.4 Results 83
5-h uptake
24-h uptake
131I turnover rate
5.5 Discussion 87
5.6 Acknowledgements 89
5.7 References 89
6 The outcome of radioiodine treatment in Graves’ disease is determined
by the 131I turnover rate and by the timing of 131I uptake measurements
6.1 Introduction 95
6.2 Patients and methods 95
Patients
Radioiodine uptake measurements
Thyroid volume measurement
Therapeutic dosage
Clinical evaluation
Statistical analysis
6.3 Results 98
Overall outcome
Age and gender
Thyroid volume and outcome
131I-uptake and outcome
Radioiodine turnover rate and outcome
131I dosage per ml (corrected for uptake) and outcome
6.4 Discussion 101
6.5 Acknowledgements 103
6.6 References 104
7 Computer tomography is not suited for thyroid volume measurements
in patients with Graves’ disease before radioiodine therapy
7.1 Introduction 109
7.2 Patients and methods 109
Acquisition
Image processing
7.3 Results 110
7.4 Discussion 110
7.5 References 112
8 A comparison of methods for thyroid volume determination
in patients with Graves’ disease
8.1 Introduction 115
8.2 Patients and methods 116
Patients
MRI
Planar scintigraphy
SPECT
Ultrasonography
Statistical analysis
8.3 Results 126
8.4 Discussion 127
8.5 Acknowledgements 129
8.6 References 129
9 General discussion: towards patient-tailored radioiodine therapy
9.1 Towards patient-tailored radioiodine therapy 134
9.2 Toxic adenoma and toxic multinodular goiter 134
9.3 Nontoxic goiter 135
9.4 Graves’ disease 136
9.5 Considerations regarding the calculation of radioiodine therapy dosages
in Graves’ disease 137
Radioiodine uptake
Radioiodine turnover rate
Thyroid volume
Antithyroid drugs
Information to the patients
9.6 Recommendations for future research 141
Dosimetric models
Investigation of very-short-term variations in radioiodine uptake
Dosage modifying factors for thyroid volume, radioiodine uptake and radioiodine
turnover rate
The influence of ATD on the radioiodine turnover rate
Triiodothyronine suppression therapy in autonomous thyroid disease
Normal thyroid function versus thyroid hormone suppletion
Adjuvant lithium medication
Low-dose recombinant human thyrotropin in patients with nontoxic goiter
9.7 Concluding remarks 143
9.8 References 144
Summary 151
Nederlandse samenvatting voor de leek 156
Dankwoord 160
Curriculum Vitae 163
Publications by the author 165
Radioiodine therapy: from medical tradition to clinical science
11
Radioiodine therapy:
from medical tradition to clinical science
Johannes W. van Isselt
Chapter One
12
Chapter One
Summary
Shortly before Becquerel’s discovery of radioactivity in 1896, the role of iodine
as a precursor of thyroid hormones had been recognized. The thyroid’s func-
tioning and metabolism had been probed with several radioactive isotopes of
iodine when in 1946 iodine-131 sodium iodide (131I) was used as a treatment
form for both benign and malignant thyroid disease. In retrospect, this can be
seen as the birth of nuclear medicine as a medical specialty.
Over the past fifty years, it has become clear that radioiodine therapy is a
safe and effective form of treatment. The mechanism of action of 131I is rela-
tively easy to understand from its physical properties and from radiobiologic
principles. Yet, it is hard to predict the outcome of radioiodine therapy. The
success rate varies significantly between different thyroid disorders, and between
patients under apparently similar circumstances. This had led to much specula-
tion about which factors influence the efficacy of radioiodine therapy, and con-
sequently to experimental adaptations of dosage calculation algorithms. In view
of the many co-existing dosage regimens, it is evident that none are perfect.
In Graves’ disease, different outcomes can be partly explained by different
starting points. It is argued that the natural course of Graves’ disease (with hy-
pothyroidism as the inevitable end-stage in most patients) doesn’t warrant an
individualized approach, because this carries a relatively high risk of persisting
hyperthyroidism. In this view, the early induction of hypothyroidism is a logi-
cal therapeutic goal. In some European countries, guided by the ALARA princi-
ple, physicians are obliged by government regulations to perform individual-
ized dosage calculations in order to keep the total radiation burden as low as
possible. This approach, leading to several years of normal endogenous thyroid
function in a majority of the patients, may well be worth the extra cost and
effort involved.
In later years, benign thyroid diseases other than Graves’ disease (thyroid
adenoma, toxic goiter and most recently nontoxic multinodular goiter) have
also gained recognition as good indications for radioiodine therapy. The therapy
goals and the therapeutic dosage assessment in benign thyroid disorders are
determined by different specifications for each of these disorders.
Improvement of the clinical results of radioiodine therapy seems to be fea-
sible, especially in Graves’ disease. This should be achieved chiefly through ad-
justments to the radioiodine dosage modeling and through standardization of
nuclear medicine procedures pertaining to the therapeutic dosage calculation,
such as thyroid volume measurements and radioiodine uptake measurements.
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1.1 The history of radioiodine therapy
“All those who drink from this remedy recover in a short time, except those whom it
does not help and who all die. Therefore, it is obvious that it fails only in incurable
cases.” This beautifully ironic quote from Galenus (130-200 AD) may serve to
illustrate how little tendency there is to question the efficacy of treatment forms
once they have established a place in common practice. Not many procedures
in nuclear medicine have as long a history or as proud a conduct record as that
of iodine-131 sodium iodide (131I-NaI, or 131I for short) in the diagnosis and
treatment of thyroid disorders. However, in comparison with more recently in-
troduced applications of radiopharmaceuticals both the technical and the clini-
cal quality assurance of radioiodine therapy have been relatively underexposed.
The clinical practice of radioiodine therapy is mostly based on long-standing
traditions, the validity of which in some cases is still to be substantiated.
The history of radioiodine therapy stems from
two roots: thyroid research and radiochemistry.
As early as 1895 Baumann established that sta-
ble iodine is present in the normal thyroid gland,1
and some twenty years later Marine found that
iodine is cleared from the blood by the thyroid.2
In 1914 Edward C. Kendall succeeded in isolat-
ing in crystalline form “the compound contain-
ing iodin, which occurs in the thyroid”, later to
be called thyroxine.3 In 1896 Henri Antoine Bec-
querel had made a discovery in an entirely dif-
ferent field of science.
While studying the phospholuminescent
properties of uranium, Becquerel came upon a
form of energy emanating from matter, which resembled the ‘X-rays’ that Röntgen
had discovered a year earlier.
Becquerel’s student Marie Curie, née Marya Sklodowska (figure 1.1), named
the newly discovered physical phenomenon ‘radioactivité’. Radioactivity would
become a lifetime commitment for Madame Curie, the first woman to receive
the Nobel Prize (for physics, which she shared with Henri Becquerel and her
husband Pierre) and later the first person ever to be awarded a second Nobel
Prize (for chemistry). Marie Curie died at the age of 66, most likely from exces-
sive exposure to radium, polonium and X-rays.4 In the same era Lord Ernest
Figure 1.1  Marie Curie.
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Rutherford had founded the physico-mathematical concepts of ‘decay constant’
and ‘half-life’ and had drawn up the formula It = I0.e–λt. Alpha, beta and gamma
radiation were discerned as different types of radiation. Pierre Curie experimen-
tally confirmed Becquerel’s accidental finding of a biological effect (skin burns)
of uranium. Within a couple of years after these discoveries, medical experi-
ments with external applications of radioactive materials were freely conducted.
Danlos and Bloch applied radium to tuberculous skin lesions, Alexander Graham
Bell suggested the use of radium sources to tumors, and Robert Abbé success-
fully handled (external) radium sources in the treatment of hyperthyroidism.5
Frederick Proescher published the first results of intravenous radium applica-
tion for a number of diseases in 1913. Many new radioisotopes were discovered
in the early years of the 20th century, and several more after Irène Joliot-Curie
(Marie and Pierre Curie’s elder daughter) and her husband Frédéric Joliot found
that radionuclides could be produced artificially.6 It took until 1924 before the
Hungarian chemist Georg von Hevesy, one of the founding fathers of nuclear
medicine, started diagnostic animal experiments with internal applications of
unsealed lead-210 and bismuth-210 sources. In 1925, almost 30 years after the
discovery of radioactivity, the first human diagnostic nuclear medicine proce-
dure in history was performed – the measurement of the circulation time by
Blumgart and Yens, who used bismuth-214 (‘radium-C’) in this experiment.7
In the 1930s, as a result of the work of Lawrence and Livingstone, the pro-
duction of radionuclides in larger quantities created the facilities for large-scale
laboratory and clinical experiments. A new window was opened to the study of
human physiology and pathophysiology. Until the foreclosure of civil radio-
physics research by the outburst of World War II substantial progress had been
made also in the therapeutic use of radionuclides. In 1935, Chievitz and Von
Hevesy demonstrated the physiological process of mineral bone component re-
newal using 32P-phosphate. A year later J.H. Lawrence applied 32P-phosphate in
the treatment of leukemia, which event marks the first documented clinical
therapeutic use of an artificial radionuclide. Pecher described the uptake of stron-
tium-89 in bone metastases. In the following years J.J. Livingood and Glenn T.
Seaborg were involved in the discovery of several radionuclides, among which
iodine-131 in 1938. Later Seaborg (now with Segré) was also responsible for the
discovery of technetium-99m, which was to become the workhorse of nuclear
medicine.
During these prewar years in vitro and in vivo experiments with radioactive
iodine isotopes had been instrumental in the elucidation of the thyroid’s physi-
ology (including the identification of the thyroid hormones) and its patho-
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physiology. In 1937, Hertz, Roberts and Evans investigated the rabbit’s thyroid
function with 128I.8 With 130I they also pursued therapeutic goals, in doses that
we now know would have been mere diagnostic if it were not for a probable
10% 131I contaminant.9 As medical interest in thyroid research was gradually
building up, 131I – a cyclotron product with a very useful half-life of 8.03 days –
was found by Livingood and Seaborg. The paucity of clinical and scientific de-
velopments during World War II is explained by the internment of many of the
allied forces’ radiophysicists at the Atomic Research Laboratory at Los Alamos,
New Mexico, for the development of a weapon with hitherto unimaginable force.
The devastating potential of radiation, as demonstrated by the bombs on Hiro-
shima and Nagasaki, drove large parts of society away from nuclear warfare,
nuclear testing, and nuclear power. The adjectives ‘atomic’ and ‘nuclear’ ac-
quired a negative connotation. To date some of the leading scientists in nuclear
medicine prefer to name their specialty ‘molecular medicine’. Nonetheless, the
postwar period was characterized by a rapid expansion of nuclear science into
the medical world. In 1942 radioiodine entered the clinical arena when two
groups independently reported on the successful treatment of hyperthyroidism
with 131I-sodium iodide, which at that time was available only in very small
quantities.10,11 In that same year Reid and Keston discovered 125I, and Seidlin,
Marinelli and Oshry successfully applied 131I in a thyroid cancer patient. The
news of a potential cure for terminally ill patients fuelled the public imagina-
tion to such a degree that it hit the political agenda.12 Effective on 1 August
1946, the Atomic Energy Act (AEA) made radioisotopes available for medical use
in the USA. This date marks the beginning of ‘atomic medicine’, later renamed
‘nuclear medicine’. In 1951, the FDA approved the use of 131I for the treatment
of benign thyroid diseases. From 1940 to 1970, countless experiments with
radioiodine have brought us knowledge of iodine uptake mechanisms, the basis
of the therapeutic effect of radioiodine, complete identification of thyroid
hormonosynthesis, serum transport of thyroid hormones, and thyroid imag-
ing. More recently immunological and molecular studies have changed the un-
derstanding of thyroid diseases.13
In the 1950s, more than fifty years after the discovery of radioactivity, studies
with radiotracers were still done with Geiger counters and scintillation probes.
Although with these instruments precise quantitative measurements could be
performed of specific physiologic processes within the human body, they lacked
imaging potential. In our day it may be hard to imagine that there once was a
time when brain tumors could not be visualized, but in 1959 the construction
16
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of the first 3-in rectilinear scanner meant a real breakthrough. Medical imaging,
until then the exclusive domain of radiology, had acquired a pathophysiologi-
cal dimension. 131I-scanning of the thyroid provided new insight in the patho-
physiology of various thyroid disorders. The development of a range of phy-
siologic radiopharmaceuticals was boosted by Hal Anger’s introduction of the
gamma camera with its revolutionary whole-body imaging technique. By this
time, the unique physical, chemical and radiobiologic properties of technetium-
99m (99mTc) were also recognized. ‘Off the shelf’ kit preparations with 99mTc
came within clinical reach by the commercial production of the 99mTc-genera-
tor in 1964, seven years after Tucker invented it. One of the simplest techne-
tium-labeled compounds, 99mTc-pertechnetate, stereometrically resembling io-
dine, caused a boom in thyroid imaging publications.
Once more military technology was to stand at the cradle of modern nu-
clear medicine. When NASA’s space program necessitated the construction of
fast mainframe computers, nuclear medicine physicists took advantage of the
emerging information technology. In less than a decade ever faster and smaller
computers accelerated the development of sophisticated gamma cameras and
dedicated software. Kuhl had already described three-dimensional image recon-
struction algorithms in 1964,14 but it took until the mid seventies before hard-
ware developments made the clinical application of single photon emission com-
puter tomography (SPECT) feasible. By that time, astrophysicists had fruitfully
brought these theorems to practice.15 Radiology’s transmission CT-scanner was
another derivative from Kuhl’s innovating activities.16 From 1976 onwards, SPECT
cameras and dedicated PET cameras have brought 3D functional imaging to the
clinic.
The growth of this new medical field had been so rapid that in 1971 nu-
clear medicine was recognized as a regular medical specialty in the USA, and in
1984 in The Netherlands. The impact of nuclear medicine is still growing. Nu-
clear medicine has been instrumental to the understanding and broadening of
several areas in medicine. Some more recent examples are: receptor scintigra-
phy in (neuro)oncology, neurology and biologic psychiatry; immunoscintigraphy
in oncology and infectious disease; and 18F-FDG PET in all of these medical areas.
In most disciplines, therapeutic applications are seen as the ultimate goal. The
‘magic bullet’ concept of specific targeting with radiopharmaceuticals is indeed
attractive. Some scientists define the future of nuclear medicine by the triad
‘quantitative emission tomography–dosimetry–radionuclide therapy’. Radio-
iodine therapy, once instrumental in the birth of nuclear medicine, is still very
much part of its future.
Radioiodine therapy: from medical tradition to clinical science
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1.2 Physical and radiobiologic properties of iodine-131
The key to the applicability of radioiodine as a therapeutic agent
Iodine as a dietary ingredient is essential for the synthesis of the thyroid hor-
mones triiodothyronin (T3) and thyroxine (T4). The recommended daily intake
varies between 150 and 200 µg.17 The thyroid’s avidity for iodine is the key to
therapeutic applications of radioiodine in thyroid disorders. The thyroid gland
is one of the few organs in the human body that can concentrate iodine, and
the only one that metabolizes it. In subjects with normal thyroid function up to
20-30% of orally administered iodine is taken up by the thyroid.17 In hyperthy-
roid patients this percentage is increased – in extreme cases close to 100% may
be incorporated – and administration of radioiodine therefore leads to a highly
specific delivery of the radiation dose to the thyroid gland and a relatively low
radiation burden to other organs. Organ doses vary with the administered amount
and with the route of administration. The radiation dose to internal organs does
not preclude the use of radioiodine for thyroid therapy except in pregnant
women.18-21 At present there is broad consensus that all benign thyroid disor-
ders associated with hyperfunctioning or with goiter can be adequately treated
with radioiodine.17
Physical characteristics of 131I
The element iodine (from the Greek iodes = violet-colored, which iodine is when
vaporized) was discovered by Courtois in 1811. Iodine-127 is the only stable
iodine isotope; for isotopes with a mass number over 127, the daughter product
is xenon. Iodine-131, which is formed by neutron bombardment of tellurium-
131, decays to stable 131Xe by beta emission (figure 1.2). Physical characteristics
Figure 1.2 Simplified decay schema of 131I.
131Xe
β–
131I
365 keV
80 keV
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of 131I: T1/2 phys = 8.04 d; β– = 0.807 MeV; 19 γ’s, ranging from 80 to 637 keV, most
abundant γ: 364 keV (83%).18,22,23 The average range of the 0.807 MeV beta
particles in soft tissue approximates 1 mm, the maximum range is about 3 mm.24
Radiation effects of 131I on the thyroid cell
The biologic effects expressed in cellular organisms following exposure to ioniz-
ing radiation result from chemical changes induced by the radiation in bio-
molecules. Such changes may be brought about directly or indirectly.19,25 Direct
action is produced predominantly by high linear energy transfer (LET) radiation,
such as from beta particles (cf. 131I). It occurs when radiation energy is deposited
within a target macromolecule that is critical for cell survival (often DNA), caus-
ing ionization or excitation of the macromolecule and thereby altering its bio-
logic function. Indirect action results when the radiation interacts with other
atoms or molecules producing free radicals that in turn react with the critical
macromolecules. A free radical is a species that has an unpaired electron in its
outer shell and is for that reason highly reactive. The simplest free radical, a
proton with a single electron (H˙), is highly reactive in aqueous medium. Be-
cause water is the major component of cells and tissues, including the thyroid
gland, the production of free radicals (H˙, OH˙) is the most common result of
irradiation of biological systems. Radiation effects are not identical for different
biological structures. Cell constituents consisting of carbohydrates, lipids or pro-
teins (e.g., enzymes or membranes) are inactivated only by very high radiation
doses, because they are present in many copies. In contrast, DNA is present in
limited copies. Furthermore, its integrity is vital for cell survival.25 For these
reasons DNA is considered a critical target for cell inactivation by ionizing radia-
tion. One sievert (1 Sv) of ionizing radiation can produce 6.1 × 1013 ionizations
per gram tissue; since each cell contains 4 × 10-12 g of DNA, 1 Sv can produce 244
ionizations in the DNA of each cell, or 5.3 ionizations per chromosome.19 Free
radicals react with both the base and sugar components of DNA; OH˙ reacts with
bases by addition to a double bond, and with sugars by hydrogen atom abstrac-
tion. These reactions can result in several types of damage to the DNA molecule:
(i) breakage of hydrogen bonds with loss of structure, (ii) loss or change in nitro-
genous base which may be lethal or may result in a mutation, (iii) DNA single
strand breaks which are enzymatically repairable, (iv) DNA double strand breaks
which may be lethal, and (v) cross-linking between two different DNA molecules
or of DNA to a protein. These effects occur after all forms of ionizing radiation,
including the beta emissions from 131I. The net result is loss of function or cell
death.
Radioiodine therapy: from medical tradition to clinical science
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Dose response relationships
One of the most difficult issues in the radioiodine treatment of thyroid disor-
ders, and particularly in Graves’ disease, is the relationship between the admin-
istered amount of 131I and its therapeutic effect. Dose response relationships are
quantitative descriptions of the effects of radiation on cells. The most widely
used in radiation biology is the cell survival curve. It reflects radiation induced
loss of reproductive capacity, i.e., damage is only expressed when a cell attempts
to divide.26 Although at the cellular level this model works, the cell survival
curve has very limited applicability to whole organs in vivo. In the earliest clini-
cal applications, the dosage was worked out by a trial-and-error method and by
successive approximations. A higher incidence of hypothyroidism generally re-
sulted from larger 131I dosage schemas, while persisting hyperthyroidism was
more frequently observed after smaller 131I dosages.22 By about 1950 the stand-
ard dosage had become 160 µCi/g (5.9 MBq/g) estimated thyroid weight.26 Esti-
mations of the optimal radiation absorbed dose to the thyroid gland in patients
with Graves’ disease at present vary from 200 Gy to 300 Gy.27 Under clinical
circumstances the theoretical optimum as well as the actually delivered doses
are not easily verified. Without calibrated dosimeters, absorbed dose calcula-
tions and measurements harbor a number of uncertainties.28
1.3 Factors influencing the outcome of radioiodine therapy
The dosage model
As was stated before, different dosage models are used depending on the thera-
peutic aim. Higher radioiodine dosages are usually administered with fixed dos-
age regimens, lower dosages with individualized schemas. Errors in 131I dosage
may result from inappropriate radiobiologic modeling or incorrect measurements.
The presently applied dosage models may be oversimplifying the biologic prop-
erties of the thyroid gland in individual patients. The radioiodine turnover by
the thyroid gland varies greatly with disease activity, and consequently affects
the effective half-life of radioiodine.29 Inaccurate 131I uptake measurements or
thyroid volume measurements have a direct bearing on calculations of the radio-
iodine therapy dosage. Although substantial changes in techniques have been
introduced after the first therapeutic dosage formula was proposed, validation
and verification are still lacking in some respects.
20
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Radiosensitivity
Given the difficulties in predicting the amount of 131I required to establish eu-
thyroidism in individual patients with Graves’ disease, the therapeutic range of
radioiodine is probably small. The therapy outcome is influenced not only by
the amount of 131I administered per gram thyroid tissue, but also by biological
properties of the thyroid gland itself. Based on empirical clinical data it has
been established that the radiosensitivity of the thyroid gland as a whole de-
creases with increasing size. There are no generally accepted radiodosimetric
models to explain this finding.25,28 The differential radiosensitivity within the
thyroid gland is probably caused by histopathologic changes such as the devel-
opment of nodular abnormalities and autonomously functioning thyroid tis-
sue,30-32 and the resulting inhomogeneous distribution of radioiodine within
the thyroid gland.17 Yet, when the maximum range of 131I beta particles (3 mm)
is taken into consideration,30 the distribution of radioiodine is relatively homo-
geneous in Graves’ disease in comparison with nodular goiters.
Thyroid blocking medication
Antithyroid drugs (ATD) are often used in the initial treatment of patients with
Graves’ disease. Medication for up 1-1.5 years is relatively inexpensive, and leads
to restoration of normal function in about 10-50% of all patients. The therapeu-
tic effect of ATD is less in patients with larger goiters.34 ATD have a decelerating
effect on iodine uptake by the thyroid, whereas the release of thyroid hormones
is not being blocked. ATD also constitute a safe patient preparation for radioiodine
treatment, preventing the rare occasions of thyroid storm in patients with very
active disease.26,35 If thyroid blocking medication is not interrupted at least three
days before radioiodine administration, a diminished therapy effect must be
anticipated.36 This is partly explained by the decrease of the radioiodine’s effec-
tive half-life through depletion of the thyroidal iodine pool, but the reduced
therapy effect is still present when Teff is compensated for. This is suggestive of a
‘radioprotective’ action of ATD.30
Iodine excess
Iodine in its nonradioactive isotopic form (127I) competes with radioiodine at
the level of the thyroid cell. Seafood (especially clams, seaweed, and some fish)
can be very rich in iodine. Although dietary iodine intake seldom leads to io-
dine excess, food additives sometimes do. In such cases maintaining an iodine-
free diet for three days may help to overcome problems of reduced radioiodine
uptake. A detailed list of drugs and contrast media interfering with radioiodine
Radioiodine therapy: from medical tradition to clinical science
21
uptake was presented by Shackett.37 Radioiodine treatment should be postponed,
sometimes for three months or more, in case such substances have been admin-
istered.
Iodide in high dosage acutely decreases the release of thyroid hormone
from the thyroid gland – apparently by inhibition of proteolysis – with a more
marked effect in thyrotoxicosis than in the normal gland. This is called the
Wolff-Chaikoff effect. Most sources of iodine excess are iatrogenic; radiologic
contrast agents and a number of drugs contain large quantities of iodine, which
may be freed and absorbed in the human body.
Lithium
Lithium blocks the release of iodine from the thyroid gland without hampering
its uptake, as a result of an apparent decrease in proteolysis of thyroglobulin.38
The intrathyroidal persistence of (radio)iodine is thus enhanced, and the effec-
tive half-life of 131I is increased.39,40 It has recently been demonstrated that the
curation of hyperthyroidism is prompter and more effective when radioiodine
is administered in combination with lithium.41 Also the shrinkage of goiters is
more effective, especially of larger goiters.
Other drugs, dietary ingredients
Many drugs have an effect on thyroid function. Amiodarone and glucocorticoids
are well-known examples, but at least a hundred other drugs are known to cause
either an increase or a decrease of thyroid hormone or TSH serum concentra-
tions.42 As with ATD, their use can hardly be titrated so there is no practical use
of these medications in controlling thyrotoxicosis. Moreover, some should be
considered as potential causes of thyrotoxicosis.
Dietary factors other than iodine may influence the functioning of the thy-
roid. Cyanoglucosides, found mostly in staples – such as cassava, corn, sweet
potatoes, bamboo shoots, lima beans, and as such consumed mostly in the third
world – are transformed in vivo to thiocyanate and isothiocyanate. These are
powerful goitrogenic agents that act by inhibiting thyroid iodide transport, and
at higher doses by competition with iodide in the organification process.43 They
may cause prolonged periods of thyroid blockage and thus interfere negatively
with radioiodine treatment.
Medicolegal background
In most Anglo-Saxon countries, treatment with relatively large amounts of radio-
iodine (up to 30 mCi, or 1.1 GBq) is allowed on an outpatient basis. In many
22
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European countries (e.g., in The Netherlands) national regulations prohibit the
therapeutic administration of radioiodine on an inpatient or outpatient basis
unless hospitals have the infrastructure and facilities designed and approved for
this use. In Germany and in some Eastern European countries outpatient treat-
ment is prohibited altogether.44 Differences in administered dosages are evident
consequences of such differences in medicolegal background, and different clini-
cal outcomes will result from otherwise similar therapeutic applications in pa-
tients treated for the same disease.45
1.4 Indications for radioiodine therapy
Over the years, several benign thyroid disorders have been recognized as good
indications for radioiodine therapy, although the therapeutic aims may vary.
The various indications and suggested radioiodine dosage models are summa-
rized.
1.4.1 Toxic nodular thyroid disorders
Although toxic multinodular goiter and toxic adenoma are often viewed as dis-
tinct and separate entities,46,47 they truly represent a spectrum of autonomously
functioning thyroid disorders.35
Toxic multinodular goiter
In 1913 Henri Plummer described a type of hyperthyroidism in which nodular
lesions are present in the thyroid.48 This disease, now known as toxic multi-
nodular goiter, mainly afflicts persons over 50 years of age. The typical pheno-
menology of the toxic goiter is a conglomerate of hyperfunctioning and hypo-
functioning nodules embedded in normal thyroid tissue, with inhomogeneous
radioiodine uptake in the thyroid. A large goiter and autonomous function of-
ten precede the onset of hyperthyroidism by many years.46,49 The natural heter-
ogeneity of thyroid cells and impulses for thyreocytes to grow form the basis of
the nodular growth.31 Presumably, in the absence of naturally occurring
goitrogens or goitrogenic drugs, hereditary as well as hormonal factors and ex-
ternal stimuli are involved in the etiology of all nodular thyroid diseases.31,50,51
The function of the follicular components of the nodular lesions is autono-
mous, i.e. independent of extrathyroidal stimulators such as TSH.
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Toxic adenoma
Goetsch in 1918 described the pathophysiology of autonomously functioning
thyroid nodules as originating from fetal rests, groups of cells found between
thyroid follicles, and rich in mitochondria. According to Studer’s later theory
focal hyperplasia and adenoma formation inevitably occur with time, since the
thyroid (similar to other organs) naturally contains a small fraction of cells with
high inborn replication power and since this property is a stable and inheritable
trait.31 Recent research in molecular biology has revealed that many toxic thy-
roid adenomas are caused by activating somatic ‘gain of function’ mutations in
the TSH receptor itself or in the Gsα protein linked to it.52 The mutation results
in the accumulation of cAMP, which causes autonomous function as well as
proliferation of adenomatous tissue. Many nodules degenerate during this pro-
cess. They are usually solitary nodules that may occur at any age from the teens
to the elderly. Only about one quarter of these are associated with hyperthy-
roidism, which usually sets in about 15 years after the first presentation of the
nodule. Autonomous thyroid nodules without hyperfunction are much more
common than toxic lesions. In patients with toxic adenoma, the degree of hyper-
functioning of adenomatous thyroid tissue can be easily demonstrated by thy-
roid scintigraphy using either 99mTc-pertechnetate or 123I-NaI. In thyrotoxic pa-
tients adenomas will take up a large portion of the radiopharmaceutical and the
normal thyroid tissue is suppressed, i.e. it hardly shows any uptake. This scinti-
graphic phenomenon is further enhanced by ‘suppression imaging’, i.e. scintig-
raphy after administration of triiodothyronine (T3) which reduces the uptake by
normal thyroid tissue through suppression of TSH.
Treatment options in toxic nodular thyroid disease
Surgery, ATD and/or levothyroxine medication and radioiodine therapy have
long been regarded as equally useful treatment options for toxic multinodular
goiter and toxic adenoma, but although ATD can normalize serum FT4, FT3 and
TSH concentrations, thyrotoxicosis recurrence after cessation of therapy is greater
than 95%.35,53 In view of this evidence it is surprising that currently many pa-
tients with these disorders are still being treated with antithyroid drugs.55 Ra-
tional use can be made of ATD to render the patient euthyroid before more de-
finitive therapy. This reduces both the risk of hypothyroidism after radioiodine
therapy, and the risk of acerbations of hyperthyroidism after radioiodine therapy
or surgery.54-56 The preferred treatment modality in individual patients varies
with the size of the nodule or goiter, the age of the patient, the percentage of
radioiodine uptake, the presence of compressive symptoms, concomitant ill-
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ness, and pregnancy or breast-feeding status.35 Large nodules and large goiters
are preferentially treated with surgery because the reduction in size is fast and
seizable. This is especially relevant if there are compressive symptoms.35 A soli-
tary toxic adenoma in a young patient is often treated by unilateral lobectomy
rather than radioiodine. This preference stems from concerns of an increased
risk of development of benign thyroid nodules or even thyroid cancer.57 How-
ever, in a very large study it was shown that the incidence of thyroid cancer is
actually lower after radioiodine treatment than after surgery.58 In patients with
toxic adenoma, subtotal thyroidectomy is associated with a low recurrence rate
(10-20%) but with a very high rate of hypothyroidism (close to 90% at 1 year).59
Radioiodine therapy has been used successfully for three decades in pa-
tients with toxic adenoma. The situation in this disorder is almost ideal for
radioiodine treatment: relatively large amounts of radioiodine can be used for a
complete ablation of the target tissue (the adenoma), whereas the normal thy-
roid tissue will be relatively spared because its iodine uptake is suppressed as a
consequence of the suppressed TSH. In a recent report, however, it was indicated
that the radiation absorbed dose to the normal thyroid tissue is higher than has
generally been assumed.60 The success of radioiodine therapy may be demon-
strated scintigraphically; if the ablation was successful the TSH level will have
normalized, and the uptake of iodine or technetium will be almost homogene-
ous.61 The radioiodine dosage may be selected using different methods, such as
the delivered dose method (e.g., 200 Gy), megabecquerel-per-gram (e.g., 3.7-7.4
MBq/g), or fixed dosage (e.g., 740 MBq).35 Dosages smaller than 370 MBq result
in treatment failures in 25% or more.62
In toxic multinodular goiter, the uptake of 131I throughout the gland is
often very inhomogeneous. The radioiodine dosage per gram thyroid tissue
should be lower than in cases of toxic adenoma if ablation of normal thyroid
tissue is to be avoided. In some patients goiter reduction is a secondary therapy
goal, under which circumstances posttherapeutic hypothyroidism may be in-
evitable. The most commonly used dosage schemas for radioiodine treatment
of toxic multinodular goiter are the megabecquerel-per-gram method (e.g., 3.7-
7.4 MBq/g) and the fixed dosage method (e.g., 185-5500 MBq).35 Toxic adenoma
and toxic multinodular goiter together now contribute about 25% to all
radioiodine treatments in The Netherlands.
1.4.2 Nontoxic goiter
The term nontoxic goiter refers to thyroid gland enlargement that is not associ-
ated with hyperthyroidism. The disease may either be sporadic or, in iodine
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deficient areas, endemic. It is the most common thyroid problem encountered
in clinical practice with a prevalence of less than 1% of the male population up
to 5% in females – which is suggestive of a hereditary factor. There is an increase
in frequency after the age of 45 to about 9% in women aged 75 or older.63 When
untreated, nontoxic goiter increases about 20% in volume every 9 months.51
Obstructive symptoms and cosmetic problems are the predominant clinical fea-
tures, and frequently a reduction of the thyroid mass is necessary. In one dou-
ble-blind controlled study it was shown that this therapy is not effective in
shrinking goiters.64 Life-long levothyroxine (LT4) therapy has an effect in shrink-
ing goiters and in arresting further growth,51 but it is associated with serious
side effects such as decreased bone mineral density and cardiac complications.
Surgery is very effective, but it carries the same risks as in toxic multinodular
goiter.65-67 After subtotal thyroidectomy a recurrence of the goiter has been found
in almost 20% of the patients.66 For these patients, as well as for those with high
surgical risk, a nonoperative reduction of the thyroid volume is desirable.
For a long time radioiodine has not been regarded as a therapeutic option,
but since the 1990s it has been used to reduce the goiter volume in this patient
group.68-72 In most of these studies the volume reduction was measured by ul-
trasound. Ultrasound equipment is relatively inexpensive, widely available, seem-
ingly easy to operate, and without harmful side effects. Ultrasonographic thy-
roid measurements have been reported chiefly in healthy volunteers and in
patients with Graves’ disease. For large nodular goiters with intrathoracic exten-
sion of the thyroid gland, this technique is much less reliable. Observer depend-
ency is substantial in the case of large goiters, because of the impossibility to
visualize the whole gland in one view. CT volume measurements of thyroid speci-
mens are within 5-10% of direct volume measurements. There have been sev-
eral reports confirming the accuracy of volumetry with CT in patients with nodu-
lar goiters.70,73-75
1.4.3 Graves’ disease
Graves’ disease is an autoimmune disease that is characterized by a course of
remission and relapse. The hyperfunctioning of the thyroid is initiated by stimu-
latory autoantibodies directed to the thyrotropin (TSH) receptor protein on thy-
rocytes.76,77 Graves’ disease is more common in young adults (15-35 years), with
an estimated incidence of between 2-5 cases per 1000 individuals, and is about
four times more frequent in women than in men.63 Three not entirely satisfac-
tory therapeutic options exist: thionamide drug therapy, subtotal thyroidectomy,
and radioiodine.53,78-80
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In areas where the diet contains sufficient iodine, like most of the USA,
11-54% of cases are still euthyroid one year after ATD treatment.77 Analyses of
prospective studies and follow-up studies in Europe have shown higher percen-
tages (50 ± 7%) one year after therapy.30,77,81
Subtotal thyroidectomy is an immediate and effective form of treatment;
however, it is associated with complications such as hypothyroidism, hypopara-
thyroidism, laryngeal nerve palsy, bleeding and infections. The relapse rate after
surgery is about 20%.30,65,67
Radioiodine has been recommended as the best treatment option for pa-
tients with Graves’ disease because of its ease, low cost and low rate of serious
complications.53,79,80,82 It is based on the unique ability of the thyroid follicular
cells to trap and organify iodine.17 After intracellular uptake, radioiodine causes
sterilization and destruction of a number of these cells: the effect is to a large
extent dependent from the absorbed radiation dose. The relative risk of late
hypothyroidism after 131I therapy is approximately 20% after two years, and
additionally 2-4% each year after treatment; the accumulated incidence of late
hypothyroidism after standard radioiodine treatment is 40-70%.53,80,83,84 In com-
parison, late hypothyroidism is found in 20-50% of surgical cases.53,67 No math-
ematical relationship has been found between the administered 131I dosage, or
the 131I dosage per gram thyroid tissue, and the appearance of hypothyroid-
ism.53,80 The risk of hypothyroidism is connected with the autoimmune nature
of the disease and with the radiosensitivity of the thyroid tissue.79,80,84 With an
administered dosage of 1.85 MBq (50 µCi) per gram thyroid tissue the relapse
rate is more than 50% after one year, and a dosage of 5.55 MBq (150 µCi) per
gram is associated with a hypothyroidism rate of 30% or more after one
year.22,53,80,85 Therefore 3.7 MBq (100 µCi) per gram may be preferable.
Dosage strategies
Controversies over the preferred dosage regimen have existed ever since the first
therapeutic dose, notwithstanding the wealth of publications over nearly six
decades.86 The indications, the therapy objective and the 131I dosage vary con-
siderably between institutions and countries.87 The therapeutic aim varies from
restoring euthyroidism with the lowest possible dose to quick induction of hypo-
thyroidism. Two dosage strategies have been advanced for Graves’ hyperthy-
roidism: the fixed dosage method (with or without modification factors for thy-
roid size, uptake, or severity of the disease), and the microcurie-per-gram
method.22 The latter seemingly more sophisticated method, while requiring a
surplus of time and effort, thus far has not brought the reward of superior clini-
cal effectiveness.
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The course of Graves’ hyperthyroidism is one of remissions and exacerba-
tions over a protracted period of time unless the gland is destroyed by surgery or
radioiodine. Hypothyroidism after many years is a frequently observed end stage
(up to 70% of all patients). Because of this, many physicians favor high doses of
131I to render the patient hypothyroid in the shortest possible time and follow
this by permanent levothyroxine (T4) replacement therapy.80,88 In this strategy
the high incidence of early hypothyroidism is counterbalanced with a low re-
currence rate. In the American clinical tradition, any treatment that results in a
cure of hyperthyroidism is regarded as successful. This is not reflected in Dunn’s
expressed opinion, less than twenty years after the very first patient was treated,
that “hypothyroidism is the most important undesired effect of radioiodine
therapy”.89 The latter view is shared by many clinicians, especially in Europe,
who consider it suboptimal to replace one disease by another (iatrogenic) dis-
ease which is irreversible.90 They are inclined to see euthyroidism as the only
true curative outcome, even if this involves repeated therapeutic interventions
in a large minority of their patients. In this approach, it is common practice to
start with ATD treatment, later combined with levothyroxine. At discontinua-
tion of the medication after 1-1.5 years, 20-50% of the patients will already have
stabilized disease with normal thyroid function.30,77,81 In patients with recur-
rent hyperthyroidism reinstating the medication appears to be of little use. Al-
though the 1-year follow-up results in this strategy are poor when compared
with the ‘American’ situation, the overall cure rates in the end are similar. The
benefit from a more conservative approach is the larger number of patients who
regain a normal thyroid function for a number of years. Not only is a prolonged
state of well-being without dependency on drugs looked upon as highly desir-
able by the patients, the functioning of the individual may be better served with
normal endogenous thyroid function than with external induction of constant
thyroid hormone levels. In patients with hypothyroidism it has been demon-
strated that partial substitution of triiodothyronine (T3) for thyroxine improves
mood and physiological and neuropsychological functions.91 Although this
observation is very suggestive of a specific effect of T3, its preliminary nature is
being stressed in an editorial comment.92 In a survey concerning the patient
valuation of radioiodine treatment of Graves’ disease, 33% of patients who were
biochemically well adjusted to thyroxine still had problems with mood, weight,
and fatigue.90
The becquerel-per-gram model presents a rational but incomplete radio-
biological principle for radioiodine treatment of Graves’ disease. It incorporates
some of the most important individual biological parameters. There is ample
evidence that with this approach normal thyroid function may be preserved in
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a large majority of patients with toxic goiter, nontoxic goiter and toxic adenoma.
There seems to be no plausible reason why the same principle would not apply
in Graves’ disease. The modest success rate of radioiodine therapy in Graves’
disease is more likely to be associated with the changes in disease activity, with
medical interventions, and possibly with technical imperfections in the pre-
therapeutic work up of patients. For these reasons, the bequerel-per-gram model
may need adjustment.
Of the presently known prognostic factors concerning therapy outcome,
the two most important are thyroid volume and radioiodine uptake. Both fac-
tors are expressed in the standard formula for therapeutic dosage calculation:
D = V × (100%/U) × C,
where D is the administered 131I dosage (in MBq), V is the thyroid volume, U
equals the 24-h radioiodine uptake percentage, and C is a constant (usually 3.7
MBq/g in patients with Graves’ disease).22
Protocols for radioiodine uptake measurements tend to be directed towards
physical quality assurance and quality control rather than towards clinical and
biological aspects.94-96 In patients with Graves’ disease, the accuracy and preci-
sion of planar 99mTc-pertechnetate thyroid scintigraphy in the assessment of the
functioning thyroid volume are not well known. In view of the important role
that is attributed to the thyroid volume in most radioiodine therapy dosage
protocols, thyroid volume measurements should be done with an acceptable
degree of accuracy.
1.5 Aims of this thesis
This thesis is aimed at the optimization of the radioiodine therapy dosage as-
sessment in patients with benign thyroid disorders. The research converges on
the following areas: establishment of rational therapeutic aims, identification
of factors that influence the clinical outcome, and optimization and standardi-
zation of procedures for radioiodine uptake and thyroid volume measurements.
A number of specific questions were formulated:
1 What is the clinical outcome after standardized radioiodine therapy for
toxic adenoma and toxic multinodular goiter?
2 Can adequate goiter reduction be obtained with radioiodine therapy in pa-
tients with nontoxic goiter?
3 Is the required radioiodine dosage for the treatment of Graves’ disease line-
arly related to the thyroid’s volume and the radioiodine uptake, as is impli-
cated by the standard dosage formula (D = V × [100%/U] × C)?
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4 How stable are the 5-h and 24-h radioiodine uptake values over time in
patients with Graves’ disease?
5 Does the timing of the radioiodine uptake measurement influence the clini-
cal outcome of radioiodine treatment in patients with Graves’ disease?
6 What is the accuracy of different imaging modalities in the assessment of
the thyroid volume in patients with Graves’ disease?
In the final chapter, a general discussion is presented of radioiodine treatment
for benign thyroid disorders, with an emphasis on the difficulties that are en-
countered in the dosage assessment in patients with Graves’ disease. General
directions are indicated for adjustments to the standard radioiodine therapy
dosage algorithms. Issues for future research are also proposed.
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Summary
Toxic adenoma (TA) and toxic multinodular goiter (TMNG) are often viewed as
distinct and separate entities, but they represent a spectrum of thyroid tissue
disorders characterized by nodular growth and autonomous hyperfunction.
Recent advances in molecular biology have helped to clarify the origin of toxic
thyroid nodules. Gain of function mutations in the TSH receptor gene which
activate the TSH receptor in the absence of its ligand result in the accumulation
of cAMP. Cyclic AMP stimulates both the growth and differentiated thyroid func-
tion of the thyroid gland. Medical treatment cannot lead to a definitive cure of
TA or TMNG. Since the decline in numbers of thyroid surgery, radioiodine has
become the treatment modality of first choice also for TA and TMNG.
The clinical outcome of radioiodine in these disorders was studied in a retro-
spective follow-up study. Linear regression and ANOVA analysis were used to
analyze the clinical results in 107 patients who had been treated with radioiodine
for TA or TMNG, and for whom follow-up data were available at least one year
after treatment.
In patients with TA, a single treatment resulted in 75% euthyroidism, 11%
hypothyroidism, and 14% persisting hyperthyroidism. Euthyroidism was re-
gained in all patients with a relapse who received repeat radioiodine treatment.
Otherwise no change occurred during extended follow-up (1.5-8 yrs). In pa-
tients with TMNG, 70% of the patients became euthyroid, 22% hypothyroid,
and 8% suffered a relapse of hyperthyroidism. Repeat radioiodine treatment
was successful in all cases.
Good clinical results can be obtained with standardized radioiodine treat-
ment in patients with toxic adenoma and in patients with toxic multinodular
goiter. Dosage schemas vary widely between different research groups. Others
had very good results with a fixed dosage (740 MBq) in patients with TA. It is
argued that scintigraphic weight estimates of thyroid adenomas may be too
inaccurate to allow their use for dosage calculation purposes. Ultrasonography
may be a better alternative.
Standardized radioiodine therapy for toxic nodular thyroid disease
37
2.1 Introduction
Adenomas are usually solitary nodules that may occur at any age from the teens
to the elderly. Only about one quarter of these are associated with hyperthy-
roidism, which usually sets in about 15 years after the first presentation of the
nodule.1,2 Most nodules degenerate during this process; nontoxic autonomously
functioning thyroid nodules are in fact much more common than toxic lesions.3
In toxic multinodular goiter multiple hyperfunctioning and hypofunctioning
nodules are present in the thyroid. The iodine uptake capacity of these follicular
nodules is as heterogenic as that of individual thyroid cells.4 In toxic adenoma
and in toxic multinodular goiter T3 toxicosis, thyrotoxicosis with elevated se-
rum T3 concentrations and less markedly elevated serum T4 concentrations, is
relatively frequent.3,5 The state of the art in the diagnosis and treatment of toxic
nodular thyroid disease has been reviewed in two recent publications.3,6
Toxic adenoma (TA) and toxic multinodular goiter (TMNG) are often viewed
as distinct and separate entities, but they represent a spectrum of thyroid tissue
disorders that are characterized by nodular growth and autonomous hyper-
function.1,7,8 After the first clinical observations by Plummer (1913) and Goetsch
(1918) and the later histopathologic studies by Studer,4 recent advances in mo-
lecular biology have had a considerable impact on several aspects of thyroidology.
Studies of ras proto-oncogene expression have shown that micronodules de-
velop from bursts of follicular cell growth.3 The identification and functional
characterization of mutations in the TSH receptor gene which activate the TSH
receptor in the absence of its ligand provide an explanation for the molecular
mechanism which is most likely responsible for the majority of the hyper-
functioning thyroid adenomas.9,10 Somatic gain of function mutations in the
TSH receptor itself or in the Gsα protein linked to it result in the accumulation
of cyclic adenosine monophosphate (cAMP).11 cAMP stimulates the growth and
differentiated thyroid function of the thyroid gland. Activating TSH receptor
mutations were identified in 20-80% of thyrotoxic nodules and multinodular
goiters.12
Therapeutic options
Antithyroid drugs (ATD) are capable of normalizing FT4, FT3 and TSH concentra-
tions in both TA and TMNG, but thyrotoxicosis recurrence after cessation of
therapy is greater than 95%.13-15 The alternative, life-long antithyroid drug (ATD)
or combined ATD and levothyroxine (LT4) medication, bears the risk of serious
side effects.16-18 Rational use can be made of ATD to render the patient euthyroid
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before more definitive therapy. This reduces the risk of acerbations of hyperthy-
roidism after radioiodine therapy or surgery.6,19,20 TA is different from TMNG
because of its singular occurrence, which offers a better target for therapeutic
interventions. Subtotal thyroidectomy provides fast results. There is a recur-
rence rate of only 10-20%, but a hypothyroidism rate of about 90% at one year
follow-up.21,22 Surgical hazards are infrequent, but potentially serious. They have
contributed to the continuing shift from surgery towards radioiodine as the
treatment of choice for toxic nodular thyroid disorders, as well as for other be-
nign thyroid disorders.23 For the treatment of a solitary TA in young patients
many physicians prefer unilateral lobectomy over radioiodine therapy because
of the reportedly increased risk of nodular disease developing after 131I.24 An
alternative therapeutic approach for solitary TA is ultrasound-guided percutane-
ous ethanol injection, which has a cure rate of about 66% one year after treat-
ment.25 It induces coagulative necrosis of the follicular cells, resulting in a re-
duction of the nodule size. The experience with this treatment form is limited.
Patients with TA and TMNG now represent about 20-25% of all referrals for
radioiodine treatment in The Netherlands. Theoretically TA forms a very good
indication for radioiodine therapy. The mass of the adenoma rather than that of
the thyroid as a whole determine the amount of radioiodine. Relatively large
amounts of radioiodine can be used for the ablation of the target tissue (the
adenoma) while the functioning of the surrounding tissue can be relatively spared
in the process. However, in a recent report it was indicated that the radiation
absorbed dose to the normal thyroid tissue is higher than has generally been
assumed.26 In toxic multinodular goiter the 131I uptake throughout the thyroid
gland is inhomogeneous. If the normally functioning thyroid tissue is to be
spared, very high radioiodine dosages should not be administered. With an
amount of 3.7 MBq (100 µCi) per gram functioning thyroid tissue, normaliza-
tion of the thyroid function is common, and the risk of hypothyroidism is
low.19,20,27-31 As the multinodular goiter itself remains,5 other nodules may be-
come toxic when endogenous TSH increases following radioiodine therapy. For
this reason repeat dosages of 131I may be required years after the first treatment.5
The aim of this study was to assess the functional thyroid status after standard-
ized radioiodine treatment in patients with toxic adenoma or toxic multinodu-
lar goiter.
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2.2 Patients and methods
Patients
A retrospective follow-up study was done in 44 (31 female/13 male) patients
with toxic adenoma and 63 (56 female/7 male) patients with toxic multinodu-
lar goiter who had been referred for radioiodine treatment, and for whom fol-
low-up data at least one year after radioiodine treatment were available. The
diagnosis at 1-year follow-up was based on the physician’s clinical impression
and on serum TSH (normal concentration 0.35-6.0 mIU/l). Extended clinical
follow-up data was available for all patients (see table 2.1), except 6 patients
with TA and 29 patients with TMNG who were all interviewed by telephone. In
these cases the diagnosis was based on the patient history and the use of thyroid
medication. One-year follow-up data were not available for 9 patients with TA
and for 17 patients with TMNG (26/133, or 20% of total).
ATD had been prescribed to 7 patients (16%) with toxic adenoma, ATD + LT4
to 1 patient (2%), no medication to 36 patients (82%). All medication had been
discontinued at least 3 days before radioiodine treatment. ATD medication was
not reinstalled after 131I therapy unless persistent hyperthyroidism had been
diagnosed. LT4 was prescribed only to those patients who became hypothyroid
after radioiodine treatment. Of all patients with TMNG 29 (46%) had no thyroid
medication at all before radioiodine treatment. 34 (54%) had received some
form of medication, for a mean period of 2.9 years (2 months-18 years); 15
patients (24%) received ATD only, 16 (25%) had ATD + LT4, and 2 (3%) had LT4
monotherapy. One patient had received symptomatic treatment with β-adren-
ergic blocking drugs only.
Methods
Before radioiodine therapy, hyperthyroidism had been confirmed by biochemi-
cal assays of TSH, T3 and FT4. All patients had also suffered from clinical symp-
toms of hyperthyroidism. A diagnosis of uninodular or multinodular goiter had
been confirmed by palpation and by 99mTc-pertechnetate thyroid scintigraphy.
Thyroid scintigraphy was also used for estimations of the size of the adenoma or
goiter. In patients with TA an estimation was made of the degree of suppression
of the normal extranodular thyroid tissue; scintigrams were scored as (near)
total suppression (uptake in the adenoma > 5 × that in normal thyroid; present
in 76% of all cases), moderate suppression (uptake in the adenoma 2-5 × that in
normal thyroid; present in 21%), or slight suppression (uptake in the adenoma
< 2 × that in normal thyroid; present in 3%).
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The therapeutic 131I dosage was standardized by using the formula:
D = W × [100%/U] × C,
where D is the administered 131I dosage (in MBq), W is the thyroid weight (in
grams), U is the 24-h 131I uptake (in %) and C is a constant (equaling 3.7 MBq
per gram functioning thyroid tissue for patients with multinodular goiter and
7.4 MBq per gram adenomatous tissue for patients with toxic adenoma).
The descriptive statistics concerning age, 5-h and 24-h radioiodine uptake,
weight of the adenoma or the goiter, the administered radioiodine dose, the
Table 2.1 Patient data.
toxic adenoma (n = 44)
n mean ± sd range
female 34
male 10
age 56.0 ± 15.3 15-81
administered dose 131I (MBq) 349.5 ± 224.0 84-950
follow-up (yrs) 3.2 ± 1.8 1.5-8.0
5-h 131I uptake (%) 25.6 ± 11.5 11-69
24-h 131I uptake (%) 41.6 ± 12.4 22-66
weight of adenoma 16.1 ± 11.2 4-44
presence of nodule (yrs) (?) (?)
presence of hyperthyroidism (yrs) 2.2 ± 3.7 0.1-17.0
toxic multinodular goiter (n = 63)
n mean ± sd range
female 56
male 7
age 65.2 ± 12.4 36.6-84.0
administered dose 131I (MBq) 892.4 ± 667.1 174-3772
follow-up (yrs) 3.5 ± 1.7 1.7-8.7
5-h 131I uptake (%) 37.0 ± 21.2 8-92
24-h 131I uptake (%) 50.7 ± 18.1 20-87
weight of goiter 117.3 ± 73.4 27-272
presence of goiter (yrs) 10.9 ± 11.7 1-50
presence of hyperthyroidism (yrs) 3.9 ± 5.7 0.3-26.0
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duration of the follow-up, the duration of the presence of the adenoma or goiter
and the duration of the hyperthyroidism for all patients are summarized in ta-
ble 2.1.
2.3 Results
Toxic adenoma
Euthyroidism was reached in 33/44 patients (75%) one year after treatment, 5
patients (11%) became permanently hypothyroid, and 6 patients (14%) suffered
a relapse of thyrotoxicosis.
For all patients an extended follow-up was available (see table 2.1). During
this follow-up period, no change was noted in any of the patients who had
become euthyroid nor in those who had become hypothyroid. 4 of the 6 pa-
tients with a relapse of hyperthyroidism had had repeat radioiodine treatment,
and all four had regained euthyroidism. In the remaining two patients ATD had
been reinstalled (since 22 months and 36 months, respectively). No side effects
of the radioiodine treatment during the follow-up period had been reported by
the referring physicians in the correspondence, or by the patients during the
telephone interviews.
The degree of suppression on thyroid scintigraphy had no bearing on the
clinical outcome. (Near) total suppression was in proportion of the clinical out-
come (13% in patients who later became hypothyroid, 16% in those who be-
came hyperthyroid). Moderate or slight suppression was seen only in those pa-
tients who later became euthyroid. Of all patients who regained euthyroidism,
67% had (near) total, 30% moderate and 3% slight suppression on thyroid scin-
tigraphy. No statistically significant relations were found between the clinical
outcome and the radioiodine uptake, the size of the nodule, the patients’ age or
gender, the administered 131I dosage, or the duration of the nodule or of the
hyperthyroidism.
Toxic multinodular goiter
One year after radioiodine treatment, euthyroidism was reached in 44 patients
(70%), hyperthyroidism persisted in 14 patients (22%), and 5 patients (8%) be-
came hypothyroid. For all patients extended follow-up was available (see table
2.1). During this follow-up 3 of the patients who had initially become euthyroid
(5%) suffered a relapse of hyperthyroidism, 1 (2%) became hypothyroid after
2.5 years, and 40 (63%) remained euthyroid. In 3/6 patients with a hypothyroid
outcome, the hypothyroidism was only transient. 11/14 patients with persist-
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ent hyperthyroidism had repeat 131I treatment, and euthyroidism was regained
in all of them; in the other 3 ATD had apparently been reinstalled (for 1.5-2.5 yrs
since radioiodine treatment). At long-term follow-up, the results were: 54 (86%)
euthyroidism, 3 (5%) hypothyroidism, and 6 (9%) hyperthyroidism. Three of
the latter were biochemically hyperthyroid but had no longer any clinical symp-
toms. No side effects from the radioiodine treatment during the follow-up were
reported by the referring physicians or by the patients themselves. There were
no statistically significant relations between the clinical outcome and the
radioiodine uptake, the size of the goiter, the patients’ age or gender, the admin-
istered 131I dosage, or the duration of the goiter or of the hyperthyroidism.
2.4 Discussion
With a single radioiodine dosage good clinical results were obtained in patients
with toxic adenoma (75% euthyroidism, 11% hypothyroidism, 14% relapse)
over a follow-up period varying from 1 to 8 years. In patients with toxic multi-
nodular goiter, 70% became euthyroid, 8% became hypothyroid and 22% suf-
fered a relapse. Repeat radioiodine therapy (3 for TA, 11 for TMNG) was successful
in all patients with a relapse. The retrospective nature of this study is a disad-
vantage because of incomplete data retrieval and the inability to set uniform
end-points. Although the risk of patient selection bias cannot be denied, a rela-
tively high percentage of patients who had dropped out of the regular clinical
follow-up but who could be reached for telephone interviews appeared to have
regained euthyroidism (90% of TA patients, 85% of TMNG patients). This may
have induced these patients’ discontinuing their regular check-up visits. It seems
fair to assume that the missing data in 20% of the patients constitutes a selec-
tion bias in the same direction.
The present results are in fair agreement with those of others, although
most authors find somewhat fewer relapses and higher hypothyroidism rates
for toxic multinodular goiter.19,20,27-32 In a number of studies, all with different
methods of dosage calculation, the recurrence rate for TMNG varied between 2%
and 52%.32-38 The lowest failure rate was obtained with a fixed dosage of 740
MBq (20 mCi).32 It seems contradictory that with this regimen the hypothy-
roidism rate (6%) was also slightly lower than what we found.
More accurate measurements of the autonomously functioning thyroid vol-
ume may be worthwhile both in TA and in TMNG.39 Scintigraphic estimations of
the volume of adenomas are difficult because of the very high uptake; these
measurements may be too inaccurate to allow their use for dosage calculation
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purposes. Ultrasonography is probably the most appropriate modality for such
measurements. Inaccuracy of our volume estimations may be one of the reasons
that a fixed dosage schema outperformed our individualized dosage regimen.
Whatever the cause may be, at this stage a fixed dosage regimen seems prefer-
able over individualized regimens.
Effective ways to determine the autonomously functioning volume of the
thyroid facilitate estimations of the radiation dose.39 Large differences in the
effective half-life of thyroidal radioiodine, varying from 1.7 to 106.5 days, have
recently been demonstrated in patients with toxic adenoma (data for toxic multi-
nodular goiter are unknown).26 This is bound to have a bearing on the effect of
a given amount of 131I. Accounting for the effective half-life leads to a better
definition of the delivered radiation absorbed dose in these patients.
In patients with toxic adenoma the autonomy of the hyperfunctioning tis-
sue can easily be demonstrated by ‘suppression imaging’, i.e. thyroid scintigra-
phy after administration of T3 which reduces the uptake by the normal thyroid
tissue through suppression of TSH. There is evidence that this intervention also
improves the precision of the calculations of required therapy dosages.28 This
procedure must however be carried out with caution, because it may provoke
atrial fibrillation or ‘thyroid storm’ in elderly patients.3
Lithium medication before and during radioiodine therapy may be consid-
ered, especially in patients with large goiters. The overall net effect of lithium is
a prolonged retention of thyroidal (radio)iodine.40-42 Consequently the effect of
a given radioiodine dosage is increased, or inversely a lower dosage will suffice
to obtain the same effect. However, it is unclear whether a quantitative relation-
ship exists between lithium serum concentration and the increase of the thyroi-
dal radioiodine retention. The risk of increased hypothyroidism rates may be
greater than the potential profit of lower dosages. Therefore, at this stage no
rational use can be made of adjuvant lithium treatment.
It is remarkable that many patients with TA or TMNG are still being treated
with antithyroid drugs, as thyrotoxicosis recurrence after cessation of therapy is
almost certain to occur.13-15
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Summary
The effect of radioiodine in the treatment of nontoxic goiter is seldom evalu-
ated quantitatively. The aim of this study was threefold: (i) to assess the effect of
131I on goiter volume, (ii) to establish a relationship between CT volume reduc-
tion and the amount of radioactivity taken up by the thyroid and (iii) to assess
the precision of scintigraphic thyroid volume measurements.
In 27 patients with sporadic nontoxic goiter, the thyroid volume was esti-
mated from a 99mTc-pertechnetate scintigram. Two different models (cylinder
model and surface model) were applied. The 131I dosage varied between 507 and
3700 MBq. In all patients, noncontrast CT scanning of the neck was performed
before therapy and 1 year after therapy.
The mean CT thyroid volume before therapy was 194 ± 138 ml. A reduction
was obtained in all patients and averaged 34% ± 17%. The volume reduction
measured by CT correlated well with the amount of 131I in the thyroid (R = 0.70).
In thyroids larger than 200 ml, both scintigraphic volume estimation methods
were imprecise. For smaller volumes, the surface model was superior. Hypothy-
roidism developed in 14% of the patients. No other side effects occurred.
Iodine-131 therapy for volume reduction in nontoxic goiter is a safe and
effective treatment. For scintigraphic estimation of thyroid gland volumes smaller
than 200 ml, the surface model is preferred.
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3.1 Introduction
The term nontoxic goiter refers to thyroid gland enlargement unassociated with
hyperthyroidism. It is the most common thyroid problem encountered in clini-
cal practice. Thyroid nodules are detected in less than 1% of the male popula-
tion but occur in 5% of all females. There is an increase in frequency after the
age of 45 to 9% in women aged 75 or older.1 Nontoxic goiter increases 20% in
volume every 9 months.2 Obstructive symptoms and cosmetic problems are
usually predominant in the clinical picture, and volume reduction is frequently
necessary.
Thyroid hormones have been used to shrink goiters and to arrest further
growth.2 In a double-blind controlled study, it has been shown that levothyroxine
(LT4) suppressive therapy is not effective in shrinking goiters.3 Furthermore, life-
long suppressive LT4 therapy is associated with side effects such as decreased
bone mineral density and cardiac arrhythmias. Surgical treatment is effective
but carries the risk of recurrent laryngeal nerve damage and permanent hypopara-
thyroidism.4 Transient voice disabilities and hypothyroidism are relatively fre-
quent complications (20% and 10%, respectively).5 Moreover, after subtotal thy-
roidectomy, a recurrence of the goiter has been found in almost 20% of the
patients.5 For these patients, as well as for those with high surgical risk, a
nonoperative reduction of the thyroid volume would be desirable.
Over decades, radioiodine (131I) has proved to be effective in the treatment
of hyperthyroidism with diffuse or nodular goiters. 131I also has been used to
shrink the goiter in nontoxic patients.6-10 In most studies, volume reduction
was measured by ultrasonography (US). The use of US for thyroid volume esti-
mations has been studied chiefly in normal thyroids and diffuse goiters. For
large multinodular goiters, however, ultrasound becomes less reliable because
of frequent intrathoracic extension. Furthermore, US is observer-dependent, es-
pecially in large goiters in which it is not possible to visualize the whole gland
in one view. Thyroid gland volume reduction by 131I has rarely been evaluated
by more reliable methods such as CT or MRI. The aims of this study were to
determine thyroid gland volume reduction by therapeutic dosages of 131I in
patients with nontoxic goiter using CT as a gold standard; to relate this volume
reduction to 131I uptake by the thyroid gland; and to determine the reliability of
scintigraphic volume measurements in patients with nontoxic goiter.
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3.2 Methods
Patients
Twenty-seven patients with sporadic nontoxic goiter were included in the study.
The group consisted of 22 women (mean age 57 yr, range 36-78 yr) and 5 men
(mean age 62 yr, range 50-81 yr). Patient characteristics are summarized in table
3.1. Inclusion criteria for 131I treatment were growth of the goiter, obstructive or
cosmetic symptoms, clinical euthyroidism and a preference of the patient for
131I therapy over surgery. Those having had previous partial thyroidectomy or
use of LT4 suppressive therapy were not excluded. None of the patients had
patient no. sex age 24-h dosage
(year) uptake* (%) (MBq)
1 F 49 29 630
2 M 50 48 1245
3 M 71 32 740
4 F 78 37 1480
5 M 58 39 1850
6 F 48 40 555
7 F 50 38 555
8 F 60 41 925
9 F 66 31 1480
10 F 69 83 600
11 F 36 40 900
12 F 68 35 740
13 F 48 42 518
14 F 51 32 1900
15 F 62 21 925
16 F 64 66 507
17 F 43 60 1850
18 F 55 39 1295
19 F 62 37 2750
20 F 55 40 1295
21 F 66 45 800
22 F 57 34 1480
23 F 59 27 1850
24 F 42 64 1480
25 M 51 41 3700
26 F 65 44 1600
27 M 81 37 1160
* Normal value for 24-h uptake: < 30%.
Table 3.1 Patient characteristics.
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previously undergone 131I therapy. Before treatment, the plasma TSH concentra-
tion was within the normal range (0.35-6.0 mU/l) in 11 patients and subnormal
in 15 patients (< 0.35 mU/l). In one patient, the plasma TSH concentration was
not available. In all patients, plasma total T4 (TT4) and free T4 (FT4) concentra-
tions were in the normal range (60-140 nmole/l and 6-23 nmol/l, respectively).
Two patients could not be evaluated for thyroid volume reduction, as they had
undergone partial thyroidectomy or a second 131I treatment within the 1-year
follow-up period.
Imaging protocol
CT and thyroid scintigraphy were performed and 131I uptake was measured within
4 weeks before radioiodine treatment. Thyroid scintigraphy was performed after
intravenous administration of 80 MBq 99mTc-pertechnetate on a round field of
view or rectangular gamma camera equipped with a low-energy, high-resolu-
tion, parallel-hole collimator. Two different scintigraphy-based methods were
used to estimate thyroid volume.
In the first, the cylinder formula (Vcyl) is applied to both thyroid lobes:
Vcyl = L ·  (0.5W)2 ·  p ,
where V represents the volume of each lobe, L is maximum length in centimeters,
and W is maximum width in centimeters (figure 3.1).
In the second method, the surface formula (Vsurf) by Himanka and Larsson11
is applied:
Vsurf = 0.33 ·  A1.5 ,
where A equals the thyroid projection area. This formula was derived experi-
mentally through determination of volumes of surgical thyroid specimens by
fluid replacement. Several of these specimens were of irregularly shaped thy-
roids. For scintigraphic estimation of thyroid surface, regions were drawn auto-
matically using a 30% threshold of the maximum counts per pixel. In cases of
very poor thyroid uptake, regions were drawn manually (figure 3.1).
The 5-h and 24-h 131I uptakes were measured after ingestion of 0.37 MBq
Na 131I tracer (Canberra 7350-PE collimator with a 2×2-inch NaI crystal). The
collimator crystal was centered at the trachea or at the 131I standard placed in a
neck phantom at a distance of 25 cm. Thyroid uptake was measured using the
formula:12
131I uptake =
neck counts – thigh background counts
standard counts – room background counts
× 100%
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Calculation of the therapeutic 131I dosage included corrections for thyroid weight
and 24-h radioiodine uptake, according to the formula:
D = (100/U) ·  Vcyl ·  C,
where D is the administered dose of 131I (in MBq), U equals the 24-h uptake (%),
Vcyl (which was used routinely for dosage calculations) represents the thyroid
volume (in ml) and C was set at 3.7 MBq/ml. Nine patients received a lower
dosage. Corrections were made: (a) for scintigraphically active thyroid volume,
(b) in case D exceeded 3700 MBq or (c) if the estimated period of mandatory
hospitalization in an isolated room was considered unacceptable. The dosage in
these nine patients was 2.1 ± 0.6 MBq/ml. Before 131I therapy, patients on LT4
had discontinued this medication for at least 4 weeks.
CT was used as the gold standard for measurement of thyroid volume before
treatment (CTpre). The use of CT for measuring thyroid volume is both accurate
and reproducible.13 Noncontrast CT of the thyroid gland was performed using
5-mm contiguous sections. Volume measurements were performed using the
summation-of-areas technique. At 12 ± 1 month(s) after treatment, CT (CTpost)
was repeated. CTpre – CTpost provides the absolute volume reduction, while [(CTpre
– CTpost)/CTpre] × 100% represents the relative volume reduction. In addition to
CT volume reduction, we investigated the relationship between the two scinti-
graphic methods of volume estimation used in this study.
Figure 3.1 Examples of scintigraphic volume estimation with the cylinder (left) and volume
models (right) in patient 9.
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Dose effect relationship
The amount of 131I per ml CT volume corrected for 24-h uptake (CCT) is related to
the percentage of volume reduction (∆CT). To describe this relationship, we used
the sigmoid Emax model, which is the simplest model for the adequate descrip-
tion of drug effects over the whole range of concentrations.14 It is also a math-
ematical description of the S-shaped curve, known from radiobiological models
describing cell-killing.15 The model is defined as:
E = 
Emax  ·  C
N
CN  + ECN50
,
where E is effect, C is concentration, N is a number influencing the slope of the
curve, Emax is the maximum effect attributable to the drug and EC50 is the con-
centration producing 50% of Emax.
For this study, the formula can be rearranged into:
D CT = 
100 ·  CNCT
CNCT + EC
N
CT50
,
where ∆CT is the percentage of volume reduction as measured by CT, 100 is the
maximum effect and ECCT5O is the concentration per MBq/ml CT volume (up-
take corrected), producing 50% volume reduction.
For comparison, the relationship between CCT and ∆CT was also tested by
linear regression.
Statistical analysis
Data were analyzed with the SYSTAT 5.2.1 program (SYSTAT, Inc., Evanston, IL).
To describe the predictive performance of the scintigraphic volumes, the mean
squared prediction error (precision) and mean prediction error (bias) were evalu-
ated.16 To assess the dose effect relationship, statistical tests were used as men-
tioned previously.
3.3 Results
Pretreatment thyroid volume measurements by CT and scintigraphy
The results of CT and scintigraphic measurements are summarized in table 3.2.
As illustrated in figure 3.2, both scintigraphic volume estimations show a better
relationship with CT measurements for smaller goiters (< 200 ml). Table 3.3 shows
the performance evaluation of Vcyl and Vsurf.
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Table 3.3 Performance evaluation of predictors Vcyl and Vsurf using mean error (me),
mean squared error (mse) and root mean squared error (rmse) for thyroid gland volumes <
200 ml and > 200 ml.
Vcyl Vsurf Vcyl Vsurf
precision (< 200 ml) (< 200 ml) (> 200 ml) (> 200 ml)
mse (ml2) 798.6 142.3 11185.3 12577.2
rmse (ml) 28.3 12 106 112
bias me (ml) 10.6 –2.3 –45.0 –88.4
Table 3.2 CT and scintigraphic* measurements.
patient Vcyl Vsurf CT volume CT volume volume
no. pretherapy pretherapy pretherapy posttherapy reduction
1 52 51 52 33 37
2 161 153 175 108 38
3 49 58 48 19 61
4 500 254 491 403 18
5 400 305 454 273 40
6 60 50 42 18 57
7 100 80 64 51 20
8 160 120 134 119 11
9 350 222 259 215 17
10 134 142 140 135 3
11 100 97 123 82 33
12 63 91 95 71 19
13 58 63 56 36 35
14 165 307 434 317 27
15 50 44 43 15 65
16 90 84 76 31 59
17 300 287 269 118 56
18 254 233 339 306 10
19 378 293 424 305 28
20 140 143 205
21 75 94 90 53 41
22 135 82 94 50 47
23 213 161 162 113 30
24 250 173 188 118 37
25 326 282 313 168 46
26 240 190 208 166 20
27 117 176 271
* All numbers in milliliters, except volume reduction measured by CT (%).
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The mean squared error (mse) of the Vsurf method is considerably smaller than
the mse of the Vcyl method for thyroid gland volumes smaller than 200 ml,
indicating a greater precision of the Vsurf method. In thyroid gland volumes
exceeding 200 ml, both methods are inadequate as demonstrated by the magni-
tude of the mean error.
Iodine-131 dosage versus thyroid volume reduction
The administered dose of 131I ranged from 507 to 3700 MBq (1289 ± 733 MBq,
mean ± sd). For the whole group, the mean administered dose corrected for Vcyl
and 24-h uptake was 3.3 ± 1.0 MBq/ml Vcyl (range: 1.1-4.8 MBq/ml Vcyl). As
mentioned previously, nine patients received a lower dosage. In these patients,
the administered dose ranged from 1.1 MBq/ml Vcyl to 2.9 MBq/ml Vcyl (mean:
2.1 ± 0.6 MBq/ml). For the remaining group (18 patients), the dosage was 3.9 ±
0.4 MBq/ml Vcyl (range: 3.5-4.8 MBq/ml Vcyl). Complete CT data were avail-
able for 25 patients. All statements about absolute and relative volume reduc-
tion are based on CT measurements unless indicated otherwise. Volume reduc-
tion was obtained in all patients. The mean volume reduction was 58 ± 48 ml
(range: 5-180 ml), and the relative volume reduction was 34% ± 17% (range:
3%-65%).
Figure 3.2 Relation between scintigraphic and CT volume measurements of the thyroid
before 131I therapy. The line through the origin is the line of identity.
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Dose effect relationship
The relationship between the percentage of volume reduction as measured by
CT (∆CT), and the amount of 131I per ml CT volume corrected for 24-h uptake
(CCT) is described by the following formula:
D CT = 
100 ·  C1.4CT
C1.4CT  + 5.3
1.4
.
Statistical parameters are correlation coefficient (R) = 0.70; F-value = 92; confi-
dence interval of ECCT5O = 3.8-6.9 MBq/ml. Linear regression analysis results in a
correlation coefficient of the same order of magnitude (R = 0.72, F-value = 26),
but from a dosimetric point of view, the sigmoid Emax model is preferred. Figure
3.3 depicts the relationship between ∆CT and CCT.
Side effects
In 21 patients, TSH values were available 1 year after treatment. Hypothyroidism
(TSH level > 6.0 mU/I) occurred in 3 of 21 patients (14%) (patients 1, 6 and 17).
Figure 3.3 Relation between the percentage of volume reduction measured by CT and the
amount of 131I uptake per ml CT volume, corrected for 24-h uptake, using linear and nonlinear
models.
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No other side effects occurred, and in particular, no clinically detectable in-
crease of goiter or exacerbation of obstructive symptoms were noted.
Clinical response
Four (15%) of the 27 patients (patients 1, 12, 20 and 27) were dissatisfied with
the volume reduction results, although the objective volume reduction was satis-
factory in patients 1 and 12 (37% and 19%, respectively). Within the 1-year
follow-up period, patient 20 had a partial thyroidectomy and patient 27 re-
ceived a second 131I treatment. All other patients reported substantial improve-
ment or complete relief of their complaints.
3.4 Discussion
This study shows 131I to be an effective therapeutic option for the reduction of
thyroid volume in patients with sporadic nontoxic goiter, with a relatively small
risk of hypothyroidism. Volume reduction was obtained in all patients. With a
dosage of 3.3 ± 1.0 MBq/ml, the mean volume reduction was 34% ± 17%, which
is of the same order as that reported by other investigators.8-9
By using the sigmoid Emax mode, and CT-based measurements, we have
found a good relationship between thyroid volume reduction and the amount
of 131I taken up per ml thyroid volume.
In our patient series, we found a wide range of thyroid volume reduction
(3%-65%). No doubt, individual differences in 131I uptake and biological half-
life of 131I in the thyroid are responsible for some of the varying responses.
However, we propose that inappropriate estimation of thyroid volume, used for
dosage calculations, is generally an underestimated factor. Accurate volume es-
timations are the basis of reliable dosimetric calculations.
It is obvious that if individual dosages can be optimized, benefits can be
expected in terms of increased therapeutic effect, minimal risk of hypothyroidism
and reduced radiation burden to the patient and the environment.
Thyroid gland volume can be estimated by several methods, of which the
CT has a documented high rate of accuracy. Up to 40 years ago, palpation was
the only way to estimate the thyroid volume.11 Afterwards, scintigraphy be-
came the only reliable method. In more recent literature, there are numerous
reports confirming the accuracy of CT volume measurements.17-20 In general, CT
volume measurements of thyroid specimens are within 5-10% of direct volume
measurements. In an earlier study, our group reported a 5% intra- and inter-
observer variability for CT.13 Some investigators have used MRI.8,9,21-23 However,
no references are available for either CT or MRI measurements for 131I therapy
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dosage calculation. Ultrasonography also is recognized as a reliable modality for
volume measurements, but only two groups have described the use of this mo-
dality for dosage calculation.6,10 In those series, no thyroid volumes over 300 ml
were reported. It is possible that one specific problem with US, i.e. imaging of
retrosternally located tissue, is the reason for this. CT and MRI apparently do not
have this drawback.
Scintigraphic estimates of thyroid volume using the ellipsoid method are
reliable in the case of normal or slightly enlarged thyroid glands with homoge-
neous iodine uptake. For nontoxic goiter, this is not self-evident. In particular,
estimation of actual functioning volume is hampered by physical difficulties,
especially the classic problems of contour detection in the presence of high
background activity and the effects of finite spatial resolution. Possibly SPECT or
PET (using 124I-NaI) measurements are more accurate for dosage calculation pur-
poses than planar scintigraphy.24-26 This needs to be confirmed by larger stu-
dies.
In a scintigraphic study of largely varying thyroid sizes and conditions,
Himanka and Larsson found that the area of the frontal projection was the sole
variable determining thyroid volume.11 This study confirms that their surface
method (Vsurf) is more accurate than the cylinder method (Vcyl) but only in
thyroid gland volumes smaller than 200 ml. For volumes greater than 200 ml,
the mse was relatively large both for Vsurf and Vcyl, indicating that scintigraphic
volume measurements are unreliable in larger thyroids. In this subgroup, CT is
recommended for therapeutic 131I dosage calculations.
3.5 Conclusion
Radioiodine is a safe and effective treatment for volume reduction of nontoxic
goiters, leading to a mean volume reduction of 34% ± 17% as measured by CT.
For scintigraphic thyroid volume estimation, the surface method (Vsurf) is to be
preferred in glands smaller than 200 ml.
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Summary
A single-center prospective follow-up study was conducted to assess the inci-
dence of hypothyroidism, euthyroidism, and recurrent hyperthyroidism follow-
ing a standard dose of 131I-NaI per gram thyroid tissue, adjusted for radioiodine
tracer uptake.
Newly diagnosed patients with Graves’ disease (n = 148) received radioiodine
treatment at a standard dose of 3.7 MBq (100 µCi) per gram thyroid tissue.
Confidence interval testing was done of the resulting thyroid status, defined by
biochemical criteria.
The overall cure rate was 70% (103 of 148 subjects), 95% confidence inter-
val 62-77%. A 90% incidence of hypothyroidism was found in patients with a
small thyroid (less than 20 grams). Recurrent hyperthyroidism was found sig-
nificantly more often in subjects with a thyroid weight exceeding 60 grams
compared to those who had a thyroid of 9-59 grams. More recurrences were
found in subjects in the highest tertile of a 24-h radioiodine uptake test (> 80%
uptake) compared to those in the lowest tertile (< 60% uptake).
No uniform treatment results expressed per thyroid weight category were
obtained, in spite of standardizing the treatment 131I-NaI dose (3.7 MBq per
gram thyroid). Graves’ disease patients with a thyroid smaller than 20 grams
and those with less than 60% 24-h radioiodine uptake have a 50-90% chance of
hypothyroidism at the 12-month follow-up.
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4.1 Introduction
Graves’ disease is an autoimmune disease characterized by a course of remission
and relapse. The hyperfunctioning of the thyroid is initiated by stimulatory
autoantibodies directed to the thyrotropin (TSH) receptor protein on thyrocytes.1,2
Graves’ disease is more common in young adults (15-35 years) with an esti-
mated incidence of between two and five cases per 1000 and is 4 times more
frequent in women.3 Three not entirely satisfactory therapeutic options exist:
thionamide drug therapy, subtotal thyroidectomy and radioiodine.4-7
Analysis of prospective studies and follow-up studies in the UK and European
countries2,8-10 have shown that drug treatment results in euthyroidism in 50 ± 7%
of cases, 12 months after therapy.10 In areas where the diet contains efficient
iodine like the USA,11 to 54% of cases are still euthyroid 1 year after drug treat-
ment [reviewed in 2, 10-12]. Subtotal thyroidectomy is an immediate and effec-
tive form of treatment; however, it is associated with direct complications such
as hypoparathyroidism, laryngeal nerve palsy, bleeding and infections.8,13 Radio-
iodine has been recommended as the best option with which to treat patients
with Graves’ disease because of its ease, low cost and low rate of serious compli-
cations.5-7,14,15 The principle of radioiodine treatment is based on the unique
ability of the thyroid follicular cells to trap and organify iodine.16,17 After intra-
cellular uptake, radioiodine causes sterilization and destruction of a number of
these cells; the effect is to a large extent dependent on the dose of 131I radiation
absorbed.14,18 The accumulated incidence of late hypothyroidism after radio-
iodine treatment is 40-70%,6,7,14,18,19 whilst late hypothyroidism is found in 20-
40% of cases with Graves’ disease who had surgery.7,14 However, no exact math-
ematical relationship has been found between 131I dose and the appearance of
hypothyroidism [reviewed in 6, 7], as this also depends on the autoimmune
nature of the disease or the effectiveness of a given 131I dose to prevent a recur-
rence.5,6,16,19 For instance, administration of 50 µCi (1.85 MBq) per g thyroid
weight has been considered to be too low a dose because of the unacceptably
high relapse rate of 54% after 1 year of follow-up,20 whereas 150 µCi (5.55 MBq)
per g thyroid has been associated with a high incidence of hypothyroidism.6,7
The present report evaluates the short-term outcome of an intermediate dose of
radioiodine therapy in Dutch patients with Graves’ disease in a prospective fol-
low-up study. Radioiodine was administered in a moderate dose of 3.7 MBq (=
100 µCi) 131I per g thyroid tissue, after adjusting for 24-h radioiodine uptake.
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4.2 Patients and methods
Patients
A follow-up study was conducted on 207 subjects who had radioiodine treat-
ment for newly diagnosed Graves’ disease between January 1990 and December
1992 at the Academic Hospital Utrecht, The Netherlands. Criteria for Graves’
disease were as follows: (i) signs and symptoms of thyrotoxicosis with elevated
plasma concentrations of thyroid hormones and a suppressed TSH (< 0.1 mU/l);
(ii) a diffuse goiter by palpation; (iii) anti-thyroid peroxidase antibodies in a
titer greater than 1:100; (iv) increased 24-h 131I uptake (normal range < 30%) in
combination with a homogeneous 131I uptake on thyroid scintigraphy; and (v)
if present, endocrine ophthalmopathy.1-3
Questionnaires were mailed to referring internists with the request for data
on patients treated before June 1992 regarding clinical outcome and thyroid
status, as determined from plasma concentrations of levothyroxine (LT4), T4 up-
take, free T4 index (FTI), TSH and T3. Data on medication (antithyroid drugs or T4
supplementation) as well as duration of treatment were also supplied. Individual
values of 5-h and 24-h thyroid radioiodine uptake and the thyroid weight esti-
mation had already been determined before the 131I-NaI (Benelux Isotope Ser-
vice, Baarle-Nassau, The Netherlands) treatment. All patients used antithyroid
drugs (ATD) in combination with LT4 (usually 100 µg/day) before therapy.21 All
thyroid medication was stopped at least 72 h before uptake measurements and
administration of the therapeutic dose 131I-NaI. After radioiodine therapy, 73
subjects remained untreated, and 75 subjects had resumed their medication 48 h
after radioiodine administration, for a period of 3 months. The decision to treat
with ATD after radioiodine was made by the referring internist. In 59 subjects,
data collection remained incomplete and these patients were not included in
this report. Age and gender distribution in these 59 subjects was identical (48
women, 11 men; 45.7 ± 12.1 years) to the group of 148 subjects reported here,
that consisted of 121 women (44.8 ± 14.6 years) and 27 men (43.7 ± 16.1 years).
To evaluate the effect of radioiodine therapy on thyroid status, the follow-
ing definitions were used. Patients were considered euthyroid when 3 months
after the radioiodine therapy no medication had been used for at least 4 weeks,
in combination with normal plasma concentrations of TSH (0.3 to 5.0 mU/l), T4
(70 to 160 nmol/l) and T3 (1.0 to 3.0 nmol/l). Recurrent hyperthyroidism was
defined by the presence of plasma concentrations of TSH < 0.1 mU/ml, T4 > 170
nmol/l and/or T3 > 3.5 nmol/l in combination with clinical symptoms of thyro-
toxicosis, necessitating reinstitution of ATD treatment [either PTU (propylthiou-
racil), MMI (methimazole) or CMI (carbimazole)]. Hypothyroidism was defined
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by plasma concentrations of TSH > 8 mU/ml and T4 < 60 nmol/l or T3 < 0.8
nmol/l in untreated subjects, at least 3 months after radioiodine. Subjects who
received de novo LT4 treatment after radioiodine were also classified as hypothy-
roid. Patients visited their physician 2 to 3 times during the first 4 months after
radioiodine treatment and biochemical tests were done at each visit.
Radioiodine therapy
Calculation of the therapeutic 131I-NaI dose included corrections for thyroid
weight and 24-h radioiodine uptake, according to the formula:
D = W × (100/U) × C,
where D is the 131I dose (in MBq) to be administered, W represents thyroid
gland weight (in g), U equals the 24-h 131I uptake (%), and C equals 3.7 MBq/g.
The average dose given in this study is 4.7 ± 3.3 mCi or 173 ± 111 MBq. The 5-h
and 24-h 131I-NaI uptakes were measured following ingestion of 0.37 MBq 131I-
NaI tracer (Canberra 7350-PE collimator with 2×2 inch NaI crystal). The collima-
tor crystal was centered for 4 min at the trachea or at the 131I-NaI standard
placed in a neck phantom at a distance of 25 cm. Thyroid uptake is calculated
using the formula:
131I uptake =
neck counts – background counts
standard counts – background counts
× 100%
The background count was measured in the room for 4 min.
Thyroid weight was estimated from the scintigraphic image by applying
the cylinder formula for each lobe:
V = L (0.5 W)2 × pi,
where V represents the volume of each lobe, L is length in cm, and W is width in
cm. Thyroid volume was assumed to represent thyroid weight (1 ml equals 1 g).
Normal thyroid weight in adults is 20 g.23 Thyroid scintigraphy was performed
after intravenous administration of 80 MBq technetium-99m-pertechnetate us-
ing an Elscint 409 round-field gamma camera equipped with a low-energy, high-
resolution, parallel-hole collimator.
Other methods
Both T4 and T3 plasma concentrations were determined by fluorescent polariza-
tion immunoassays (Abbot Diagnostics, Chicago, IL, USA).24,25 The FTI is the prod-
uct of total T4 and resin uptake (RU): FTI = T4 × RU. TSH (normal 0.3-5.0 mU/l) was
measured by immuno-enzymometric assay (Boehringer Mannheim, Mannheim,
66
Chapter Four
 T
ab
le
 4
.1
O
ut
co
m
e 
in
 r
el
at
io
n 
to
 t
hy
ro
id
 w
ei
gh
t 
fo
llo
w
in
g 
13
1 I
-N
aI
 t
he
ra
p
y.
re
cu
rr
en
t
su
bj
ec
ts
hy
p
er
th
yr
oi
di
sm
eu
th
yr
oi
di
sm
hy
p
ot
hy
ro
id
is
m
cu
re
 r
at
e+
th
yr
oi
d 
w
ei
gh
t#
(n
)
[n
 (
%
)]
[n
 (
%
)]
[n
 (
%
)]
(%
)
  9
-1
9
13
1 
(8
%
)
0 
(0
%
)
12
 (
92
%
)*
92
%
*
20
-2
9
24
5 
(2
1%
)
11
 (
46
%
)
8 
(3
3%
)
79
%
30
-3
9
37
11
 (
30
%
)
13
 (
35
%
)
13
 (
35
%
)
70
%
40
-4
9
26
9 
(3
5%
)
9 
(3
5%
)
8 
(3
0%
)
65
%
50
-5
9
16
3 
(1
9%
)
6 
(3
7%
)
7 
(4
4%
)
81
%
co
m
bi
ne
d 
9-
59
 g
11
6
29
 (
25
%
)
39
 (
34
%
)
48
 (
41
%
)
75
%
95
%
 c
on
fid
en
ce
 in
te
rv
al
16
.9
-3
4.
7%
*
24
.7
-4
4.
2%
31
.2
-5
1.
3%
65
.3
-8
3.
1%
co
m
bi
ne
d 
60
-1
50
 g
32
16
 (
50
%
)
7 
(2
2%
)
9 
(2
8%
)*
50
%
*
95
%
 c
on
fid
en
ce
 in
te
rv
al
37
.4
-7
4.
5%
*
12
.3
-4
5.
9
14
.7
-4
9.
4
37
.4
-7
4.
5
to
ta
l o
ut
co
m
e
14
8
45
 (
30
%
)
46
 (
31
%
)
57
 (
39
%
)
70
%
95
%
 c
on
fid
en
ce
 in
te
rv
al
22
.8
-3
8.
0%
23
.4
-4
1.
5%
30
.9
-4
6.
5%
62
.0
-7
7.
2%
* 
P<
 0
.0
5 
ve
rs
us
 c
or
re
sp
on
di
ng
 c
at
eg
or
y.
#  
Th
yr
oi
d 
w
ei
gh
t 
w
as
 e
st
im
at
ed
 fr
om
 t
he
 t
hy
ro
id
 s
ci
nt
ig
ra
p
hi
c 
im
ag
e 
(s
ee
 P
at
ie
nt
s 
an
d 
m
et
ho
ds
).
+  
Th
e 
‘c
ur
e 
ra
te
’ i
s 
de
fin
ed
 a
s 
th
e 
nu
m
be
r 
of
 h
yp
ot
hy
ro
id
 p
lu
s 
eu
th
yr
oi
d 
su
bj
ec
ts
 d
iv
id
ed
 b
y 
th
e 
to
ta
l n
um
be
r 
of
 a
ll 
p
at
ie
nt
s 
tr
ea
te
d.
Standardized radioiodine therapy in Graves’ disease
67
Germany).24,25 Autoantibodies to thyroid peroxidase were determined by a com-
mercial kit (FujiZoki, Tokyo, Japan). Statistical analysis was performed using
confidence interval (C.I.) testing.26 Subjects were divided into tertiles according
to their 24-h radioiodine uptake values or into categories of thyroid weight.
Student’s t-tests or ANOVA were used to compare variables (SPSS/PC + version 5.0).
Data are reported as 95% C.I. or as mean ± sd. The two-sided level of signifi-
cance was P < 0.05.
4.3 Results
Of the 148 patients with Graves’ disease, 46 patients remained euthyroid (31%;
38 women and 8 men), 57 patients became hypothyroid (39%; 47 women and
10 men), and recurrent hyperthyroidism was observed in 45 patients (30%; 36
women and 9 men) (table 4.1). The follow-up was for 12 ± 6 months.
Thyroid weight and outcome
Hypothyroidism developed in 12 of 13 patients with a thyroid weight under 20
g (92%; C.I. 76.8-99.8%). By contrast, recurrent hyperthyroidism was observed
in 50% of the subjects with a thyroid weight exceeding 60 g (i.e. three times
enlarged). This is a significantly higher incidence compared with the group of
subjects who had a thyroid weight under 60 g (P < 0.05; table 4.1). In subjects
with thyroid weights exceeding 110 g, recurrent hyperthyroidism was found in
7 of the 9 individuals.
In general, thyroid weight was significantly higher in patients who relapsed
(57.6 ± 35.9 g) compared to subjects who became hypothyroid (38.9 ± 23.0 g;
P < 0.01) or remained euthyroid (44.8 ± 27.5 g; P < 0.05).
24-h 131I uptake and outcome
Subjects were divided into tertiles of 24-h radioiodine uptake (figure 4.1). Indi-
viduals with a 24-h radioiodine uptake value under 60% showed significantly
more hypothyroidism (30 of 56 subjects, or 54%; C.I. 40-66%) than relapse (n =
12, 21%; C.I. 14-40%; P < 0.05). To this group of 56 subjects belonged the 12
subjects with a thyroid weight under 20 g. By contrast, patients with a 24-h
iodine uptake exceeding 80% had a lower incidence of hypothyroidism (14%;
C.I. 2.5-31.2%; P < 0.05) and a higher relapse rate (59%; C.I. 31.3-72.2%; P <
0.05). Only 10 of 22 subjects with uptake values exceeding 80% had a thyroid
weight exceeding 60 g. No linear relationship was present between 24-h uptake
and gland weight, and therefore a high thyroid weight (> 60 g) did not necessa-
rily imply a high 24-h uptake (figure 4.2).
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In general terms, radioiodine uptake was significantly higher in patients
who suffered a relapse compared with subjects who became hypothyroid. The
average 24-h uptake in all 148 subjects with Graves’ disease was 64.8 ± 14.5%
(normal range, < 30%). Subjects who relapsed had an average 24-h uptake of
70.4 ± 15.3% (P < 0.001 versus the hypothyroid group: 60.7 ± 12.4%).
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Figure 4.1 Relation between 24-h radioiodine uptake values and thyroid status following
radioiodine therapy (3.7 MBq per g thyroid). *: P < 0.01 versus euthyroid and hyperthyroid
subjects in this category; #: P < 0.01 versus proportion of hypothyroid subjects in category
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Outcome and other variables
No differences in short-term outcome were observed between male and female
patients. Hypothyroidism developed in 37 subjects within 6 months and in 20
subjects within 7 months after therapy; no new cases developed during 12 months
follow-up. Twenty-six patients had a recurrence within 3 months, 13 patients
relapsed between 7 and 9 months after radioiodine, and 6 patients relapsed
within 10 months. No differences in clinical outcome were found between the
75 patients who resumed ATD medication plus levothyroxine immediately after
radioiodine (23 subjects remained euthyroid, 24 relapsed and 28 became hy-
pothyroid) and the 73 subjects who used no ATD after radioiodine (23 remained
euthyroid, 21 relapsed and 29 became hypothyroid). Also, no significant differ-
ences were found with regard to age: 45.3 ± 15.8 years in the hypothyroid group,
46.0 ± 14.8 years in the euthyroid group, and 42.7 ± 12.4 years in the hyperthy-
roid group. No patient older than 70 years (n = 7) suffered a relapse.
4.4 Discussion
Administration of a standard dose of 3.7 MBq 131I per g thyroid tissue, adjusted
for 24-h radioiodine uptake, did not yield uniform treatment results when ex-
pressed per thyroid weight category. The present study showed a 90% incidence
of hypothyroidism within 3 months of follow-up in patients who had a small
thyroid gland of less than 20 g. The cure rate is conventionally defined as the
number of hypothyroid plus euthyroid subjects. The highest cure rate (75%;
C.I. 65-83%) was obtained in the thyroid weight range of 9-59 gram. Signifi-
cantly lower success rates were found in subjects with a thyroid greater than 60
g and in subjects with a higher than 80% radioiodine uptake, the latter with a
41% cure rate. The overall cure rate in the present study was 70% (C.I. 60-78%)
which is significantly better (P < 0.01) than the cure rate (49.8 ± 7.0%) calcu-
lated by meta-analysis in 10 prospective studies on ATD treatment conducted
between 1975 and 1991 and comprising a total of 937 patients with Graves’
disease.10,21
Variability in the effectiveness of radioiodine in Graves’ disease is related to
factors that influence the biological half-life of 131I and therefore the actual
radiation effect on the thyroid, and to clinical factors.17,22,27-29 Factors that de-
termine the actual radiation effect of 131I are thyroid size, 24-h radioiodine up-
take (representing the avidity of the thyroid for iodine), the effective half-life of
131I in the thyroid gland [estimated at 5.4 days in ref. 28]. Clinical factors in-
clude ATD treatment that affects the biological half-life of iodine.22,27,28 In prac-
tice, it is time-consuming to determine the 131I biological half-life in individual
70
Chapter Four
patients because it requires several visits prior to definite radioiodine treat-
ment.27,28 The approach taken in this study used a standardized ‘µCi/g’ method
based on calculations of thyroid volume and radioiodine uptake. These calcula-
tions may have suffered from inherent variability as a result of inaccuracy (which
may be as high as 6-20%) in the estimate of thyroid size.22,23 However, thyroid
volumes estimated by magnetic resonance imaging correlated well with esti-
mates derived from planar thyroid scintiscanning (R = 0.94; n = 20),30 and we
ourselves found a good correlation between CT scanning estimates and scintig-
raphy in the range up to 175 ml (R = 0.97; n = 13) (see Chapter Three). These
recent data suggest that variability in estimates of thyroid size may not be a
sufficient explanation of the variability in outcome observed in different thy-
roid weight categories. With respect to the potential variability introduced by
ATD treatment, a higher incidence of relapse in ATD users after radioiodine treat-
ment has been reported28 as well as a reduction in short-term hypothyroi-
dism.19,28,29 However, all patients in the present study used ATD and LT4 prior to
radioiodine therapy, and absence or presence of ATD treatment after radioiodine
did not correlate with therapy outcome. The explanation for this discrepancy
must be the fact that our patients received the combination of ATD treatment
and LT4 substitution instead of a titrated dose of ATD.
The reduced effectiveness of radioiodine in larger Graves’ thyroids is in
agreement with observations that neither a lower standard radioiodine dose per
gram tissue,6,19 nor a higher standard dose,6 nor compensation factors for thy-
roid weight20 could correct the relationship between rate of recurrence and thy-
roid weight. The presence of autonomous tissue with functional differences in
uptake and organification of iodine may be an additional explanation for the
fact that larger Graves’ thyroids are less 131I sensitive (figure 4.2),8,9,31,32 similar
to observations in multinodular goitre.18,31 Recurrent hyperthyroidism after treat-
ment is usually caused by autonomous production of thyroid hormones in au-
tonomously functioning areas,2,31,32 or alternatively by increased stimulation of
thyrocytes by TSH receptor antibodies.2,10 However, measurement of TSH receptor
antibodies has not accurately predicted recurrences after ATD treatment,2,8-10
although the risk of relapse was significantly reduced by 65% in the absence of
TSH receptor antibodies.10 It has been suggested that some remissions are related
to depletion of the thyroid iodine pool after ATD.2,22,27 On the other hand, some
of the relapses have been related to the development of autonomous function-
ing tissue in large Graves’ thyroids.33 Thyroid nodules can be found in 5-15 % of
patients with Graves’ disease, which is at least a twofold increase compared to
the normal population. Thyroid nodules and neoplasms in Graves’ disease pre-
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sumably result from the development of autonomous follicles in the course of
this disease and do not result from 131I treatment.6,7,15,34-36
Important recent data show that radioiodine treatment causes no increased
risk of cancer in patients with Graves’ disease after a follow-up of 15 to 28 years.15
Radioiodine treatment may cause an exacerbation of already present endocrine
ophthalmopathy,37 and preventive measures have to be considered in patients
at risk.38,39 Prevention of recurrent hyperthyroidism in Graves’ disease is not
only the goal of immediate therapy but can be regarded as a potential method
with which to reduce the observed excess long-term mortality,15,40 which ap-
pears to depend on the severity of the hyperthyroid state.40 The present data
and current literature suggest several strategies to reach such an objective. In
the thyroid weight range of 9-60 g, a satisfactory cure rate of 75% has been
consistently observed.7,14,20 Improvements can therefore be expected in the treat-
ment of patients with large thyroids by increasing the dose of radioiodine in
subjects who have high (> 80%) 24-h uptake values.6,7 Subtotal thyroidectomy
is a second-choice option in patients with Graves’ disease who have a large
thyroid (> 60 g).
In conclusion, treatment of patients with Graves’ disease with 131I-NaI, stand-
ardized to 3.7 MBq per g thyroid weight and corrected for 24-h radioiodine
uptake, revealed persistent significant differences in outcome per thyroid weight
category. Graves’ disease patients with a thyroid of less than 20 g and those with
a 24-h radioiodine uptake less than 60% have a 50-90% chance of hypothyroidism
at 12 months of follow-up. In the thyroid weight range of 9-60 g, a satisfactory
cure rate of 75% was observed. Aiming for improvement in the outcome in
Graves’ disease patients with large thyroids is a challenge because of the govern-
ing principle of radioiodine therapy to keep the administered dose as low as
reasonably achievable.15
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Summary
From a Dutch questionnaire, it was apparent that nearly all institutions used
the percentage of radioiodine uptake for the radioiodine dosage calculation in
Graves’ disease. Although there is a general belief that fluctuations in radioiodine
uptake might occur, with few exceptions relatively long intervals were accepted
between the uptake measurement and the actual therapy dosage. With the aim
of optimizing the pretherapeutic work up, we evaluated the stability of iodine
uptake over time in patients with Graves’ disease who were referred for 131I
therapy.
131I uptake was measured in 300 consecutive patients for the calculation of
the required 131I therapy dosage; data were complete in 291 patients (97%).
After discontinuing thyroid medication for 3 days, standardized thyroid probe
measurements were performed at 5 and 24 h after ingestion of a capsule con-
taining 0.37 MBq 131I-NaI. Measurements were performed at the time of scinti-
graphic diagnosis (test 1), as well as immediately before 131I therapy (test 2). The
time interval between test 1 and test 2 ranged from 2 to 421 (median 40) days.
A relative increase or decrease greater than 10% between tests 1 and 2 oc-
curred in 180/291 cases (62%) at 5 h, and in 158/291 patients (54%) at 24 h.
These changes were not related to the interval between the tests, or to initial
uptake values, thyroid mass, gender, or age. Rapid turnover of radioiodine (5/24-h
uptake ratio >1) was present in 17% of the patients during test 1 and in 15%
during test 2. Rapid turnover was persistent (present in both tests 1 and 2) in
only 9%.
Patients with Graves’ disease show considerable changes in 131I uptake over
relatively short periods of time, and the turnover rate of 131I in this condition is
not constant.
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5.1 Introduction
In Europe, patients with clinical and biochemical evidence of hyperthyroidism
due to Graves’ disease are usually treated with antithyroid medication, typically
for 1-1.5 years. Up to 50% of all patients become euthyroid after discontinuing
this medication. In patients with persisting or recurrent hyperthyroidism, little
benefit can be expected from re-initiating antithyroid medication.1 Definitive
treatment may then be achieved either by subtotal thyroidectomy or by radio-
iodine (131I) therapy. 131I is recognized as the simplest, safest, cheapest and most
convenient form of therapy for patients with persisting hyperthyroidism.2-4
In the treatment of Graves’ hyperthyroidism there is no general agreement
on the 131I dosage or even the therapy objective.5 Many clinicians favor a large
131I dosage with the aim of inducing hypothyroidism, which is then treated by
permanent levothyroxine replacement therapy.6,7 Others consider it undesir-
able to replace one disease by another irreversible disease.8,9
Alternative options include the ‘fixed dosage’ regimen (with or without
modifying factors for thyroid volume, iodine turnover rate, age and gender),10
and the so-called becquerel-per-gram method.2 With the latter method, the thera-
peutic 131I dosage is calculated as a fixed dosage per gram functioning thyroid
tissue, usually 3.7 MBq/g (100 µCi/g). The dosage calculation is given by the
formula:
D = W × (100/U) × 3.7  MBq,
(where D is the 131I dosage in MBq, W is the thyroid weight in grams, and U is
the 24-h radioiodine uptake in %);2 reliable information is required regarding
thyroid volume and 131I uptake. Useful estimations of the thyroid weight can be
made from planar scintigraphy;11,12 radioiodine uptake is measured with a tracer
amount of 131I and a scintillation probe.13 In most euthyroid people with a
sufficient iodine supply the maximum radioiodine uptake is reached between
24 and 48 h. In hyperthyroid patients, radioiodine uptake may reach a peak
sooner than 24 h, and it is recommended that uptake is measured at a relatively
early stage (4-6 h) as well as at 24 h.14 If the 5/24-h uptake ratio is > 1 this is
defined as ‘rapid iodine turnover’.15  Rapid turnover implies a short effective
half-life (Teff) of 131I and a diminished therapeutic effect. Under these circum-
stances, increased therapeutic 131I dosages are advocated to reduce the risk of
recurrent disease.15
Most authors in their methodological descriptions of uptake measurements
state the time after ingestion of the tracer dose, but not the time interval be-
tween the uptake test and the actual therapy dosage; however, there are excep-
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tions.16 Recommendations for performing the radioiodine uptake test are often
solely directed towards technical quality assurance of the thyroid probe. Only
very recently, the North-American and the German Societies of Nuclear Medi-
cine have addressed the issue of the timing of uptake measurements, but with-
out substantiating literature references.17,18
5.2 Dutch radioiodine therapy survey
In The Netherlands and at least five other European countries (Germany, Aus-
tria, Hungary, the Czech Republic and Slovakia) all or most patients have to be
Table 5.1 Results of the Dutch radioiodine therapy survey.
n % days
number of nuclear medicine departments 70
respondents to the questionnaire 70 100
number of nuclear medicine departments
with 131I therapy facilities 32 45.7
number of radioiodine treatments in 1998
for Graves’ disease 40 85
131I uptake tests used for dosage calculation?
yes (departments) 29 90.6
(all patients) 3910 95.7
no (departments) 3 9.4
(all patients) 175 4.3
interval between 24 h 131I uptake test and treatment
typical (i.e., effectively done in most patients)
mean (departments) 7.1
(all patients) 9.8
range 0-60
minimum observed
mean (departments) 4.2
(all patients) 4.5
range 0-14
maximum observed
mean (departments) 75.5
(all patients) 88.4
range 0-730
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hospitalized for 131I treatment.19 At our department, owing to fluctuations in
the waiting list and patients’ preferences, the interval between the diagnostic
test and the admission for the radioiodine therapy typically varied from 2 days
to just over 1 month. We have conducted a survey of the practice of radioiodine
uptake measurements for the calculation of therapeutic 131I dosages in The Neth-
erlands. The response to the questionnaire was 100% (for results see table 5.1).
The general conclusions that can be drawn from the Dutch questionnaire are:
(i) at most nuclear medicine departments, the intention is to treat patients within
4-8 days after the 24-h uptake measurement; (ii) most patients, however, receive
the therapeutic radioiodine dosage about 10 days after the uptake measurement;
(iii) 56% of all departments regard an interval of 1-4 weeks between uptake
measurement and therapy dosage to be acceptable; one-third accept intervals of
1-24 months; (iv) in only one department is a same-day protocol for 24-h up-
take measurements and therapy dosage administration maintained.
In clinical practice, there appears to be a considerable time interval be-
tween the 24-h 131I uptake measurement and actual therapy.
The main aim of the present study was to define if, and to what extent, changes
in 5 and 24-h 131I uptake values occur over time in patients with Graves’ disease.
A secondary aim was to assess changes in the radioiodine turnover rate
over the same time intervals in the same patients. The study was approved by
the hospital’s ethics review board.
5.3 Patients and methods
Patients
Three-hundred consecutive patients with Graves’ disease were enrolled in the
study, all of whom had been referred for radioiodine therapy. All suffered from
recurrent hyperthyroidism (TSH levels < 0.10 mU/l after 1-1.5 years of antithy-
roid drug medication in combination with thyroxine. Criteria for Graves’ dis-
ease were: (i) signs and symptoms of thyrotoxicosis with elevated plasma con-
centrations of thyroid hormones and a suppressed TSH (< 0.1 mU/l); (ii) a diffuse
goiter upon palpation; (iii) increased 24-h 131I uptake in combination with ho-
mogeneous 99mTc-pertechnetate uptake on scintigraphy; (iv) (if available) an-
tithyroid peroxidase antibodies in a titer greater than 1:100; and (v) (if present)
endocrine ophthalmopathy.20-22 At the time of the 131I therapy all patients were
clinically euthyroid.
In 291 patients (242 females, 49 males) the follow-up data were complete.
The age of the females and males was comparable (females: 46.5 ± 15.9 year,
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median 44.8 year; males: 47.7 ± 15.4 year, median 49.1 year). Thyroid weight
ranged from 10 to 190 g (47 ± 31 g, mean ± sd).
Uptake measurements (‘test 1’)
Before all measurements, thyroid medication had been discontinued for 3 days.
Care was taken that no iodine containing drugs (e.g., amiodarone, kelp) had
been ingested and that no radiographic contrast agents had been administered
in the 3 months before uptake measurement. On the first day, patients were
allowed a light breakfast. Thyroid uptake measurements were carried out in a
standardized manner.13 The 131I uptake (‘test 1’) was measured 5 and 24 h after
ingestion of a capsule containing a tracer dose of 0.37 MBq 131I-NaI (Mallinckrodt
Medical B.V., Petten, The Netherlands). A scintillation probe (Canberra 7350-PE
collimator with a 2×2" NaI crystal) was positioned at the site of the patient’s
thyroid area for 4 minutes, at a fixed distance of 25 cm. For the purpose of
background (BKG) correction, the probe was then positioned at the patient’s
thigh, also for 4 minutes and at the same distance. After correction for BKG, the
activity (counts per minute, cpm) over the thyroid region was compared with
the activity (cpm) measured from a standard containing 0.37 MBq 131I, placed
in an anthropomorphic perspex thyroid/neck phantom, after correction for room
BKG activity. The percent 131I uptake (U) by the thyroid is:
U = [(cpmneck – cpmthigh)/ (cpmstandard – cpmroom BKG)] × 100%.
Quality assurance and regular quality controls were performed: energy peak cali-
bration of the scintillation probe was performed before use each day and energy
resolution tests were performed annually.23
Follow-up measurements (‘test 2’)
5 and 24-h 131I uptake measurements were repeated shortly before 131I therapy
(‘test 2’), using the same procedure and with the same precautions as for test 1.
The therapeutic capsule was administered 48 h after the diagnostic capsule (i.e.
one day after the 24-h uptake measurement). The interval between test 1 and
test 2 ranged from 2 to 421 days, with a mean (± sd) of 52.3 ± 24.8, and a median
of 40.0 days. In most cases (185 patients, 64%) it was between 21 and 60 days, in
40 cases (14%), it was less than 3 weeks.
We investigated changes in 5 and 24-h 131I uptake values and changes in
turnover state (normal or rapid) between the two tests. Statistical analysis was
performed of the 131I uptake changes in relation to the time interval between
the first and the second test, the initial uptake values, the patients’ thyroid
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weight, gender and age. We also assessed the influence of the time of year on
the measurements, in view of potential seasonal variations in the dietary iodine
intake. The 131I uptake values from ‘test 2’ were treated as the reference data or
true values, since they were the closest possible approximation of the biological
state of the thyroid at the time of treatment.
The precision of the 131I content of the therapy capsules, if ordered one day
before use, is 10%. Therefore only differences in 5 or 24-h 131I uptake greater
than 10% were considered to be relevant with regard to therapy dosage adjust-
ment. The choice of the 10% level was supported by (i) the good reproducibility
of the uptake measurements (see paragraph Reproducibility), and (ii) the high
precision with regard to the 131I content of the diagnostic capsules (see para-
graph Product specifications of 131I capsules).
Changes from normal to rapid 131I turnover rate, or vice versa, were also
considered to be relevant for dosage calculation purposes, because rapid iodine
turnover warrants a larger therapeutic dosage.15
Reproducibility
The reproducibility of thyroid uptake measurements in 20 patients was assessed
by three nuclear medicine technologists. The coefficient of variance (%CV) for
the measurements was 1.79% for thyroid and background, and 1.00% for the
131I standard in a neck phantom. The overall precision of the uptake measure-
ment was:
1.79 2 + 1.00 2  = 2.06%.
Product specifications of 131I capsules
In the formulation that we used, the 131I is carrier-free. Radionuclide purity ≥
99.9% and radiochemical purity ≥ 95% are guaranteed (Mallinckrodt Medical
International Catalogue). The 131I diagnostic capsules and the 131I standard are
delivered in one batch. As stated by the manufacturer, the coefficient of vari-
ance (%CV) between capsules from the same batch is not more than 1.0%. This
was confirmed by spot checks.
Measurements of functioning thyroid volume
All thyroid volume estimates have been derived from standard planar thyroid
scintigraphy and dedicated software. Fifteen minutes after the intravenous ad-
ministration of 80 MBq 99mTc-pertechnetate a 2-min anterior view (256×256
matrix) of the thyroid was made on an Elscint 409 round-field-of-view gamma
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camera, equipped with a low-energy, all-purpose collimator. A rectangular re-
gion of interest (ROI) was outlined, so that it contained the entire thyroid gland
and excluded the salivary glands. This ROI typically contained about 100 kcnts.
Within the thyroid, a small rectangular ROI (size 5×8 pixels) was outlined over
the area of the thyroid with the highest radioactivity content per pixel. The
value representing 30% of the average count density in this ROI was taken as a
threshold for automatic thyroid contour delineation. The area within the con-
tour was then converted from pixels to square centimeters. For the calculation
of the functioning thyroid volume (V) we used the surface area (A) formula as
described earlier by Himanka and Larson:24
V = 0.33 × A3/2.
In a different group of patients (with nontoxic goiter) we found that this for-
mula had a good precision for measurement of thyroid volumes up to 200 ml.25
Biochemical parameters
Patients who were referred from within our own hospital had documented posi-
tive antithyroid peroxidase antibodies at the time of diagnosis. Antibodies had
not been assessed in most patients referred from other hospitals. Therefore we
did not analyze antibody titers versus the stability of radioiodine uptake. Serum
T3, FT4 and TSH levels were not included in the analysis either, because the avail-
ability of biochemical data from the thirteen referring sites at specific times
before and after 131I treatment varied widely.
Statistical analysis
Statistical analysis was performed with the SYSTAT® 5.0 program (SYSTAT Inc.,
Evanston, IL). The agreement between the two sets of test results was assessed
with the method described by Sheiner and Beal.26 The precision (expressed as
the root mean squared error, rmse) is a measure for the correctness of test 1 as an
‘outcome predictor’ of test 2 in individual cases. The method of Sheiner and
Beal gives a description of systematic components of any errors in test 1 com-
pared with test 2 in the form of the mean prediction error (bias). A parallel
analysis was done with the method of Bland and Altman.27
The correlation coefficient and the paired t-test for test 1 versus test 2 were
used for comparison of the grouped results. Regression analysis was applied to
analyze the correlation of uptake values with gender, age, the time between the
tests, or seasonal influences.
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5.4 Results
5-h uptake
For the group as a whole, the mean, median and range of the 5-h uptake values
remained unchanged from test 1 to test 2. The uptake values from test 1 and test
2 correlated well (R = 0.85, P < 0.01; table 5.2 and figure 5.1a). For individual
patients the 5-h uptake was much less stable: changes > 10% were noted in 62%
of all cases. The observed uptake changes were not related to the duration of the
interval between measurements, the initial uptake value, the patients’ thyroid
weight, gender or age, or seasonal influences (table 5.3 and figure 5.1b). With
regard to the 5-h uptake, the precision of test 1 was poor compared with test 2
(mse = 151.4, rmse = 12.3). Bias (0.83) was negligible (figure 5.1c).
24-h uptake
The mean, median and range of the 24 h uptake values from test 1 and test 2 did
not differ for the group as a whole, and the two test sets correlated well (R =
0.79, P < 0.01, table 5.2 and figure 5.2a). However, individual changes greater
than 10% were noted in 54%. When the 24-h uptake had increased in compari-
son with test 1, this increase averaged 28 ± 18%. In patients with decreased
uptake, the decrease averaged 13 ± 11%. Regression analysis showed no relation
Table 5.2 Summary of the 131I uptake measurement results.
5-h 131I uptake 24-h 131I uptake
test 1 (mean ± sd) 54.2 ± 21.9% 62.6 ± 17.3%
test 2 (mean ± sd) 55.1 ± 22.7% 64.4 ± 18.5%
correlation R = 0.85, P < 0.01 R = 0.79, P < 0.01
number of patients (%) with change >10% 180/291 (62%) 158/291 (54%)
increase
number of patients (%) 100/291 (34%) 97/291 (33%)
relative increase (mean ± sd) 25 ± 14% 28 ± 18%
decrease
number of patients (%) 80/291 (28%) 61/291 (21%)
relative decrease (mean ± sd) 17 ± 13% 13 ± 11%
rmse 12.3 11.8
radioiodine turnover
increased at test 1 50/291 (17%)
increased at test 2 44/291 (15%)
increased at both test 1 and test 2 27/291 (9%)
change from normal to increased or vice versa 40/291 (14%)
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Figure 5.1a 5-h radioiodine uptake: relation between tests 1 and 2;
y = 7.343 + 0.880x; R2 = 0.719.
%
 5
-h
 u
p
ta
ke
 (
te
st
 2
)
% 5-h uptake (test 1)
100
80
60
40
20
0
0 20 40 60 80 100
Figure 5.1b The relative changes in 5-h radioiodine uptake between tests 1 and 2 are
independent of the interval between the tests; y = 6.956 – 0.029x; R2 = 0.002.
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Table 5.3 The observed changes in 131I uptake in relation to other parameters.
5-h uptake changes 24-h uptake changes
interval between measurements R = 0.039; P = 0.50 R = 0.033; P = 0.57
thyroid weight R = 0.042; P = 0.47 R = 0.112; P = 0.06
gender R = 0.005; P = 0.94 R = 0.015; P = 0.80
age R = 0.014; P = 0.81 R = 0.011; P = 0.86
seasonal influences R = 0.017; P = 0.77 R = 0.031; P = 0.60
between the changes observed in 131I uptake and the interval between measure-
ments, the initial uptake value, the patients’ thyroid weight, gender or age, or
seasonal influences (see table 5.3 and figure 5.2b). With regard to the 24-h up-
take, the precision of test 1 compared with test 2 was no better than for the 5-h
uptake (mse = 139.0, rmse = 11.8). Bias (1.75) was again negligible (figure 5.2c).
131I turnover rate
The prevalence of rapid iodine turnover was similar for both tests: in 50 patients
(17%) at the first measurement and in 44 patients (15%) at the second measure-
ment. It was persistent (present in both tests) in only 27 patients (9%). Changes
in iodine turnover state, from normal to rapid or from rapid to normal, were
observed in 40 of 291 patients (14%). These changes were not related to the
initial 5 or 24-h uptake values or to the interval between the two measurements.
Figure 5.1c Difference versus mean for the 5-h-uptake values of test 1 and test 2.
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Figure 5.2a 24-h radioiodine uptake: relation between tests 1 and 2;
y = 11.635 + 0.842x; R2 = 0.622.
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Figure 5.2b The relative changes in 24-h radioiodine uptake between tests 1 and 2 are
independent of the interval between the tests; y = 5.920 + 0.018x; R2 = 0.001.
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Nor were they related to seasonal influences, the patients’ age, gender or thy-
roid weight. The correlation between the turnover rates from the first and the
second test was very poor (R = 0.311, P < 0.01). There was no bias (0.01).
5.5 Discussion
Quantitative approaches towards radioiodine therapy dosing are generally aimed
at reducing the risk of early hypothyroidism. From the first year after radioiodine
therapy, the increase in hypothyroidism progresses at about the same rate (2-4%
per year) regardless of the dosage used. Long-term cure rates are similar to those
with fixed dose protocols.2 Our own experience shows that the rate of hypothy-
roidism depends on thyroid weight and radioiodine uptake at the time of treat-
ment.28
Reasons to strive for euthyroidism were recently reinforced by Bunevicius
et al., who found that an adequate supply of triiodothyronine substantially en-
hances the patients’ well-being.9 It may be argued that the same is true for en-
dogenous T3 production. Not only clinical arguments but also radiation safety
considerations may lead to generally lower radioiodine dosages. Based on the
ALARA principle, an individualized dosage regimen is required by law in Ger-
many and some Eastern European countries.16 The avoidance of an unnecessary
Figure 5.2c Difference versus mean for the 24-h uptake values of test 1 and test 2.
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radiation burden alone is deemed to balance out the extra time burden. Radia-
tion safety can be guaranteed only if optimal dosage calculations are possible.
Optimization of the radioiodine uptake procedure is essential. It follows directly
from the formula that the therapeutic 131I dosage is inversely related to the
percent of 131I uptake.
We have found that in most patients with Graves’ hyperthyroidism the
radioiodine uptake varies greatly over time, even over relatively short periods.
None of the parameters that we analyzed had a significant correlation with the
variations in uptake. We have demonstrated that there is no correlation be-
tween the time between the measurements and the observed uptake changes.
The group results were moderately correlated for the 5 and 24-h uptake
measurements (R2 = 0.72 and 0.62, resp.), and the average uptake values varied
only marginally between the two tests. At an individual level, however, signifi-
cant deviations were found. Relative changes > 10% were seen in 60% of the
patients. A few individuals showed extreme differences. The correctness of test
1 as an ‘outcome predictor’ of test 2, expressed as the precision, appeared to be
unacceptable.
Whereas the prevalence of rapid turnover in our study at each measuring
point (15-17%) was in line with previous research, it was persistent in only 9%
of the patients. In 14%, the turnover rate had either increased or decreased
significantly. This implies that, on the basis of iodine turnover alone, 1 in every
7 patients would have received inappropriate 131I therapy dosages if the uptake
values from test 1 had been used for the dosage calculation.
Factors that may be responsible for variations in radioiodine uptake in-
clude the activity of the immune process itself, stress factors surrounding the
clinical setup, and day-to-day variations in dietary iodine intake. Geographic
variations in the alimentary iodine intake are unlikely, because all patients in
this study live in the same (iodine-sufficient) area in The Netherlands. We have
not been able to investigate the relation between 131I-uptake and serum concen-
trations of T4, FT4, T3, and anti-TSH antibodies. However, the thyroid medication
had been identical in the periods leading up to tests 1 and 2, and in all cases it
had been discontinued 3 days before each of the uptake measurements.
At most institutions in The Netherlands – and elsewhere probably – radio-
iodine treatment takes place several days or even weeks after the radioiodine
uptake test. In view of the intra-individual changes in both 131I uptake and
iodine turnover, this policy might well be responsible for a substantial number
of inappropriate therapeutic dosages calculations. If the becquerel-per-gram
method is used for therapy dosage calculation, it is our belief that 131I-uptake
measurements are best performed as shortly as possible before radioiodine treat-
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ment. In the present study, only a small number of cases experienced an inter-
val of less than 1 week between test and therapy. Therefore, definite conclusions
are not possible at present. The predictive value of the uptake test for the actual
retention of therapeutic dosages is not absolutely certain. Bockisch et al. have
investigated this in patients with various thyroid disorders,29 but the number of
patients with Graves’ disease in their series was limited.
It will be of interest to know whether the proposed adaptation leads to
improved therapy results. Using the adapted protocol in a prospective study, we
are now investigating the clinical outcome of radioiodine therapy in patients
with Graves’ disease.
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Summary
In a previous study of radioiodine therapy in patients with Graves’ hyperthy-
roidism, we established that the clinical outcome was not linearly related to the
radioiodine uptake and to the thyroid volume. Later we demonstrated that the
timing of the uptake measurements influenced the measurement results.
Others had found that the 5/24-h 131I uptake ratio could serve as an alternative
to multiple measurements of the effective half-life.
A re-evaluation of the radioiodine therapy results was made, using a proto-
col in which the uptake measurements immediately preceded the radioiodine
treatment. With other parameters essentially unaltered, the radioiodine therapy
results were compared with the results from the former protocol. The value of
the 5/24-h 131I uptake ratio was also assessed.
The percentage of patients with euthyroid outcome had not changed but a
significant shift had occurred from hypothyroidism to persistent hyperthyroi-
dism. This effect was most pronounced for patients in the low radioiodine up-
take tertile and in patients with small thyroids. The 5/24-h 131I uptake ratio
(mean ± sd) was 0.74 ± 0.16 for patients with a hypothyroid outcome, 0.81 ±
0.17 for patients with a euthyroid outcome, and 0.88 ± 0.16 for patients with
persistent hyperthyroidism.
Because of variations in radioiodine uptake over short periods of time, up-
take measurements directly preceding the radioiodine treatment are recom-
mended. This recommendation has a significant influence on the outcome of
radioiodine therapy. The 5/24-h uptake ratio appears to be a strong predictor of
the radioiodine therapy outcome.
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6.1 Introduction
For radioiodine treatment of Graves’ hyperthyroidism there are roughly two
strategies with regard to dosage calculation, i.e. fixed and individualized schemas.
Each have their own advantages and disadvantages. In several European coun-
tries, primarily for reasons of radiation safety, individualized dosage schemas
are a legal requirement.1 The most widely used is the becquerel-per-gram method,2
necessitating measurements of the radioiodine uptake and of the thyroid vol-
ume.3,4 Despite this additional effort the short-term cure rate is no better than
with fixed dosage schemas.4 In an earlier study of patients with Graves’ disease,
using the becquerel-per-gram method, we obtained a 70% cure rate (31% euthy-
roidism, 39% hypothyroidism) one year after treatment.5 In that study, long
intervals had been allowed between uptake measurements and radioiodine treat-
ment. Later we demonstrated that substantial intraindividual variations in
radioiodine uptake and radioiodine turnover rate occur over relatively short
periods.6 A recommendation to minimize the time between uptake measure-
ments and radioiodine therapy was recently included in the guidelines of the
American Society of Nuclear Medicine,7 and was also mentioned in a textbook
of nuclear medicine.8 It seemed apposite to study the clinical effects of these
recommendations.
A prospective investigation was conducted with a view to studying the ef-
fects of the timing of the radioiodine uptake measurement on the clinical out-
come of radioiodine therapy in patients with Graves’ disease. A protocol main-
taining a 1-day interval between uptake measurements and therapy was com-
pared with the protocol used in a historic control group in which arbitrary in-
tervals had been allowed. The investigation was approved by the hospital’s eth-
ics committee.
6.2 Patients and methods
Patients
A follow-up study was conducted on 204 patients with Graves’ hyperthyroidism
who had been referred for radioiodine therapy by internists from 16 regional
hospital sites. Patients who were referred for retreatment were not accepted for
inclusion in this study. In 17 patients, a double radioiodine dosage was admin-
istered because an increased radioiodine turnover rate had been established at
the first uptake test (see Radioiodine uptake measurements); these patients were
excluded from the analysis. Also excluded were 22 patients who had been lost
to follow-up. A total of 165 evaluable patients remained. The classic criteria for
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Graves’ disease,5 used in the historic control group, were also applied here. All
patients had used antithyroid drugs (ATD) in combination with levothyroxine
(LT4) for 1-1.5 years before radioiodine therapy, and all had had a relapse after
discontinuation of the medication. In all cases, ATD and LT4 were withheld for 3
days before the radioiodine uptake measurements; without exception the pa-
tients were clinically euthyroid at the time of radioiodine treatment. The medi-
cation was not resumed until the fourth day after radioiodine therapy.
Radioiodine uptake measurements
As part of a study of the stability of radioiodine uptake values,6 the 5-h and 24-h
radioiodine uptake measurements had been performed twice: first at the time of
referral for diagnosis (‘test 1’) and second immediately preceding the radioiodine
treatment (‘test 2’). A scintillation probe (Canberra 7350-PE collimator with a
2×2" NaI crystal) was used for the radioiodine uptake measurements. Quality
assurance and regular quality controls of the probe were procured.1,9 The 131I
uptake was measured 5 h and 24 h after ingestion of a capsule containing a
tracer dose of 0.37 MBq 131I-NaI (Mallinckrodt Medical bv, Petten, The Nether-
lands). On the first day patients were allowed a light breakfast only.10 The probe
was positioned at the patient’s thyroid region for 4 min, at a fixed distance of 25
cm. To allow background (BKG) correction, the probe was then positioned at the
patient’s thigh, also for 4 min and at the same distance. After correction for BKG,
the activity in the thyroid was compared with the activity measured from a
standard containing 0.37 MBq 131I, placed in an anthropomorphic perspex thy-
roid/neck phantom, after correction for room BKG that was measured for four
minutes. In terms of percentage the 131I uptake by the thyroid is:
131I uptake = [(cpmneck – cpmthigh)/(cpmstandard – cpmroom BKG)] × 100%.
Thyroid volume measurement
Immediately after the 24-h uptake measurement, an estimation of the thyroid
volume was made from planar thyroid scintigraphy. The acquisition was done
on an Elscint Apex 609 gamma camera with LEHR collimator, 20 min after intra-
venous administration of 80 MBq 99mTc-pertechnetate. The patient was in a
supine position, with the neck slightly extended. Acquisition parameters: ante-
rior view, 128×128×16 matrix, pixel size 4.42×4.42 mm (19.54 mm2), zoom fac-
tor 1, acquisition time 300 s. The volume calculation was exercised with the
surface model instead of the cylinder model. These two methods correlate well
for thyroid volumes up to 200 g.11 The surface model, a semi-automated com-
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puter algorithm, was preferred as it eliminates observer variations. This model is
based on the empirical formula:
V = 0.33 × A3/2,
where V is the thyroid volume and A is the thyroid’s surface which is derived
from the frontal projection area.12 After applying a 30% threshold to the scinti-
graphic image, the thyroid’s surface was measured automatically.
Therapeutic dosage
The therapeutic 131I dosage was based on the standard formula:
D = V × (100%/U) × C,
where D is the therapeutic 131I-NaI dosage (MBq), V is the thyroid volume (ml),
U is the 24-h uptake (%), and the constant C equals 3.7 MBq/ml.4 The dosage
was corrected for changes in the 5-h uptake value between tests 1 and 2. The
actual amount of 131I administered per gram thyroid tissue varied from 2.7 to
5.3 MBq/ml (at 24 h). The therapeutic 131I dosage was administered on the day
following the final measurements. All diagnostic and therapeutic dosages were
administered as capsules (Mallinckrodt Medical bv, Petten, The Netherlands).
Clinical evaluation
In order to assess the influence of the timing of the radioiodine uptake proce-
dure, all methods had been essentially unaltered in comparison with that of the
historic control study.5 Subjects were divided in tertiles according to the 24-h
uptake (< 60%, 60-79%, and 80-100%) or in two categories of thyroid volume
(< 60 ml and ≥ 60 ml). The clinical outcome was evaluated after a follow-up
period of 13.9 ± 8.3 months (mean ± sd). A diagnosis of euthyroidism, hypothy-
roidism or persistent hyperthyroidism was based on clinical presentation, TSH
levels (normal 0.35-5.0 mIU/l) and use of medication. In addition, we investi-
gated the relation between the clinical outcome and biological parameters such
as radioiodine turnover, age and gender.
Statistical analysis
The results from the two studies were compared using the chi-square test, the
one-way ANOVA test and linear regression analysis. P = 0.05 was maintained as
the limit of statistical significance. Statistical calculations were executed with
SPSS v6.1 for Macintosh (SPSS Inc., Chicago, IL).
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6.3 Results
Overall outcome
In comparison with the former treatment protocol the overall incidence of early
hypothyroidism was reduced from 39% to 27%, while persisting hyperthyroidism
had increased from 30% to 40% (Pearson’s chi-square = 5.30, P = 0.021); these
differences were just below the level of significance when euthyroid outcomes
were also included in the analysis (P = 0.069). The number of euthyroid out-
comes was unaltered (31% versus 33%, n.s.).
Age and gender
The female-to-male ratio in this study was 5:1 (see table 6.1). There were no age
differences between the sexes (P = 0.64). The clinical outcome was affected nei-
ther by age (P = 0.97), nor by gender (P = 0.36), see table 6.2.
Table 6.1 Patient data for female, male, and all patients with regard to thyroid volume,
131I uptake, 131I turnover rate, 131I dosage per gram, and age.
137 female patients 28 male patients all patients
(mean ± sd) (mean ± sd) (mean ± sd)
thyroid volume (ml) 45.6 ± 28.9 48.9 ± 22.1 46.2 ± 27.8
5-h uptake (%) 55.5 ± 22.3 60.1 ± 22.2 56.3 ± 22.3
24-h uptake (%) 65.2 ± 18.6 70.9 ± 16.6 66.2 ± 18.4
5/24-h uptake ratio 0.82 ± 0.18 0.82 ± 0.17 0.82 ± 0.17
dosage/ml at 24h (MBq) 3.8 ± 0.5 4.0 ± 0.5 3.8 ± 0.5
age (years) 45.8 ± 15.0 47.3 ± 14.3 46.0 ± 14.8
Table 6.2 Clinical outcome in relation to thyroid volume, 131I uptake, 131I turnover rate,
131I dosage per gram, and age by gender.
hypothyroid euthyroid hyperthyroid
(mean ± sd)  (mean ± sd) (mean ± sd)
thyroid volume (ml) 38.7 ± 22.3 43.9 ± 23.7 52.9 ± 32.4
5-h uptake ‘test 2’ (%) 46.5 ± 23.2 54.9 ± 20.0 63.8 ± 20.8
24-h uptake ‘test 2’ (%) 59.5 ± 19.9 65.8 ± 16.6 70.8 ± 17.5
5/24-h uptake ratio 0.74 ± 0.16 0.81 ± 0.17 0.88 ± 0.16
dosage/ml at 24h (MBq) 3.9 ± 0.6 3.8 ± 0.5 3.8 ± 0.5
age (years)
all patients 44.3 ± 14.9 47.9 ± 15.5 45.7 ± 14.3
female patients 44.1 ± 14.5 47.3 ± 15.8 45.6 ± 14.8
male patients 44.7 ± 17.0 50.9 ± 14.4 46.4 ± 11.3
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Thyroid volume and outcome
The mean thyroid volume for female and male patients is given in table 6.1. As
in the historic control group, the thyroid volume had a pertinent influence on
the outcome of radioiodine therapy (P = 0.03). In comparison with the historic
controls there was a significant decrease of hypothyroidism accompanied by an
increase of persistent hyperthyroidism in patients with a thyroid volume < 60
ml (chi-square = 4.7, P = 0.02); the percentage of euthyroidism remained un-
changed. In patients with thyroids ≥ 60 ml the same tendency was observed,
but the changes in this relatively small group were not significant (chi-square =
1.6, P = 0.21; see table 6.2). A comparison of the results from the two studies is
represented in table 6.3.
131I-uptake and outcome
The mean 5-h and 24-h uptake percentages (of test 2) for female and male pa-
tients are given in table 6.1. The relation between the radioiodine uptake and
the clinical outcome which had been observed in the historic control group was
confirmed in the present study (see table 6.2). The relation with the clinical
outcome was somewhat clearer for the 5-h uptake than for the 24-h uptake. In
comparison with the former protocol there was a nonsignificant decrease of
hypothyroidism and a concurrent increase of hyperthyroidism in the lower
uptake tertiles (uptake < 60%: chi-square = 2.5, P = 0.12; uptake 60-80%: chi-
square = 3.14, P = 0.08; see also tables 1, 2 and 3).
Radioiodine turnover rate and outcome
The turnover rate (mean ± sd, 95% confidence interval between brackets) was
0.74 ± 0.16 (0.69-0.79) for patients with a hypothyroid outcome, 0.81 ± 0.17
(0.76-0.84) for those who became euthyroid, and 0.88 ± 0.16 (0.84-0.92) for
those with persistent hyperthyroidism (see figure 6.1). The mean turnover rate
in the group of patients with persisting hyperthyroidism differed significantly
from the others (P < 0.05). The correlation between the radioiodine turnover
rate and the 5-h uptake (R2 = 0.69, P < 0.0001) as well as the 24-h uptake (R2 =
0.32, P < 0.0001) was not strong, but highly significant. As the radioiodine turn-
over rate had not been taken into account in the historic control group, a com-
parison of this parameter could not be made.
131I dosage per ml (corrected for uptake) and outcome
The amount of 131I administered per ml thyroid tissue corrected for 24-h uptake
ranged from 2.7 to 5.3 MBq/ml (70-140 µCi/ml). The mean and standard devia-
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tion of the 131I dosages was significantly different in the three outcome groups.
Most patients who had received dosages > 3.9 MBq/ml (105 µCi/ml) became
hypothyroid (see table 6.1).
6.4 Discussion
The importance of standardized methodology can hardly be overemphasized.
In the area that was presently investigated – standardization of the timing of the
uptake measurements before radioiodine therapy – a significant shift was ob-
served in the clinical outcome from hypothyroidism to persistent hyperthy-
roidism (or more likely from hypothyroidism to euthyroidism, and from euthy-
roidism to hyperthyroidism) in comparison with our earlier study. As the net
percentage of euthyroid outcomes remained unaltered, the ‘cure rate’ (defined
as the number of patients with euthyroid or hypothyroid outcome divided by
the total number of patients treated) had dropped from 70% to 60%. We and
others regard euthyroidism as the only true cures and hypothyroidism as a rela-
tively undesirable outcome. The prevention of hypothyroidism after radioiodine
therapy may have greater clinical implications than is usually acknowledged. In
a recent study it was stated that the functioning and the well-being of hypothy-
roid patients is better with combined T3/T4 medication than with T4 alone.13 We
Figure 6.1 The posttherapeutic thyroid status as a function of the pretherapeutic 131I
turnover rate.
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argue that the same advantages may be expected from the preservation of nor-
mal thyroid function. In another study, a patient valuation study of radioiodine
treatment of Graves’ disease, 33% of patients who were biochemically well ad-
justed to thyroxine still had problems with mood, weight, and fatigue.14
It is not certain whether the time-standardized uptake measurements truly
reflect the functional state of the thyroid gland at the time of radioiodine treat-
ment, but a shorter interval is not feasible. A comparison of pretherapeutic up-
take measurements with posttherapeutic measurements such as was done by
Bockisch et al. in a small number of patients with Graves’ disease,15 could possi-
bly elucidate this matter but methodological problems should not be underesti-
mated.
The relation between thyroid volume and clinical outcome, also demonstrated
by others,2,16 was again confirmed. It has been proposed that the deviant re-
sponse of large Graves’ thyroids to radioiodine therapy may result from the
presence of autonomous tissue with functional differences in uptake and
organification of iodine, or from increased stimulation of thyrocytes by TSH
receptor antibodies;17-19 such changes are unpredictable and therefore difficult
to account for. Interestingly, the clinical outcome after medical treatment of
Graves’ disease shows a similar relation with goiter size: relapse is seen signifi-
cantly more often in patients with larger goiters.20 In the present study (as well
as in the historic control study) all patients who were referred for radioiodine
treatment had persisting hyperthyroidism after medical treatment. It seems rea-
sonable to presume that larger goiters were overrepresented in our study; it is
inferred that such a selection bias would have a negative influence on the cure
rate. Earlier we have argued that the correlation between thyroid volume and
clinical outcome may be in part the result of inaccurate volume measurements.5
The accuracy of planar scintigraphy in measuring the functional thyroid vol-
ume as such is questionable.21-26 Planar scintigraphy and alternative modalities
such as SPECT and ultrasonography need critical validation.
The 5-h uptake value appeared to be a better indicator of the clinical out-
come than the 24-h uptake value; this was also reported by Hayes et al.27 This
finding may be secondary to the fact that the correlation with the 5/24-h up-
take ratio is substantially better for the 5-h than for the 24-h uptake value.
As in the previous study, there was no relation between the clinical out-
come and the patients’ gender or age. The fact that other researchers did find
such a relation might be explained by the clear association that they observed
between age, gender, and higher thyroid volumes.28
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The radiation absorbed dose delivered to the thyroid gland is the most im-
portant factor concerning the clinical outcome of radioiodine therapy in pa-
tients with Graves’ hyperthyroidism. Accurate dosimetry, however, is very com-
plex.29 Several factors contribute positively or negatively to the radiation ab-
sorbed dose. Thyroid volume, 131I uptake, 131I turnover rate and administered
131I dosage per volume thyroid tissue were the most pertinent in our study.
Antithyroid medication has a strong influence on the outcome of radioiodine
therapy.30 ATD had been invariant in all patients in this study and its influence
could therefore not be studied.
One of the drawbacks of the classic dosage formula, D = V × (100%/U) × C, is
that it does not account for the effective half-life (Teff) of thyroidal radioiodine.
Teff varies with the biological half-life (Tbiol), which may be 24-100 days in eu-
thyroid individuals, about 6 days in most hyperthyroid patients, and as little as
3 days in hyperthyroid patients with rapid turnover (‘small iodine pool’).2,31,32
Assessment of the Teff is often regarded as cumbersome, because it entails multi-
ple measurements over a 5-7 day period. Teff is a function of Tbiol, and the radio-
iodine turnover rate has a nonlinear inverse relation to Tbiol.33 Aktay et al. had
already established a relation between the radioiodine turnover rate (defined as
the 5/24-h radioiodine uptake ratio) and the therapy outcome;31 by their defini-
tion the turnover rate was ‘rapid’ when it was greater than 1. In the present
study we found relatively clear cut-off points at 0.75 and 0.85 for the radioiodine
turnover rate with respect to posttreatment outcome (even after exclusion of
patients with a turnover rate > 1 at ‘test 1’). A combination of risk factors accen-
tuated the differences in clinical outcome: hypothyroidism occurred in 44% of
patients who had a thyroid volume < 60 ml combined with an 131I turnover rate
< 0.75, whereas only 12% hypothyroidism occurred in patients with a combina-
tion of thyroid volume > 60 ml and 131I turnover rate > 0.85.
We support the opinion that the turnover rate is a useful alternative to
multiple uptake measurements over several days.31 Identification of patients
with increased risk of hypothyroidism or persistent hyperthyroidism could pos-
sibly lead to quantifiable adjustments to the standard dosage formula.
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Summary
A pilot study was done to investigate the feasibility of native CT for thyroid
volume measurements in patients with Graves’ disease. In 4 out of 5 patient
studies, the interface between the thyroid and its surroundings could not be
adequately defined in a majority of the cross-sections, due to a lack of soft-tissue
contrast. Contrast enhanced CT is no option in the work up for 131I treatment
because iodinated contrast agents may block the thyroid’s radioiodine uptake
capacity for several weeks. It was concluded that CT is not suited for thyroid
volume measurements in patients with Graves’ disease who are referred for
radioiodine therapy.
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7.1 Introduction
Accurate thyroid volume data are indispensable for individualized dosage calcu-
lations in patients who are referred for radioiodine therapy.1-4 In clinical cir-
cumstances, the thyroid volume is usually measured with planar scintigraphy
or with ultrasonography.5,6 A good correlation has been demonstrated between
scintigraphic or ultrasonographic data and surgical thyroid specimens.7,8 For
these comparisons, however, equipment had been used (viz., rectilinear scan-
ners for scintigraphy, and static B-scanners for ultrasonography) that is no longer
regarded as state of the art. In individual patients, the accuracy of modern gamma
cameras or real-time ultrasound scanners for thyroid volume measurements has
not been assessed with a gold standard.
The aim of the present study was to assess the feasibility of thyroid volume
measurements with native computer tomography (CT) in patients with Graves’
disease. Radiographic contrast media are contra-indicated in patients who are
scheduled for radioiodine therapy, as the relatively small content of free iodine
(contamination) in these agents is enough to block the thyroidal radioiodine
uptake for weeks or even months.1,4,9,10 Generally speaking, CT is a reliable stand-
ard for organ volumetry.11,12 The value of native CT for thyroid volume meas-
urements has earlier been demonstrated in patients with nontoxic nodular
goiter.13
7.2 Patients and methods
Native CT-scanning was performed in addition to the standard pretherapeutic
work up (131I uptake test and 99mTc-pertechnetate thyroid scintigraphy) in 5
patients with Graves’ disease who had been referred for radioiodine therapy.
Written informed consent had been obtained from all patients. The study was
approved by the hospital’s ethics committee.
Acquisition
Spiral CT without contrast enhancement was performed with a commercially
available scanner (Tomoscan SR 7000, Philips Medical Systems, Best, The Neth-
erlands). A volume acquisition was performed with the following protocol: 120
kV at 250 mA (± 40 seconds continuous exposure); 5 mm collimation (slice
thickness); 5 mm/s table speed with a reconstruction index of 3 mm. Patients
were in a supine position and were requested not to swallow. Scanning was
performed in descending order over approximately 20 cm (mandibular angle to
aortic root) with a field of view of 200 mm, a 512×512 matrix, and the plane of
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section perpendicular to the cervical spine. All studies were reviewed independ-
ently by two readers.
Image processing
For analysis of thyroid volumes the summation-of-areas technique was used, a
method of volume calculation from sequential CT images. This method required
manual outlining of the thyroid gland with a mouse on all thyroid-containing
CT cross-sections on screen, using the volume measurement function on an
Easyvision® workstation (Philips Medical Systems). For each cross-section this
function calculates the volume in cubic centimeters within the region of inter-
est, taking into account magnification factor, slice thickness and reconstruction
index. The thyroid volume was determined by adding up the volumes calcu-
lated from the separate slices.
7.3 Results
In 4 out of 5 studies, accurate manual segmentation of the entire thyroid gland
was not feasible. In a majority of the cross-sections, the interface between the
thyroid gland and the surrounding tissues (dermal structures, fat, muscles) could
only partially be identified. This is illustrated in figures 7.1a-d. In the one re-
maining study (figure 7.1e) the thyroid contour could be identified in most
cross-sections, enabling a reliable volume measurement of the thyroid gland.
7.4 Discussion
In patients with Graves’ disease, the delineation and manual segmentation of
the thyroid gland was not feasible with native CT. This is contrary to findings in
patients with nontoxic nodular goiter.13 The discordant results with CT-scan-
ning in different thyroid disorders lead to some speculation.
Iodine is stored in the thyroid gland in the form of colloidal tri- and
tetraiodothyronine. In euthyroid subjects the iodine content approximates 500
µg per gram thyroid tissue.14,15 In hyperthyroid patients the iodine turnover is
increased,16 which is reflected in a reduction of the thyroidal iodine pool.17,18
We argue that the lower (endogenous) thyroidal iodide content in Graves’ dis-
ease patients causes a lower signal intensity on CT, which in turn leads to a
diminished contrast between the thyroid gland and the surrounding tissues in
comparison with euthyroid subjects.
 With concern to contrast, the properties of newer developments such as
multi-array CT are no different from standard or spiral CT.
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With native CT, proper segmentation of the thyroid gland is problematic in
most patients with Graves’ disease. Contrast enhancement with radiographic
contrast media is contraindicated if radioiodine treatment is considered. In con-
clusion, CT-scanning is not suited for thyroid volume measurements in patients
with Graves’ disease who are referred for radioiodine therapy.
Figure 7.1 CT images of 5 patients (a-e), at the level of the thyroid gland. Four cross-
sections with interslice gaps of approximately 1.5 cm are shown for each patient study.
c
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Summary
The measurement of the thyroid volume is one of the cornerstones of the calcu-
lation of individualized radioiodine therapy dosages for patients with Graves’
hyperthyroidism. Thyroid volume determinations are usually made with ultra-
sonography or with thyroid scintigraphy, although the accuracy of these tech-
niques is not well known. The aim of this study was to assess the accuracy of
three modalities for the determination of the thyroid volume in patients with
Graves’ disease: ultrasonography (US), planar scintigraphy (PS) and single pho-
ton emission computer tomography (SPECT) with attenuation correction and
scatter correction.
A comparison was made of these three modalities versus magnetic reso-
nance imaging (MRI) as the gold standard. Thyroid volume measurements were
done in 25 patients with Graves’ disease. Thyroid segmentation was performed
manually in gadolinium enhanced T1-weighted MRI images and a summation-
of-areas technique was used for the volume measurements. With US, the vol-
umes were calculated using the ellipsoid volume model for two-dimensional
measurements. After filtering and thresholding, a standard volume formula was
applied to the PS images. The SPECT data were filtered, and after applying a thresh-
old method, an automatic segmentation algorithm was used for the volume
determinations.
The thyroid volumes as they were calculated with MRI were 25.0 ± 13.8 ml
(mean ± sd, range: 7.0-56.3 ml). PS correlated poorly with MRI (R2 = 0.61), and
showed a relatively large bias (–4.0 ± 17.6 ml, mean ± 2 sd). The correlation with
MRI was appreciably better for SPECT (R2 = 0.84) than for planar scintigraphy,
with a small bias but a large standard deviation (1.8 ± 11.9 ml). US had an excel-
lent correlation with MRI (R2 = 0.96), but it had the largest bias (–6.6 ± 8.8 ml).
Functional imaging (PS or SPECT) remains a requirement for choosing the proper
dosage regimen.
Substantial improvement over currently used methods for measuring the
thyroid volume may be obtained with one of three options: MRI + PS, SPECT, or
US (if a correction factor is applied) + PS. A definitive choice in the clinical envi-
ronment will be based on clinical, logistic and financial considerations.
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8.1 Introduction
Individualized treatment protocols for radioiodine (131I) therapy in patients with
Graves’ disease are based on measurements of thyroid volume and radioiodine
uptake.1-3 This is expressed in the formula:
D = V × (100%/U) × 3.7 MBq,
where D equals the 131I therapy dosage (MBq), V is the thyroid volume (ml), U is
the 24-h thyroidal radioiodine uptake (%) and 3.7 is a constant (MBq/g).4 From
this formula it follows that the accuracy of the therapy dosage is directly de-
pendent from the accuracy of thyroid volume measurements and radioiodine
uptake measurements. The importance of further standardization of the latter
has recently been described.5 Validation of the most frequently applied modalities
for thyroid volume measurements – ultrasonography and scintigraphy – is lack-
ing.
Worldwide, ultrasonography (US) is probably the most frequently used mo-
dality for thyroid measurements in the routine clinical setting. It is a relatively
inexpensive and easily accessible technique. In the past, validation studies for
volume measurements have been conducted with static B-scanners, using a sum-
mation-of-areas technique.6,7 For real-time US scanners operated with hand-held
transducers, volume estimations are generally made from measurements of the
largest dimensions along the three principal axes, using an ellipsoid model.8
Scintigraphy is the second most frequently applied modality for thyroid
volume measurements, as thyroid scintigraphy is also used for a functional di-
agnosis in the work up for radioiodine therapy. Different mathematical models
(ellipsoid, cylinder and surface models) coexist for the calculation of the thy-
roid volume from two-dimensional scintigraphic data.9,10 Validation studies have
been conducted with rectilinear scanners,9 but rarely with gamma cameras.11
Single photon emission computer tomography (SPECT) has been advocated
for thyroid volume measurements. Although reportedly SPECT is more precise
than planar imaging for such measurements,12-16 most of the described meth-
ods are not applicable with ‘off-the-shelf’ hardware and software, which hin-
ders their clinical implementation. Substantial improvement of standard SPECT
results has been reported with attenuation correction and scatter correction.17
Currently such corrections can be applied with commercially available equip-
ment.
124I PET has great research potential,18-21 but this modality has far too lim-
ited accessibility and is too expensive to be considered for clinical use.
Native CT is not suitable for thyroid volume measurements in patients with
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Graves’ disease.22 Radiographic contrast media are no option in this patient
group, as they may block the thyroid’s radioiodine uptake for weeks or even
months.3,4,23,24
Magnetic resonance imaging (MRI) has a documented place in thyroid im-
aging.25-31 MRI provides excellent delineation of the thyroid from the surround-
ing tissues, either with or without gadolinium contrast enhancement.30-32 The
summation-of-areas technique has been well standardized and validated, and
its reproducibility (with an error of about 1-2%) is very good.27,28
Ultrasonography and thyroid scintigraphy have become standard clinical
practice for measurements of the thyroid volume. The aim of this study was to
assess the accuracy of these modalities.
8.2 Patients and methods
Patients
Twenty-five consecutive patients with Graves’ hyperthyroidism who had been
referred for radioiodine therapy were accrued. The study was approved by the
hospital’s ethics committee. Written informed consent was obtained from all
patients. One patient suspended her participation with only the SPECT study
lacking. In one patient, the MRI scan was incomplete at the caudal end, and
consequently MRI volume measurements could not be done in this patient. Due
to computer failures one SPECT study and one US study were lost after acquisi-
tion.
MRI
In all patients, the volume of the thyroid gland was measured on a Philips
Gyroscan™ ACS-NT 1.5 T Powertrak 6000 (Philips Medical Systems, Best, The
Netherlands). T1-weighted scans were acquired before and after intravenous ad-
ministration of dimegluminegadopentetate, 469.01 mg/ml (Magnevist®, Schering
AG, Germany) (TR/TE: 552/20 msec; FOV 25 cm; 16 transverse slices, thickness 6
mm/interslice gap 0.6 mm; NSA 2; total scanning time 3.47 min). A typical ex-
ample of an MRI study is given in figure 8.1.
The images were processed on a Gyroview™ workstation (Philips Medical
Systems, Best, The Netherlands). The circumferences of the thyroid gland were
depicted and segmented manually with a mouse, and the area was calculated on
each slice. The thyroid volume was then calculated with a summation-of-areas
technique, using a multiplication factor of 1.1 to correct for the interslice gaps.
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Figure 8.1 T1-weighted gadolinium enhanced thyroid MRI study in patient #6 (only 6 cross-
sections shown).
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Planar scintigraphy
On the day before therapy, 2-13 days after the MRI scan, thyroid scintigraphy
was done in all patients 20 min after intravenous administration of 120 MBq
99mTc-pertechnetate. The acquisition was done with a rectangular field-of-view
gamma camera (ADAC Argus™, ADAC Laboratories, Milpitas, CA) with LEHR colli-
mation and with the patient in a supine position. Acquisition parameters: ante-
rior view, 128×128×16 matrix, zoom factor × 1, pixel size 4.2 mm, acquisition
time 300 s.
A 5×5-point median filter was applied to reduce image noise.33 A rectangu-
lar region of interest (ROI 1) was drawn including the entire thyroid gland and
leaving out all nonthyroidal radioactivity concentrations, most notably the sali-
vary glands. Within ROI 1, an area of 5×8 pixels with maximum count density
was computed automatically. Using a lower threshold of 30% of this maximum
value, an isocontour was created automatically around the thyroid (ROI 2). The
30% threshold level had been derived from phantom studies with volumes rang-
ing from 10 to 40 ml. The thyroid surface was the number of pixels in ROI 2
Figure 8.2 Thyroid scintigraphy in patient #6; a: box ROI around the thyroid; b: automatic
contour detection with a 30% threshold; c: image after segmentation.
a b c
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multiplied by the pixel size (4.2×4.2 mm). The thyroid volume was calculated
with the empirical formula:
V = 0.33 × A3/2,
where V equals the thyroid volume (in cm3), and A the thyroid surface projec-
tion area (in cm2).9 In figure 8.2, the PS images are displayed for the same pa-
tient as in figure 8.1.
SPECT
One intravenous administration of 120 MBq 99mTc-pertechnetate was used for
both the planar scintigraphy and the SPECT acquisition. Zoom factor (× 1) and
matrix size (128×128×16) for SPECT were the same as for planar scintigraphy.
An ADAC VertexTM dual-detector rectangular FOV SPECT camera with Van-
tageTM transmission hardware and software was used, with the two detectors
(with VantageTM extra high-resolution collimators) in a perpendicular position.
With the patient in the supine position, a 180° anterior rotation, starting from
the 270° position, was completed with 32 azimuths at 25 s/azimuth. A matrix
size of 128×128 was chosen for both SPECT and planar scintigraphy as a compro-
mise between partial volume effect and acquisition time. Using a 153Gd trans-
mission line source (containing approximately 175 MBq), transmission scan-
ning was done during 24 s/azimuth simultaneously with the emission scan.
Total scanning time was 26 min. A scatter window (111-125 keV) was set be-
tween the 153Gd transmission source peak (100 keV) and the 99mTc photopeak
(140 keV).
The reconstruction of the transmission scan was done with filtered back-
projection, attenuation correction and correction for down-scatter of 99mTc into
the 153Gd window. For the emission scan an iterative maximum likelihood re-
construction algorithm with attenuation correction and scatter correction and
resolution recovery was used (ADAC EXSPECTTM). Post-processing measurements
were done on a Silicon GraphicsTM workstation (MIPS 10000 processor) (Silicon
Graphics, Mountain View, CA), using standard software. For noise reduction, an
edge-preserving filter was applied.33 Within the largest transaxial cross-section
of the thyroid a ROI of 4×4 pixels was placed in the center of the largest thyroid
lobe. If both lobes appeared equally large, the right lobe was chosen. Within
this ROI the average maximum pixel value was calculated. A threshold of 45% of
this value was applied for the segmentation of the thyroid gland. This threshold
value had been established with a least-squares method in experiments using
different thresholds with 5% increments. In figure 8.3, the SPECT reconstruc-
tions are displayed for the same patient as in figure 8.1.
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Ultrasonography
A real-time ultrasound scanner (Pie Medical Scanner 350, Pie Medical, Maastricht,
The Netherlands) was used with a 7.5 MHz linear array transducer (width 3.8
cm). With the patient in a supine position and the neck slightly overextended,
the thyroid lobes were scanned separately, and measurements were done in the
three largest dimensions along the principal axes. In figure 8.4, transaxial US
cross-sections are displayed for the same patient as in figure 8.1.
Figure 8.3 Thyroid SPECT in patient #6; a: transaxial cross-sections, and b: the same cross-
sections segmented with a 45% threshold.
a
b
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Figure 8.4  Thyroid US in patient #6: transaxial cross-sections with approximately 1.5 cm
interslice gaps.
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Table 8.1 Results of thyroid volume measurements with all four modalities.
patient # MRI SPECT PS US
(ml) (ml) (ml) (ml)
25 – 43.9 89.4 61.3
4 7.0 9.9 10.7 6.3
5 7.9 15.9 26.0 4.3
8 10.9 11.2 11.0 7.9
22 12.2 17.7 22.0 8.6
18 12.5 11.5 19.6 9.1
17 12.9 15.2 16.9 9.6
23 13.2 13.7 22.2 8.1
15 13.8 13.2 29.6 8.5
12 15.1 17.4 24.0 11.5
24 18.9 15.8 21.2 12.1
1 20.8 22.5 39.0 20.0
11 21.1 20.4 22.8 11.3
13 21.4 – 24.0 –
9 24.8 22.3 23.4 14.4
7 28.1 21.9 19.2 23.8
3 29.1 21.9 38.0 21.4
6 31.2 29.5 24.8 20.7
14 34.3 42.0 43.1 20.2
2 34.5 27.7 46.0 30.0
21 41.0 – 38.2 39.1
20 41.1 25.4 26.7 26.8
10 41.8 31.1 52.7 31.5
19 49.5 41.2 43.7 34.3
16 56.3 49.3 57.5 45.8
The volume of each lobe was calculated with the formula for ellipsoid vol-
umes:
V= pi/6 × L × W × D,
where L is the maximum length, W the maximum width and D the maximum
depth, measured along the three principal axes of the thyroid lobes. The thy-
roid volume was the sum of the volumes of the two lobes.
Statistical analysis
All quantitative results from the PS, SPECT and US studies were compared with
MRI as the gold standard. The statistical analysis was done with linear regression
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Figure 8.5 Linear regression analysis. Scatter plots for thyroid volumes measured with MRI
versus (a) planar scintigraphy, (b) SPECT, and (c) ultrasound.
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Figure 8.6 Difference versus mean. Bland and Altman plots for thyroid volumes measured
with MRI versus (a) planar scintigraphy, (b) SPECT, and (c) ultrasound. Reference lines indicate
+2 sd and –2 sd.
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Figure 8.7 Thyroid volumes measured with MRI versus (a) planar scintigraphy, (b) SPECT,
and (c) ultrasound. Y-axis: difference with MRI, expressed as a percentage of the MRI volume.
Reference lines indicate deviations of +20% and –20%, respectivley, from MRI measurements.
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analysis, and with a method for the comparison of measurements as proposed
by Bland and Altman,35 describing the accuracy of measurements in terms of
bias and precision.
8.3 Results
Either with or without gadolinium contrast enhancement, MRI images showed
excellent contrast between the thyroid and the surrounding soft tissues in all 25
patients. Both readers found it easier to do the segmentation on the gadolinium
images, but no difficulties were experienced in the native images. The mean ±
sd for the thyroid volumes measured with MRI was 25.0 ± 13.8 ml (range 7.0-
56.3 ml). The results of the volume measurements with the four modalities are
presented in table 8.1.
Comparisons of PS and MRI were available in 24 cases. The scintigraphic
measurements had a low precision and a considerable bias, as illustrated in table
8.2 and figure 8.5a. The differences between planar scintigraphy and MRI were
essentially independent of the thyroid size (figure 8.6a). The percentual differ-
ence (mean ± sd) between PS and MRI was –33.2 ± 57.6 (figure 8.7a).
SPECT and MRI data were compared in 22 cases. The differences between the
volume estimations with these modalities were essentially independent of the
thyroid size. The precision and bias were substantially better than for planar
scintigraphy (see table 8.2 and figures 8.5b and 8.6b). The percentual difference
(mean ± sd) between SPECT and MRI was –2.3 ± 30.5 (figure 8.7b).
A comparison between US and MRI could be made in 23 cases. Although the
bias was large, the precision was good, and there was an excellent correlation
with MRI (see table 8.2 and figure 8.5c). Larger differences were found in pa-
tients with larger thyroid volumes (figure 8.6c). The percentual difference (mean
± sd) between US and MRI was 27.8 ± 12.3 (figure 8.7c).
Table 8.2 Correlation, bias and precision for planar scintigraphy, SPECT and US versus MRI.
linear regression R2 bias precision
planar scintigraphy (PS) PS = 0.73 × MRI + 10.87 0.61 –4.00 17.64
SPECT SPECT = 0.70 × MRI +   5.47 0.84 1.83 11.86
ultrasonography (US) US = 0.77 × MRI –   1.12 0.97 6.79 7.46
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8.4 Discussion
MRI is recognized as a gold standard for volume measurements in general. Gado-
linium enhanced MR imaging does not interfere with radioiodine therapy, as
gadolinium chelates do not influence the iodide uptake or organification by the
thyroid gland.26,29 In spite of the excellent imaging capabilities of MRI in several
thyroid disorders,31,32 the limited availability and capacity as well as the rela-
tively high cost have restrained its clinical application for thyroid volume meas-
urements in patients with Graves’ disease. Even research in this field is scarce.30
In an adjacent clinical area – volume measurements of large multinodular goiters
– excellent inter- and intraobserver agreement were found.31
The correlation of PS measurements with MRI was poor. Another indicator
of the disappointing performance of scintigraphy is the percentual difference
from MRI measurements, as displayed in figure 8.7a. At an acceptance level of
20% difference from the MRI results, untoward volume estimations were ob-
tained in two-thirds of all planar scintigraphic studies. The mean error was 33%;
large overestimations and large underestimations were encountered. Similar prob-
lems were reported in other studies on Graves’ disease. Igl et al. found that thy-
roid volumes measured with scintigraphy were 33% larger than measured with
US.36 Veen et al. demonstrated a moderate correlation (R2 = 0.72) in a direct
comparison of presurgical scintigraphic measurements and surgical thyroid speci-
mens in 13 patients with Graves’ disease.11 Especially larger thyroid volumes
were severely underestimated with scintigraphy.
Somewhat better results have been reported in patients with thyroid disor-
ders other than Graves’ disease. Using a rectilinear scanner for their scintigraphic
measurements in patients with large nodular goiters, Huysmans et al. found
observer variations of 17% in comparison with MRI.28 Wesche et al. compared
scintigraphic volume measurements with US (using a static B-scanner), also in
patients with large nodular goiters.37 With a 20% threshold, they found smaller
differences with a surface model than with an ellipsoid model, but in small
diffuse goiters the discrepancies appeared to be larger with the surface model.
The relative imprecision of the surface model (with an average error of about
20%, maximum about 40%) was already stipulated by Himanka et al. at the
introduction in 1955.9 This model was originally tested with a rectilinear scan-
ner; it has never been properly validated for use with a gamma camera. Never-
theless, Himanka’s formula has enjoyed great popularity for over forty years. It
should be noted that other mathematical approaches (including ellipsoid mod-
els) thus far have not yielded better results.10
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The point spread function for collimated gamma camera systems of about
1-1.5 cm and the need for background subtraction result in less favorable spatial
resolution and in less accurate measurements of small objects.38,39 The accuracy
of scintigraphic thyroid volume measurements is too low to justify their use for
therapy dosage calculations in patients with Graves’ disease.  On the other hand,
thyroid scintigraphy is still considered by most physicians as essential for a func-
tional diagnosis in the work up for radioiodine therapy.
In the present investigation, SPECT with attenuation correction and scatter
correction yielded a seizable improvement over PS. In comparison with the gold
standard, both the mean difference and the range were smaller than those of PS,
and so were the percentual differences with MRI. However, at an acceptance
level of 20% deviation from the MRI measurements, untoward volume estima-
tions were still observed in one-third of all cases. The largest errors occurred in
the lower volume range (< 10 ml). The semi-automatic SPECT segmentation pro-
cedure that we propose is fast, easy to perform, and not liable to observer varia-
tions. It can be performed with standard commercial hardware and software.
Others have indicated that more accurate volume determinations with SPECT
are feasible with customized hardware and dedicated algorithms.12-17 It has been
shown that the optimal threshold value depends on object size and contrast.16
The small size of the thyroid gland in combination with the limited system
resolution makes this a challenging research area.
Thyroid SPECT may be a more cost-effective tool for thyroid volume meas-
urements if it is substituted for, rather than added to, planar scintigraphy. This
is a realistic option, as the differentiation of diffuse goiter from uni- or multi-
nodular goiter is easily made with SPECT.
The large percentual differences between MRI and US are presented in figure
7c. At an acceptance level of 20% deviation from the MRI measurements, all US
studies resulted in untoward volume estimations. This was caused by a substan-
tial bias, viz. a large underestimation by US. The discrepancies were most pro-
nounced for larger thyroid glands. The correlation of US with MRI, however, was
near perfect (R2 = 0.96) and from figure 7c it is apparent that a large percentage
of US results could be quite acceptable if a correction factor were applied.
More accurate results had been obtained with static B-scanners.6,7,40,41 This
type of US equipment provides a set of spatially well-defined cross-sections that
can be accurately computed to a three-dimensional volume, with a summation-
of areas technique similar to those used in CT and MRI. The manufacturing of
static B-scanners, however, has ceased a number of years ago. The ellipsoid models
that are generally used for volume estimations with modern real-time scanners
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are principally different; these models do not account for irregular organ shapes
such as present in the thyroid.
The cost of US (which has to be added to that of scintigraphy) is moderate.
This is one of the reasons for its widespread availability in clinics all over the
world. 3D-US scanners are now being developed in which the transducer’s posi-
tion signal and the 2D-image signal are integrated into a 3D-volume set. When
this modality becomes commercially available, a controlled study of its accu-
racy in measuring thyroid volumes is warranted.
At present scintigraphy is frequently used for thyroid volume measurements. In
view of the large errors, this practice may be responsible for a substantial number
of inadequate radioiodine therapy dosages. Thyroid scintigraphy is still consid-
ered as indispensable for a functional diagnosis. For this purpose, SPECT may be
a good alternative. US is precise, but the accuracy may vary for specific scanners.
Calibration of real-time US scanners is highly recommended before their imple-
mentation for volume measurements. We conclude that one of three options
may be pursued for thyroid volume measurements: MRI + scintigraphy, ultra-
sound + scintigraphy, or SPECT. In a clinical environment the accuracy, the avail-
ability, the capacity and the cost of the various imaging modalities ultimately
determine the physician’s choice.
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9.1 Towards patient-tailored radioiodine therapy
After half a century of radioiodine therapy the questions “Where do we stand?”
and “What have we learned?” are still being asked in leading medical journals.1,2
Although several issues are no longer controversial, others still divide the ranks.
The therapy aim and the preferred dosage strategy of radioiodine treatment evi-
dently vary not only with the thyroid disorders that are to be cured, but also
from country to country or even from clinic to clinic. We argue that individual-
ized treatment protocols are the most appropriate way to improve the success of
radioiodine therapy. As a general rule, medical interventions should be tailored
to meet the patient’s needs. On the other hand, patients should be made aware
of the limitations of medical knowledge. In the following we describe our ef-
forts to identify the parameters that influence the clinical outcome of radioiodine
therapy in benign thyroid disorders, and we discuss the clinical consequences
thereof. In the final paragraph proposals are made for future research.
9.2 Toxic adenoma and toxic multinodular goiter
In toxic adenoma and toxic multinodular goiter the primary therapeutic aim,
the restoration of normal thyroid function, is widely acknowledged. With the
decline in numbers of subtotal thyroidectomies performed, radioiodine has be-
come the first treatment option.3,4 Antithyroid drugs (ATD) do not constitute a
rational treatment form. Thyrotoxicosis recurrence after cessation of therapy is
greater than 95%.5,6 The alternative, lifetime medication with ATD and levo-
thyroxine (LT4), is associated with serious side effects.3,6 In this perspective it is
remarkable that many patients with toxic nodular goiter are still being treated
with ATD for several years. In patients with toxic adenoma, thyrotoxicosis is
caused by autonomously hyperfunctioning adenomatous tissue, usually present
in one nodule with increased iodine uptake. The thyroid hormone production
is high (most pronouncedly the T3 production), therefore the TSH concentra-
tions are low, and the function of the extranodular thyroid tissue is suppressed.
In the present study, it was confirmed that in most patients the normal
thyroid function is not compromised by radioiodine therapy, even if the 131I
dosage is high enough for ablation of the adenoma. With a 131I dosage of 7.4
MBq per gram adenomatous tissue at 24 h, the administered amount was 349 ±
224 MBq (mean ± sd, equaling 9.4 ± 6.1 mCi). Euthyroidism was reached in 75%
of all patients, hypothyroidism occurred in 11%, and hyperthyroidism persisted
in 14%. Euthyroidism was restored in all patients with a relapse who received a
second treatment with radioiodine. After a follow-up of 2-7 years, no new cases
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of hypothyroidism or recurrences of hyperthyroidism were seen. In a number of
other studies, all with different methods of dosage calculation, the recurrence
rate varied between 2% and 52%.7-13 The lowest failure rate was obtained with a
fixed dosage of 740 MBq (20 mCi).10 It seems contradictory that with this regi-
men the hypothyroidism rate (6%) was also lower than what we found.
In toxic multinodular goiter, the circumstances are different because the
iodine uptake by the thyroid is much more heterogeneous. Therefore, the therapy
dosage for toxic multinodular goiter should be lower than for toxic adenoma.
With a standard dosage of 3.7 MBq/g thyroid tissue at 24 h, euthyroidism was
reached in 74% of the patients, hypothyroidism occurred in only 7%, but hyper-
thyroidism persisted in 19%. These results concur with those of others, although
some authors find fewer relapses and higher hypothyroidism rates for toxic
multinodular goiter.10,14-20 They indicate that standardized radioiodine therapy
yields good functional results in a large majority of patients with toxic nodular
thyroid disease.
Further optimization studies may be limited to a few issues. It has been put
forward that further improvement of the measurements of the autonomously
functioning thyroid volume may be worthwhile.21 In order to prevent the up-
take of radioiodine by the normal thyroid tissue, suppression therapy with triiodo-
thyronine (T3) may be useful in preparing patients with these disorders for
radioiodine therapy.16 Thereby with the same amount of 131I an increased and
better targeted effect might be obtained. Lithium enhances the retention of
radioiodine in the thyroid and thus increases the effect of radioiodine therapy.22,23
To date there are no large clinical studies of the quantitative aspects of the in-
creased efficacy of these adjuvant medical approaches.
9.3 Nontoxic goiter
Many patients with large nontoxic goiters are still being treated with levo-
thyroxine, although (as in toxic nodular thyroid disease) it has been demon-
strated that medication constitutes no meaningful treatment, with the excep-
tion of small goiters.24,25 A discrete disadvantage of medical treatment is that is
has to be life-long, with concomitant cardiac complications and loss of bone
mineral.26-28 The proper treatment for nontoxic goiter used to be surgical
debulking. Surgery is a fast and effective treatment form but it is associated with
a small but not negligible morbidity and mortality. Until less than a decade ago
nontoxic goiter was not seen as a good indication for radioiodine treatment.
Results from small patient series indicated a poor clinical effect. More recent
research has revealed that with a standardized radioiodine dosage regimen very
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satisfying results can be obtained.25,29-31 Hypothyroidism after radioiodine treat-
ment is a relatively infrequent occurrence (5-15%). The subsequent develop-
ment of autoimmune hyperthyroidism in seen in response to radioiodine therapy
in 3-4% of all patients.32
The effect of radioiodine in nontoxic goiter has been evaluated quantita-
tively with ultrasonography in a few studies.9,24,25 In the present investigation
we have objectified the effect of radioiodine treatment with computer tomogra-
phy (CT). CT has an advantage over ultrasound in patients with intrathoracic
extension of the thyroid gland, which is a frequent observation in nontoxic
goiter.6 The aim of the study was threefold: (i) to assess the effect of 131I on
goiter volume, (ii) to establish a relationship between the amount of radioactiv-
ity taken up by the thyroid and the posttherapeutic volume reduction and (iii)
to assess the precision of scintigraphic thyroid volume measurements in this
thyroid disorder. In 27 patients with sporadic nontoxic goiter, the thyroid vol-
ume was estimated by planar 99mTc-pertechnetate scintigraphy. Noncontrast (‘na-
tive’) CT scanning of the neck was performed before therapy and one year after
therapy. A clinically significant reduction was obtained in all patients (34% ±
17%, mean ± sd).33 Hypothyroidism developed in 14% of the patients, and no
other side effects occurred. It was concluded that for volume reduction in non-
toxic goiter radioiodine treatment is safe and effective. The correlation of the
volume reduction with the amount of 131I retained at 24 h per gram thyroid was
weak (R2 = 0.49). Scintigraphic volume estimations were imprecise in thyroids
larger than 200 ml; for smaller goiters the surface model was adequate for dos-
age calculation purposes. In conclusion, the results of radioiodine therapy for
nontoxic goiter were quite satisfying, which is in agreement with other research-
ers’ findings.25,29-31
Huysmans et al. have shown that the homogeneity of the radioiodine up-
take increases significantly after low doses of recombinant human thyrotropin
(rhTSH).34 It is reasonable to expect a positive impact of rhTSH on radioiodine
treatment results. An application for registration of this drug is pending in The
Netherlands, but as yet only for the diagnostic follow-up of thyroid cancer pa-
tients.
9.4 Graves’ disease
In Graves’ disease, the therapeutic approach is more challenging than in nodu-
lar thyroid disorders, most likely because of the variations that occur in the
disease activity. Three not entirely satisfactory treatment options exist: surgery,
medication, and radionuclide therapy.5,35-37 Subtotal thyroidectomy is an im-
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mediate and effective form of treatment, with a relapse rate of about 20% one
year after surgery. Hypothyroidism is seen in 10-20% immediately postopera-
tively, and an additional 1-2% each year during follow-up.4,37 The direct surgi-
cal risks, as in cases of nodular goiter, are infrequent but potentially serious.
Antithyroid drug (ATD) treatment is the first choice if the therapy aim is to
restore normal thyroid function. Prospective studies and follow-up studies in
the UK and European countries have shown that one year ATD medication re-
sults in euthyroidism in 50 ± 7%.38,39 For the USA only 11-50% euthyroidism
was reported. The remission rate is higher for patients with smaller thyroids,
and lower for patients with larger goiters. Lifetime medication with methima-
zole and carbimazole is not favored because it is associated with infrequent but
potentially serious side effects such as granulocytopenia and pancytopenia;40
lifetime levothyroxine suppletion is associated with an increased risk of atrial
fibrillation and other cardiac complications, and bone loss.26,41 In Europe pa-
tients who are scheduled for radioiodine treatment or surgery are often pretreated
with ATD. This is definitely recommended in overtly thyrotoxic patients to re-
duce the risk of a ‘thyroid storm’ – a sudden, life-threatening exacerbation of
thyrotoxicosis as a result of the acute release of large amounts of thyroid hor-
mones.42,43
Radioiodine therapy has nowadays become the therapy of first choice in
the USA,6 and the use of ATD is mostly restricted to adolescents and to the pre-
treatment of patients with overt hyperthyroidism. Radioiodine therapy is less
effective after patients have been on ATD for longer periods.44 This is often re-
ferred to as decreased radiosensitivity of the thyroid’s follicular cells as a result
of the medication, but evidence for this hypothesis is not abundant. The dimin-
ished response to radioiodine may be better explained by the blockage of thy-
roid hormone synthesis and the reduced radioiodine uptake in combination
with uninhibited release of preformed thyroid hormones. These events lead to a
depletion of the intrathyroidal iodine pool. A combination of smaller amounts
of thyroidal radioiodine and shorter residence times thereof would certainly
render radioiodine treatment less efficacious.
9.5 Considerations regarding the calculation of radioiodine therapy
dosages for Graves’ disease
In the standard radioiodine dosage formula,
D = V × (100%/U) × C,
the thyroid volume (V) and the radioiodine uptake (U) have a prominent place.45
138
Chapter Nine
By applying this formula it is implicated that a linear relationship exists be-
tween these two factors and the required 131I therapy dosage. We did a follow-
up study of the results of standardized radioiodine therapy in patients with
Graves’ disease (‘standardized’ in this context means ‘with a fixed amount of
131I per gram thyroid tissue at 24 h after dosing’). The clinical outcome, with a
success rate of 70%, was in good agreement with reports by others. Further analy-
sis of the data revealed a persistent effect of both the radioiodine uptake and the
thyroid weight on the functional thyroid status after therapy.46
Radioiodine uptake
With identical radioiodine dosages per gram 24 h after dosing, patients with
high iodine uptake (> 80%) had a significantly greater risk of relapse and pa-
tients with low uptake (< 60%) more frequently became hypothyroid.46 Because
of the apparently nonlinear relation between the radioiodine uptake and the
therapy outcome, quantitative adjustments to the standard dosage formula are
recommendable. A reduction of the 131I dosage by an arbitrary factor should be
considered for patients with an uptake value < 60%, and likewise an increase by
an arbitrary factor for patients with a 24-h uptake value > 80%. In view of our
present results we suggest that – as long as the optimal corrections can not be
quantified for individual patients – 25% would be a reasonable value for this
‘arbitrary factor’. One should be aware of the restrictions that apply to these
recommendations in view of potential differences between clinics regarding
pretreatment, patient selection, uptake measurement techniques, and so forth.
From a survey of the clinical practice in The Netherlands it appeared that
considerable time intervals are sometimes allowed between the radioiodine up-
take measurement (for the calculation of the therapy dosage) and the treatment
itself.47 After investigating the stability of the radioiodine uptake, we found large
intraindividual variations over relatively short periods. There was no apparent
relation between the degree of such variations and the length of the interval. It
must be noted that the prevalence of intervals shorter than one week was too
low to allow a separate quantitative analysis of these cases.
Subsequently we have investigated the clinical relevance of this finding. In
comparison with a treatment protocol allowing various intervals between the
uptake measurement and the therapeutic dosage administration, statistically
significant differences in therapy outcome were found when the dosage calcula-
tion was based on uptake measurements immediately before the 131I-treatment.
More specifically, there was a reduced incidence of hypothyroidism at the cost
of more relapses.48 A recommendation to keep the interval between the meas-
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urements, the dosage calculation and the radioiodine treatment as short as pos-
sible (not longer than 7-10 days) was recently included in the revised guidelines
for radioiodine treatment of the Dutch Society of Nuclear Medicine, NVNG.49
Radioiodine turnover rate
The radioiodine turnover rate was defined by Aktay et al. as the 5/24-h radioiodine
uptake ratio.50 A high turnover rate indicates a short biological half-life, which
in turn implies a decreased therapeutic effect of 131I. From the investigation
described above we learned that the iodine turnover rate shows substantial
intraindividual variations over time.47 This is another strong argument to mini-
mize the interval between the diagnostic measurements and the actual radio-
iodine treatment. In a follow-up study, we demonstrated that the relation be-
tween the clinical outcome and the radioiodine turnover rate was even more
significant than between the outcome and the thyroid weight or the radioiodine
uptake. The radioiodine turnover rate and the 5-h radioiodine uptake were also
significantly related; this may be the main reason for the reduced therapy effect
in patients with high radioiodine uptake.
For the assessment of the effective half-life (Teff) of 131I, serial measurements
over a 5-7 day period are required. It has been suggested that the 5/24-h uptake
ratio can be effectively substituted for Teff.50 In the present study we found evi-
dence that ‘rapid’ radioiodine turnover should not be defined as a 5/24-h up-
take ratio > 1. A ratio > 0.85 appeared to be a strong indicator of therapy failure;
we argue that in these cases therapy dosage adaptations should be considered.
As long as an accurate quantitative approach is not available, an arbitrary in-
crease of the therapeutic 131I dosage by 50-100% seems to be reasonable; for
patients with a 5/24-h uptake ratio > 1.0 such increments are already customary
at some institutes. Likewise for patients with a 5/24-h uptake ratio < 0.75 a
dosage reduction (by 25-50%, arbitrarily) may be considered. Because of the
interdependence of the radioiodine turnover rate and the radioiodine uptake,
care must be taken that adaptations to the therapy dosage are not made for both
factors at the same time. It is our view that if the turnover rate is available this
factor should have priority.
Rapid turnover is linked to the concept of a ‘small thyroidal iodine pool’.
As a result of the small thyroidal iodine pool the amount of circulating protein
bound iodine (PBI) is highly increased.44 Consequently very large amounts of
131I would be required for an effective treatment, whereas under such circum-
stances large quantities of circulating radioactive protein bound iodine (PB131I)
would cause excessive total body radiation absorbed doses. This problem could
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possibly be circumvented by lithium co-medication, as lithium blocks the re-
lease of thyroid hormones and causes a fall of posttherapeutic serum PB131I lev-
els without hampering the radioiodine uptake.22
Thyroid volume
The thyroid weight (often used as a synonym of thyroid volume) is another
classic dosage-determining factor. In many schemas the dosages are expressed
in MBq/g. The linearity between the clinical outcome and the thyroid volume
which is implied by this expression was denied by the two follow-up studies in
patients with Graves’ disease that were described above. With identical radio-
iodine dosages per gram, a relapse of hyperthyroidism was seen significantly
more often in patients with thyroids larger than 60 grams, and hypothyroidism
occurred significantly more often in patients with thyroids smaller than 60 grams.
We concluded that adaptations to currently used dosage calculation schemas
are advisable. Higher dosages than the customary 3.7 MBq per gram thyroid
tissue are recommended for patients with larger goiters, and lower dosages for
smaller goiters. Based on empirical data, adaptations to standard dosages had
already been occasionally suggested in the earlier years of radioiodine therapy.42
Accurate and cost-effective thyroid volume measurements are required for
therapy dosage calculations. We have shown that in patients with Graves’ dis-
ease CT is no option for this purpose.51 MRI can be seen as the gold standard,52,53
but the high cost and the limited availability and capacity of this modality have
thus far prohibited its use for this indication. We did a comparative study of
planar scintigraphy, SPECT (with attenuation correction and scatter correction)
and ultrasonography, in comparison with MRI as the gold standard.54 The accu-
racy of SPECT was much better than for planar thyroid scintigraphy. Ultrasonog-
raphy (US) measurements had a high precision but low accuracy. Because of the
poor accuracy of planar scintigraphy, this method should not be recommended
for thyroid volume estimations in patients with Graves’ disease. It is argued that
inappropriate scintigraphic thyroid volume measurements may have caused a
substantial number of inadequate radioiodine therapy dosage calculations in
the past, and they might be partly responsible for the relative lack of success
with individualized dosage regimens. New developments such as three-dimen-
sional US and dedicated SPECT algorithms could necessitate a review of this study.
Another tentative hypothesis deals with technical matters in regard to a
hitherto unexplained clinical observation, i.e. an increase of the posttherapeutic
hypothyroidism rate (with dosage modeling and patient preparation unchanged)
from 1951 to 1975.55,56 This period reflects the transition from rectilinear scan-
ning to scintigraphy with gamma cameras. A concomitant overestimation of
General discussion: towards patient-tailored radioiodine therapy
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thyroid volumes with scintigraphic measurements, as was found in the present
study, might have ensued.
Antithyroid drugs
Whereas the use of ATD in toxic adenoma, toxic multinodular goiter and non-
toxic goiter could be qualified as irrational, in Graves’ disease 1-1.5 years ATD
medication results in permanent euthyroidism in 20-40% of patients, as the
disease undergoes spontaneous remission.43 If ATD does not result in a definitive
cure of hyperthyroidism, it is still regarded as an adequate preparation for
radioiodine therapy.42 It is again stressed that the effect of radioiodine is re-
duced by prior ATD medication. An even greater reduction of the therapeutic
effect of 131I is to be anticipated if ATD are continued during radioiodine treat-
ment. Discontinuation of these drugs at least 3 days before 131I treatment is
generally recommended. In the context of radioiodine treatment it is interest-
ing that antithyroid drug treatment, too, is less effective in patients with large
goiters than in those with small goiters.57 The cause of this phenomenon is not
understood, but failure of medical treatment is likely to constitute a negative
selection of patients who are referred for radioiodine treatment. Following this
line of thought, primary referrals for radioiodine treatment would theoretically
result in higher cure rates.
Information to the patients
In a survey conducted among patients who were treated with radioiodine a
majority of responders were not satisfied with the treatment result.58 It was
concluded that the patient information had not been adequate. Patients should
be well informed about the uncertainties that exist in the prognosis of the out-
come after radioiodine therapy. The different options (quick induction of hy-
pothyroidism or cautiously striving for euthyroidism) should be thoroughly dis-
cussed. This is a task for both the referring internist and the nuclear medicine
physician.
9.6 Recommendations for future research
Dosimetric models
A study is recommended of the clinical applicability of Monte-Carlo based meth-
ods for dosimetric measurements with thyroid SPECT. The concept of 131I con-
centration measurements within the thyroid gland with SPECT (as a substitute
for thyroid volume measurements and 131I uptake measurements) as suggested
by Muller et al.,59 warrants further investigation.
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Investigation of very-short-term variations in radioiodine uptake
Uptake measurements, order placement and delivery of therapy capsules take a
minimum of 3-4 days. It is therefore relevant to study intraindividual variations
in radioiodine uptake over very short periods (e.g., 1-7 days) for an assessment
of the feasibility of the currently proposed radioiodine uptake protocol, and to
investigate the validity of prolonged measurements (up to 7 days) for the assess-
ment of Teff. The legal aspects of radioiodine treatment form another interesting
and complicating aspect. In The Netherlands in-patient treatment is required
by law if the therapy dosage is > 400 MBq. This can not be predicted in most
patients before testing. The patients in question will be scheduled for hospital
admittance at a later date, and the physician responsible for the dosage calcula-
tion should know whether or not to repeat the radioiodine uptake test.
Dosage modifying factors for thyroid volume, radioiodine uptake and radioiodine
turnover rate
The development of computerized dosage calculation algorithms with modify-
ing factors (for thyroid volume, radioiodine uptake and radioiodine turnover
rate) requires a multifactorial analysis of very large clinical databases and long-
term prospective testing.
The influence of ATD on the radioioine turnover rate
Rapid iodine turnover is associated with the activity of Graves’ disease and with
the depletion of the thyroidal iodine pool by ATD. It is uncertain what changes
may occur in the thyroid iodine pool of patients who have used ATD for pro-
longed periods. Serial measurements of protein bound iodine are indicated to
shed more light on the causes and the effects of rapid iodine turnover.
Triiodothyronine suppression therapy in autonomous thyroid disease
Triiodothyronine (T3) reduces the radioiodine uptake of the normal thyroid tis-
sue in autonomously hyperfunctioning nodular thyroid disorders (toxic adenoma
and toxic multinodular goiter). With T3 co-medication, the therapeutic effect of
radioiodine could possibly be targeted more effectively at the adenomatous tis-
sue. A prospective clinical investigation both in patients with toxic adenoma
and in patients with toxic multinodular goiter is warranted to establish the op-
timal T3 dosage, and to see whether subgroups of patients can be identified who
profit most from this treatment.
General discussion: towards patient-tailored radioiodine therapy
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Normal thyroid function versus thyroid hormone suppletion
Recent studies by Van Houten et al. and Bunevicius et al. have indicated that T4
monotherapy may not be the most appropriate replacement for normal endo-
genous thyroid function.58,60 It seems worthwhile to do an open-label study of
the physical and psychological functioning of combined T4/T3 medication ver-
sus T4 alone in patients who have become hypothyroid after radioiodine therapy,
and compare these with the functioning of patients who have become euthy-
roid.
Adjuvant lithium medication
Lithium may be effective inasmuch it enhances the retention of 131I in the thy-
roid.22 We propose a study of the effect of adjuvant lithium medication with
radioiodine therapy for Graves’ disease, toxic adenoma, toxic multinodular goiter
and nontoxic goiter. Prospective randomized trials should be designed to assess
whether good clinical results may indeed be obtained with lower therapeutic
131I dosages. This is important from a radiation protection perspective (ALARA),
and might lead to cheaper (viz., fewer in-patient) treatments. The main ques-
tion to be answered is whether a quantitative relationship can be established
between the lithium dosage and its effect on the thyroidal retention of radio-
iodine.
Low-dose recombinant human thyrotropin in patients with nontoxic goiter
The use of low-dose recombinant human thyrotropin (rhTSH) in patients with
nontoxic goiter should be investigated in large clinical trials. The reported abil-
ity of this drug to enhance the relative radioiodine uptake in drug-naive ‘cold’
thyroid areas could lead to substantially increased efficacy of radioiodine therapy
in this patient category.34
9.7 Concluding remarks
Of all thyroid disorders that are being treated with radioiodine, Graves’ disease
(the one thyroid disease with a homogeneously distributed function) has the
largest variations in the clinical outcome. The relative failure of individualized
therapy dosage schemas in the treatment of Graves’ hyperthyroidism can only
in part be attributed to the use of inappropriate estimations of thyroid volume
and radioiodine uptake. The dosage schemas themselves are imperfect because
they do not account for the nonlinear relation between the clinical outcome
and either the thyroid volume or the radioiodine uptake. The radioiodine turn-
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over rate, a potential substitute for the effective half-life, may deserve a place in
these schemas.
Proposals for adaptations of existing dosage protocols are useless unless
they are easily implemented in a routine clinical setting. Preferably, no addi-
tional investigational modalities or multiple patient visits are introduced, and
extra cost is to be avoided or minimized. We have tried to define the general
directions for adequate and clinically applicable dosage adjustments supported
by clinical evidence. Over the coming years adjustments will be applied and
fine-tuned in prospective study protocols. No doubt, some will disappear into
oblivion. If some may seem to be viable after a thorough clinical ‘test-run’, their
reproducibility and validity shall have to be scrutinized in multicenter clinical
trials before general implementation may be considered.
All recommendations that were given for radioiodine dosage adjustments
have been based on our own clinical data, and their intended use is restricted to
radioiodine treatment under these conditions. Some important parameters (pa-
tient selection, patient preparation, measurement techniques) may vary between
clinics. Legal requirements may prohibit implementation of these recommen-
dations in some countries.
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Summary
The general aim of this thesis was to investigate the value and the shortcomings
of the becquerel-per-gram method for radioiodine therapy in various benign
thyroid disorders. The history of this treatment form, which goes back to the
late 1940s, is described in Chapter 1. Almost fifty years after the discovery of
radioactivity, the first clinical experiences with 131I-treatment were reported in
the United States. A simple and effective treatment form had emerged as an
alternative to surgery and antithyroid drug (ATD) therapy in Graves’ disease.
The efficacy of radioiodine was initially tested – and demonstrated – in patients
who could not be cured with ATD medication. With increasing experience in the
management of Graves’ disease, it became apparent that the outcome of radio-
iodine treatment was difficult to predict. No more than half of all patients treated
became euthyroid with one 131I administration. Higher or lower dosage protocols
made the difference for the outcome in the other 50%. In other words, there
was the choice between a greater risk of early hypothyroidism or persistent hyper-
thyroidism. The development of different schools with regard to the desired
therapy outcome (i.e., rapid cure of hyperthyroidism, or restoring euthyroidism)
did not hamper the furthering of radioiodine therapy. By the late 1980s,
radioiodine had replaced surgery as the first choice for the curation of Graves’
hyperthyroidism, toxic adenoma and toxic multinodular goiter.
After this introduction, a number of items relevant to radioiodine treat-
ment are reviewed: the physical and radiobiologic properties of iodine-131; pros
and cons of different therapeutic aims; and factors influencing the outcome of
radioiodine therapy. A statement of the aims of this thesis concludes Chapter 1.
In Chapter 2, we present the clinical follow-up results of radioiodine treatment
in patients with toxic adenoma and in patients with toxic multinodular goiter.
The prevalence of both these disorders is relatively low in comparison with dif-
fuse toxic goiter (Graves’ disease), and consequently the number of cases in-
cluded in this investigation is limited. Because of their similar histopathologic
and clinical profiles, they have been studied as one group. A standardized dos-
age of 3.7 MBq per gram thyroid tissue was applied in patients with multinodu-
lar goiter, and a dosage of 7.4 MBq per gram adenomatous tissue was used in
patients with toxic adenoma. With a single radioiodine treatment good clinical
results were obtained in patients with toxic adenoma (75% euthyroidism, 11%
hypothyroidism, 14% relapse) over a follow-up period varying between one and
eight years. In patients with toxic multinodular goiter, 70% became euthyroid,
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22% suffered a relapse of thyrotoxicosis and 8% became hypothyroid. Repeat
radioiodine therapy (3 for TA, 11 for TMNG) was successful in all patients with a
relapse. Most other researchers have found somewhat fewer relapses and higher
hypothyroidism rates for toxic multinodular goiter; the recurrence rate for TMNG
varied between 2% and 52%. The lowest failure rate was obtained with a fixed
dosage of 740 MBq (20 mCi). It seems contradictory that with that regimen also
the hypothyroidism rate (6%) was slightly lower than what we found. At this
stage, a fixed dosage regimen seems preferable over the more laborious indi-
vidualized regimen. The underperformance of the individualized protocol could
possibly be explained by inaccurate volume measurements, especially in toxic
adenoma. Further optimization of the standardized regimen for these disorders
may be expected from T3 suppression medication and from lithium co-medica-
tion. Both may have the ability to increase the effect of a given amount of 131I,
although the mechanisms of action are entirely different.
The aim of radioiodine therapy in patients with nontoxic goiter is the reduction
of goiter size, while simultaneously preserving the normal thyroid function.
This item is dealt with in Chapter 3. In 27 patients with sporadic nontoxic goiter,
a therapeutic dose of 3.7 MBq per gram functioning thyroid tissue led to sub-
stantial objective reduction of the goiter mass (by 34% on average). The subjec-
tive results were more than adequate: 85% of all patients reported substantial
improvement or complete relief of their complaints. Hypothyroidism resulted
in 3/27 (11%) of the patients. Thyroid volume measurements with 99mTc-pertech-
netate scintigraphy were carried out for therapy dosage calculations as well as
for follow-up measurements. For an objective assessment of the goiter reduc-
tion, CT-scanning was used as the gold standard. It was concluded that the accu-
racy of planar scintigraphic volume determinations in nontoxic goiter is suffi-
cient for dosage calculation purposes if the thyroid volume does not exceed 200
ml. However, as the therapy results were no less in patients with thyroid vol-
umes over 200 ml than in patients with smaller goiters, the accuracy of these
measurements does not seem to carry much weight. Recently, other researchers
have reported equally satisfying results in the reduction of goiter size. It seems
that the indication for radioiodine therapy in patients with nontoxic goiter may
be broader than has thus far been assumed.
In Chapter 4, a summary is given of the radioiodine therapy results using a
standardized megabecquerel-per-gram dosage protocol in patients with Graves’
disease. The overall results are in compliance with the results of other research
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groups. We found a cure rate of 70% (including 39% hypothyroidism), and re-
current hyperthyroidism in 30%. The thyroid’s radioiodine uptake capacity and
the thyroid’s mass appeared to be important factors with regard to the progno-
sis of the therapy outcome. Patients with thyroid weights > 60 g more often
suffered a recurrence of hyperthyroidism, whereas those with thyroid weights
< 60 g appeared to be prone to a hypothyroid therapy outcome. Likewise, pa-
tients with radioiodine uptake values < 60% had a higher risk of becoming hy-
pothyroid than those with uptake values > 80%.
From the preceding four chapters we may conclude that the standard therapy
dosage formula D = W × (100%/U) × 3.7 MBq (where D is the therapy dosage in
MBq, W is the thyroid weight in grams, and U is the 24-h radioiodine uptake
percentage) is adequate for radioiodine therapy in all thyroid conditions under
consideration, except in Graves’ disease. It remained unclear what particular
dynamics of Graves’ disease make the prediction of the therapy outcome so
much more difficult than in other thyroid disorders. We have looked into the
technical, biologic and logistic aspects of the two cornerstones of the radioiodine
dosage calculation, viz. the iodine uptake measurement and the scintigraphic
thyroid volume measurement. Chapter 5 sets off with a survey of the clinical
practice in The Netherlands, of radioiodine uptake measurements that are used
for therapeutic 131I dosage calculations in patients with Graves’ hyperthyroidism.
From the response to a nation-wide questionnaire it was concluded that at most
departments the radioiodine uptake was measured (and the therapy dosage was
computed) several days or even weeks before the actual therapy date. Large dif-
ferences prevailed between institutions. This survey is followed by an analysis
of the clinical consequences of said practice. Variations in radioiodine uptake of
over 10% occurred – within a short time – in more than half the patient popula-
tion (62% of all patients with regard to the 5-hr 131I uptake and 51% with regard
to the 24-hr uptake). The radioiodine turnover rate, too, was recognized as a
relevant parameter for the dosage calculation. The incidence of increased radio-
iodine turnover as earlier reported in the literature (about 16%) was confirmed
in our study, but in 14% of all patients the turnover rate had changed from
normal to increased or vice versa during an interval of 6 weeks on average.
The results of radioiodine treatment in patients with Graves’ hyperthyroidism
were again reviewed; in comparison with the methods as used in Chapter 4 only
one variable was altered, viz. the time-point of the 131I uptake measurements. In
the repeat study, described in Chapter 6, the uptake was measured on the day
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before therapy. The results differed significantly from those in the historic con-
trols. A significant shift occurred from hypothyroidism to persisting hyper-
thyroidism. The outstanding significance of the radioiodine turnover rate as a
predictor of the clinical outcome was also recognized in this investigation. For
patients who had become euthyroid after radioiodine therapy, the radioiodine
turnover rates (i.e., 5/24-h 131I uptake ratios) were 0.76-0.84 (95% confidence
interval, C.I.), whereas in patients with persisting hyperthyroidism the turn-
over rates were 0.84-0.92 (95% C.I.). There was some overlap between patients
with euthyroid and hypothyroid outcomes (rates 0.69-0.79, 95% C.I.), but the
differences were still highly significant. It seems that the radioiodine turnover
rate has great predictive potential with regard to the therapy outcome. On the
basis of the present data, proper quantitative dosage corrections can not yet be
performed, but indicatively 131I therapy dosage adaptations may be realized.
The second cornerstone of ‘classic’ 131I therapy dosage calculations, the thyroid
volume, forms the center of interest in Chapters 7 and 8. Based on our earlier
experience with CT-scanning in patients with nontoxic goiter, this modality
was also chosen as the gold standard in a pilot study of 5 patients with Graves’
disease (Chapter 7). However, adequate manual segmentation was not feasible
with native CT in 4 out of 5 patient studies. As CT with contrast enhancement is
contra-indicated when radioiodine treatment is scheduled, it was concluded
that CT is not suited for thyroid volume measurements under these conditions.
It was argued that the discrepancies between the results in patients with non-
toxic goiter and in patients with Graves’ disease may be caused by the relatively
small thyroidal iodine pool in the latter. The lower iodine content would cause
a lower signal intensity on CT, and less contrast between the thyroid gland and
the surrounding tissues.
In 25 patients with Graves’ disease, a direct comparison was made between pla-
nar scintigraphy, ultrasound (US), and SPECT (with attenuation correction and
scatter correction, using standard commercial hardware and software), while
MRI was used as the gold standard. In this investigation (Chapter 8), it was con-
cluded that MRI, SPECT, or US may be pursued for thyroid volume measurements.
Planar scintigraphy is very inaccurate, and should be discarded as a means of
pretherapeutic thyroid volume measurements. SPECT can be used as an alterna-
tive to planar scintigraphy for the qualitative functional diagnosis; MRI or US
should only be used as an ‘add-on’ to scintigraphy.
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A general discussion of radioiodine therapy for benign thyroid disorders is pre-
sented in Chapter 9. In view of the good results in all nodular thyroid disorders
under study, it was concluded that adjustments to the standard dosage formula
are not indicated. In patients with Graves’ disease, it is much harder to make an
accurate prognosis of the therapy outcome. It is argued that attempts to pre-
serve normal endogenous thyroid function through a ‘patient-tailored’ model
is to be preferred over the quick induction of hypothyroidism and subsequent
levothyroxine substitution. Generalized proposals are made for adjustments to
the standard radioiodine therapy dosage formula, making use of all optimiza-
tion factors that were found in the investigations described in Chapters 2-7.
This chapter is concluded by proposals for future research, primarily aimed
at optimization of radioiodine dosage calculations in patients with Graves’ dis-
ease. Dosimetric models and computer algorithms are needed to adjust for vari-
ations in thyroid volume, 131I uptake and radioiodine turnover rate. SPECT meas-
urements of the 131I concentration within the thyroid gland, instead of the thy-
roid volume and the absolute amount of 131I in the thyroid gland, deserve fur-
ther investigation. Because of the clinical implications, we also propose a study
of very-short-term variations in radioiodine uptake. The influence of antithy-
roid drugs on the radioiodine turnover rate warrants further study, as well as a
quantification of the dose-effect relationship of lithium co-medication in pro-
longing the retention of radioiodine in the thyroid. Other proposed medication
studies include the investigation of the clinical value of triiodothyronine (T3)
suppression therapy in autonomous thyroid disease, and of the clinical value of
low-dose recombinant human thyrotropin (rhTSH) in patients with nontoxic
goiter. Finally, it seems worthwhile from an endocrinologic viewpoint to do an
open-label study of the merits of combined T3/T4 medication versus T4 alone in
patients who have become hypothyroid after radioiodine therapy.
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Nederlandse samenvatting voor de leek
Behandeling met radioactief jodium (131I) wordt sinds 1946 toegepast bij pa-
tiënten met goedaardige schildklieraandoeningen. De benodigde hoeveelheid
131I bleek bij individuele patiënten echter moeilijk voorspelbaar te zijn. In de
praktijk zijn momenteel verschillende methoden in zwang om de therapeuti-
sche 131I-dosering te berekenen. Twee belangrijke ‘scholen’ kunnen worden
onderscheiden. De eerste hanteert een geïndividualiseerd doseringsschema (bijvoor-
beeld met de ‘becquerel-per-gram’ methode, waarbij gebruik wordt gemaakt van
de formule D = G × (100%/U) × C), waarin D staat voor de toe te dienen dosis
131I, U de 24-uursopname van 131I representeert, en C een constante is, waar-
voor per ziektebeeld een andere waarde kan worden gehanteerd. De tweede ge-
bruikt een vaste dosering 131I voor alle patiënten (eventueel met gestandaardis-
eerde dosisaanpassingen voor schildkliergewicht, jodiumopname, leeftijd, en-
zovoort). Geïndividualiseerde schema’s voor behandeling met 131I zijn erop ge-
richt om een zo hoog mogelijk percentage euthyreoïdie (dat wil zeggen normale
schildklierfunctie) te bereiken. Toch leveren ze geen wezenlijk betere resultaten
op dan de vaste doseringsschema’s. Dit is moeilijk te begrijpen op grond van de
ons bekende relaties tussen gegeven hoeveelheden straling en de effecten daar-
van op menselijke weefsels. Het leek daarom zinvol om de mogelijke oorzaken
van dit fenomeen verder te onderzoeken. Bovendien zijn er redelijk sterke aan-
wijzingen dat een normale endogene productie van schildklierhormoon een
betere kwaliteit van leven geeft dan suppletiebehandeling met schildklier-
hormoontabletten (levothyroxine) bij patiënten met een te lage schildklier-
functie.
Allereerst werd het resultaat nagegaan van 131I-behandeling met hantering van
bovenvermelde standaarddoseringsformule. Bij de nodulaire schildklierafwij-
kingen (het toxische adenoom, de toxische multinodulaire struma en de euthy-
reotische multinodulaire struma) blijken met deze benadering goede resultaten
bereikt te kunnen worden. Bij patiënten met een toxisch adenoom of een toxi-
sche multinodulaire struma wordt in een hoog percentage een normale schild-
klierfunctie bewerkstelligd. Afwijkende uitkomsten van de behandeling met 131I
zijn relatief gering in aantal, en bij een deel daarvan kan met een tweede behan-
deling met 131I het gestelde doel alsnog worden bereikt. Als rationeel alternatief
voor de behandeling met radioactief jodium geldt hier alleen chirurgie. Deze
geeft weliswaar snel resultaat, maar de risico’s van operatief ingrijpen zijn groter
dan die van behandeling met 131I. Behandeling met medicamenten is geen reële
optie, omdat deze slechts de symptomen bestrijden en de ziekte niet genezen.
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Patiënten met een euthyreotische multinodulaire struma werden tot tien jaar
geleden in de regel geopereerd wanneer klachten ontstonden van obstructieve
ofwel van cosmetische aard. Het betreft hier echter grote chirurgische ingrepen
(veelal bij oudere patiënten) die niet zonder risico zijn. Medicamenteuze behan-
deling leidt in ongeveer de helft van de gevallen tot een redelijk goed resultaat,
maar alleen wanneer deze in een vroeg stadium van de ziekte wordt toegepast.
Bij stoppen van de medicijnen treedt weer groei van de krop op. Van behande-
ling met 131I van patiënten met een euthyreotische multinodulaire struma-aan-
doening waren nog weinig resultaten bekend. Het doel van deze behandeling is
om verkleining van de struma (krop) te verkrijgen, zo mogelijk met behoud van
normale schildklierfunctie. Met toepassing van de standaarddoseringsformule
werd bij de patiënten in ons onderzoek een subjectief en objectief goed resultaat
bereikt (gemiddeld 34% volumereductie). Circa 90% van de patiënten behield
daarbij een normale schildklierfunctie.
Belangrijke aanpassingen in de 131I-dosering lijken bij de nodulaire schild-
klierziekten daarom niet noodzakelijk.
Bij de ziekte van Graves (een stoornis van het afweersysteem, die onder meer
gepaard gaat met een verhoogde schildklierfunctie) leverde ons onderzoek inte-
ressante nieuwe gezichtspunten op. Het in de standaarddoseringsformule im-
pliciet aangegeven lineaire verband tussen de optimale dosering van het 131I
enerzijds, en het schildkliergewicht en de jodiumopname anderzijds, kon in
deze patiëntengroep niet worden bevestigd. Wanneer het schildkliergewicht gro-
ter was, bleek de kans op een succesvol behandelresultaat significant af te ne-
men. Dit was al in de jaren zeventig een empirisch gegeven; toch werd hiervoor
in later jaren geen correctie in de formule aangebracht. Voorts werd aangetoond
dat patiënten bij wie het percentage van het door de schildklier opgenomen
radioactief jodium hoog is een verhoogde kans hebben op persisterende hyper-
thyreoïdie, terwijl bij patiënten met een lage jodiumopname het risico op het
ontstaan van hypothyreoïdie na 131I-behandeling relatief groot is.
In de tweede plaats werd van algemeen toegepaste technieken nagegaan of ze
accuraat zijn (dat wil zeggen of ze correcte meetresultaten geven) en of ze juist
worden toegepast. Het onderzoek betrof in concreto de schildklierscintigrafie
voor de berekening van het schildkiergewicht en de jodiumopnamemeting van
131I (ter bepaling van het door de schildklier opgenomen percentage van een
oraal toegediende dosis 131I).
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Van de jodiumopname door de schildklier werd vastgesteld dat deze binnen één
individu in de loop van dagen tot weken in sterke mate kan variëren. Omdat
bovendien in een vervolgonderzoek werd aangetoond dat de uitkomsten van
behandeling met radioactief jodium afhankelijk zijn van het tijdstip waarop de
(voor de dosisberekening gebruikte) jodiumopnamemeting wordt uitgevoerd, is
dit gegeven voor de kliniek zeer relevant. Uit een landelijke enquête bleek dat
het in de praktijk gehanteerde interval tussen de meting (inclusief de bereke-
ning van de therapiedosis) en de behandeling binnen één afdeling nucleaire
geneeskunde en tussen verschillende afdelingen sterk kon variëren. Mede op
basis van het hier beschreven onderzoek werd de geldende landelijke aanbeve-
ling met betrekking tot de jodiumopnamemeting aangepast.
De ‘radioiodine turnover rate’ is de snelheid waarmee de schildklier het eenmaal
opgenomen radioactieve jodium omzet, en in andere vorm weer afstaat aan het
bloed. Deze omzettingssnelheid wordt gedefinieerd als de verhouding tussen de
jodiumopnamepercentages zoals die bij de patiënt worden gemeten (5/24-uurs-
opnameratio). In het boven beschreven onderzoek werd aangetoond dat ook
deze ‘turnover rate’ binnen een tijdsbestek van dagen tot weken niet constant
is, en dat er bovendien een sterke correlatie bestaat tussen deze parameter en de
uitkomst van de behandeling met radioactief jodium. Dit is op zich begrijpelijk:
hoe korter een bepaalde hoeveelheid 131I in de schildklier verblijft, hoe korter
het gewenste (stralings)effect kan optreden. Bij patiënten die na behandeling
een normale schildklierfunctie kregen, bleek de 5/24-uurs uptake ratio 0,76-0,84
te hebben bedragen. Bij patiënten die na behandeling nog steeds een te hoge
schildklierfunctie hadden, was deze ratio 0,84-0,92. Ten opzichte van patiënten
die een te lage schildklierfunctie kregen, bestond enige overlap (ratio’s 0,69-
0,79), maar ook hier waren de verschillen significant. De ‘turnover rate’ lijkt dus
een goede voorspellende maat te zijn voor het behandelresultaat. Een kwan-
tificeerbare correctiefactor voor de toe te dienen therapiedosis is daarmee nog
niet bepaald, maar indicatief zouden nu al doseringsaanpassingen kunnen wor-
den gerealiseerd.
Het schildkliervolume moet exact bekend zijn om een correcte therapiedosis te
kunnen berekenen bij patiënten met de ziekte van Graves die een behandeling
met 131I zullen ondergaan. Om de waarde van de traditioneel gebruikte meet-
methode (schildklierscintigrafie) te kunnen toetsen, werd een vergelijkend on-
derzoek voorbereid. In eerste instantie werd als gouden standaard de CT-scan
gekozen, omdat hiermee bij patiënten met een euthyreotische struma goede
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ervaringen waren opgedaan. Bij patiënten met de ziekte van Graves blijkt de CT-
scan zonder contrasttoediening echter niet bruikbaar te zijn. Mogelijk komt dit
doordat de schildklier bij deze patiëntengroep relatief weinig jodium bevat, en
daardoor op de foto slechts weinig contrast ten opzichte van de omgeving be-
staat. Uit vergelijkend onderzoek van andere methoden om het schildkliervolume
te meten, is ons gebleken dat de traditionele schildklierscintigrafie een onvol-
doende betrouwbare techniek is voor dergelijke metingen. Modaliteiten die hier-
voor wel geschikt zijn, betreffen – in volgorde van afnemende accuraatheid –
MRI, echografie, en SPECT (scintigrafie met plakjesfoto’s). Op dit terrein zijn mo-
menteel veel technische ontwikkelingen gaande die over enkele jaren wellicht
tot nieuwe aanbevelingen kunnen leiden.
Al met al zijn in de loop van het onderzoek drie factoren geïdentificeerd die de
uitkomst van 131I-therapie bij patiënten met de ziekte van Graves in hoge mate
beïnvloeden: (i) de snelheid waarmee het radioactieve jodium door de schild-
klier wordt omgezet, (ii) het volume van de schildklier, en (iii) de hoogte van de
jodiumopname. De laatstgenoemde hangt sterk samen met de eerstgenoemde,
en is daarom mogelijk van mindere betekenis als onafhankelijke factor. Er be-
staat geen lineaire relatie tussen de drie genoemde factoren en de uitkomsten
van therapie met 131I in een gestandaardiseerde dosering (3,7 MBq per gram
schildklierweefsel). Voor al deze factoren dient dus gecorrigeerd te worden bij
geïndividualiseerde dosisberekeningen voor 131I-behandeling. Hoewel uit het
huidige onderzoek nog onvoldoende gegevens bekend zijn om een exacte kwan-
titatieve correctie aan te kunnen geven, wordt het onderzoek voortgezet op ba-
sis van de hier (zeer voorlopig) voorgestelde aanpassingen.
Ten slotte worden aanzetten gegeven voor toekomstig onderzoek. Er worden
wegen aangeduid die tot vermindering van de therapiedosis zouden kunnen
leiden zonder dat daarbij voor een verminderd behandeleffect behoeft te wor-
den gevreesd. Laatstgenoemde aanpassingen zijn niet in de eerste plaats gericht
op het verbeteren van de behandelingsresultaten, maar op het verminderen van
de belasting van mens en milieu door radioactieve stoffen.
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